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5Introduction
Alzheimer’s disease was first identified by Alois Alzheimer in 
1906. However not until the 1970’s did it become a major and 
significant area of research. Since that time much has been 
discovered about the mechanisms of the disease, however the 
precise biological processes in the disease are mostly unknown 
and the large variance in its progression amongst patients with 
the disease needs to be better understood. 
Alzheimer’s disease is a neurodegenerative disease that effects 
memory, behavior and eventually leads to death within an aver-
age of 8 years of diagnosis, the last three of which are typically 
spent with full time care or in an institution. 
The changing demographics worldwide and with the baby boom 
generation reaching ages 70 and beyond has led Alzheimer’s 
disease to become one of the biggest healthcare concerns in 
the developed world. This greater prevalence and incidence of 
Alzheimer’s disease, the largest cause of dementia, has created a 
huge burden on society. 
Millions of Americans have Alzheimer’s disease and other forms 
of dementias. An estimated 5.4 million Americans of all ages had 
Alzheimer’s disease in 2016. One in nine people aged 65 years 
or older and about one third (32%) of people aged 85 and older 
have the disease (Herbert et al., 2013). 
The future projections for Alzheimer’s disease are equally bleak. 
Approximately 476,000 people will develop the disease in the 
United States in 2016, with the numbers increasing dramatically 
with age. There will be 63,000 new cases among people aged 65 
to 74 and 241,000 new cases among people aged 85 and older. 
Because of the ageing demographics in the United States, these 
numbers are projected to double by 2050 (Herbert et al., 2001). 
Alzheimer’s disease is one of the leading causes of both mortal-
ity and morbidity in the United States. It is currently the sixth 
leading cause of death for those 65 years and older. According 
to data from the National Center for Health Statistics of the 
Centers for Disease Control and Prevention (CDC), 84,767 
people died from it in 2013. These numbers only consider 
those who have cause of death listed as Alzheimer’s disease on 
their death certificate. Death certificates for individuals with 
Alzheimer’s disease often list other acute conditions, such as 
pneumonia, as the primary cause of death and therefore death 
due to Alzheimer’s is most likely underreported. 
The cost of the disease is very substantial, both in terms of the 
value of the unpaid caregiving for Alzheimer’s disease which has 
been estimated at $221.3 billion in 2013, and the total payments 
made which in 2016 was estimated at $236 billion. Overall the 
cost of healthcare, long term care and hospice care for indi-
viduals with the disease makes it one of the costliest chronic 
diseases to society (Hurd et al., 2013). 
Alzheimer’s disease is characterized by a gradually worsening 
ability to remember new information. This occurs because the 
first neurons to be damaged and destroyed are in the area of 
the brain responsible for creating new memories. As the disease 
causes the destruction of neurons in other regions of the brain, 
symptoms worsen and individuals experience other difficulties 
such as challenges in problem solving and planning, confusion 
with time and place, decreased and poor judgement, and with-
drawal from social activities and work. 
There are about 100 billion neurons in the adult healthy brain. 
During the development of Alzheimer’s disease, the connec-
tions and synapses between neurons is hindered and the overall 
number of neurons decrease. The destruction of neurons and 
the disruption of the cellular neuronal circuits lead to many of 
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the symptoms. The brains of people with advanced Alzheimer’s 
disease show inflammation, dramatic shrinkage from cell loss 
and widespread debris from dead and destroyed neurons. Some 
of these brain changes can begin 20 years prior to the onset of 
symptoms for the disease (Villemagne et al., 2013). 
No simple test currently exists for diagnosis of Alzheimer’s dis-
ease, rather an individual’s physician together with the help of a 
neurologist will use a variety of methods to assist in a diagnosis. 
These include obtaining a family history and medical history of 
the patient which may include psychiatric, cognitive and behav-
ioral histories. In addition, diagnosis is often aided by conducting 
cognitive tests and physical and neurological examinations. Finally, 
a physician will typically use blood tests and brain imaging to rule 
out other possible causes of behavioral and memory changes 
such as tumor formation or nutrient deficiencies. 
Much research has focused on a potential precursor to 
Alzheimer’s disease known as Mild Cognitive Impairment (MCI). 
An individual with Mild Cognitive Impairment will experience 
mild but measurable changes in thinking abilities that are no-
ticeable to friends and families of the affected person but that 
do not affect the person’s ability to carry out normal everyday 
functions and activities (Roberts & Knopman, 2013). It is esti-
mated that about 20% of people over the age of 65 have Mild 
Cognitive Impairment. Recent studies have shown that an aver-
age of 32% of people with MCI will develop Alzheimer’s disease 
within 5 years. However, some with MCI will see their cognitive 
decline stabilize, and in some cases, they may even return to 
normal cognition (Ward et al., 2013). 
In a small percent of those diagnosed with Alzheimer’s disease 
the development of the disease can be attributed to genetic 
mutations. Three genes have been implicated in its development. 
These are the genes which encode for the amyloid precursor 
protein (APP),  the genes for presenilin-1 and for presenilin-2. 
Mutations in both the APP gene and the presenilin-1 gene result 
in guaranteed development of the disease, while a mutation in 
the presenilin-2 gene leads to a 95% chance of its development. 
Individuals with mutations in any of these three genes will usual-
ly develop symptoms as young as age 30, unlike the vast majority 
of Alzheimer’s cases, which are late onset where symptoms typi-
cally develop at age 65 and over (Bekris et al., 2010). 
People with Down syndrome are born with an additional copy 
of chromosome 21 and have a greater risk of developing all 
forms of dementia including Alzheimer’s disease. Studies have 
found that more than 75% of people with Down Syndrome 
aged 65 and over have Alzheimer’s. While the exact relationship 
between Down Syndrome and Alzheimer’s is not entirely clear, 
one possible explanation might be that the gene that codes for 
amyloid precursor protein is located on chromosome 21 and 
the additional copy of this gene increases the likelihood of the 
development of the plaques associated with the amyloid precur-
sor protein. By age 40 most people with Down Syndrome have 
high levels of beta amyloid plaques in their brains, a marker for 
Alzheimer’s disease (Lott & Dierssen, 2010). 
Besides for the genetic factors in Alzheimer’s disease much re-
search has been conducted on the effects of environmental and 
modifiable risk factors. Studies have shown that regular physical 
activity, and management of cardiovascular risk factors such as 
obesity, smoking and high blood pressure reduce the risk of the 
development of Alzheimer’s disease and dementia. There is also 
evidence that a healthy lifestyle and diet as well as continued 
engagement in learning can prevent cognitive decline in old age 
(Baumgart et al., 2015). 
Current treatment options for Alzheimer’s disease are limited. 
None of the pharmacological treatments available cures or 
stops the damage the disease causes to the brain. The six drugs 
that have thus far been approved by the U.S Food and Drug 
Administration (FDA) focus primarily on increasing the levels 
of neurotransmitter present in the brain. While this helps deal 
with the symptoms of Alzheimer’s disease such as memory loss 
and reduced cognitive capacity, these drugs don’t deal with the 
underlying issues in the disease, and their effectiveness is limited 
to the early stages of the disease. 
This paper attempts to review some of the complex molecular 
mechanisms involved in Alzheimer’s disease. It will explore the 
current research on the molecular mechanisms in Alzheimer’s 
disease to better understand the development of the disease 
and the wide variance in disease progression, and explain possi-
ble areas of future research in the development of more effec-
tive therapeutic agents. 
Methods
This study was performed through the analysis of various origi-
nal and peer reviewed articles which were accessed using data-
bases such as the Touro Database, PubMed, and Google Scholar. 
The research collected in this study was used to understand the 
molecular processes in Alzheimer’s disease, and to evaluate the 
various hypotheses postulated in the formation of the disease. 
Discussion
Since the systematic biochemical analysis of patients with 
Alzheimer’s began in the early 1970’s much knowledge has been 
acquired concerning the possible mechanisms responsible for 
the disease. The earliest research into neurochemical abnormal-
ities that are present in Alzheimer’s disease led to the formula-
tion of the cholinergic hypothesis.
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Cholinergic Hypothesis
Acetylcholine was the first neurotransmitter to be identified 
and is the neurotransmitter used in all cholinergic neurons. It is 
fundamental in both the central nervous system (CNS) and the 
peripheral nervous system (PNS). 
Successful neurotransmission of acetylcholine is dependent on 
proteins needed for its synthesis, transport, degradation and re-
uptake. Acetylcholine synthesis takes place in the cytoplasm of 
cholinergic cells. The enzyme, choline acetyltransferase (ChAT) 
catalyzes the combination reaction of dietary choline and Acetyl-
CoA, generated by the mitochondria, to form the product ace-
tylcholine. Three forms of the ChAT enzyme have been found in 
humans. Formation of acetylcholine is followed by its transfer to 
the synaptic vesicles before release. This step is enabled by the ve-
sicular acetylcholine transporter (VAChT). When the cholinergic 
neurons are depolarized, acetylcholine is released by exocytosis 
into the synaptic cleft. On the post synaptic neuron, acetylcholine 
can activate both muscarinic and nicotinic receptors. Nicotinic 
ACh receptors are ion gated channels which are selective for 
cations including sodium, potassium, and calcium. Nicotinic recep-
tors are made up from a combination of five different subunits. 
The large variance in the properties and functions of the different 
nicotinic receptors is a direct result of the many different possible 
combinations of subunits that form each receptor. In the PNS the 
activation of these receptors results in the transmission of the 
signal to ganglion cells and the innervation of muscles and glands. 
In the CNS the role of nicotinic receptors is regulatory rather 
than purely the transmission of excitatory or inhibitory signals. 
In the PNS the nicotinic receptors are mostly located on the 
post synaptic neuronal membrane, where they are activated by 
acetylcholine and facilitate the transmission of signals. However, 
in the CNS the receptors are mostly located on the pre-synaptic 
neuronal membrane where their activation regulates the release 
of acetylcholine and other neurotransmitters into the synapse. 
The activation of these receptors results in an increase in calcium 
levels in the presynaptic neuron, which is a crucial step in the 
exocytosis of neurotransmitters such as GABA, glutamate, do-
pamine and serotonin into the synapse. Muscarinic receptors are 
G-protein coupled receptors, and unlike the nicotinic receptors, 
their role is largely in the transmission of signals. Five isoforms of 
the receptor have so far been identified. M1, M3 and M5 are ex-
citatory receptors and their activation results in the formation of 
second messengers by phospholipase C which results in closure 
of K+ channels enabling the greater depolarization of the cell 
and the transmission of signal down the axon.  M2 and M4 are 
inhibitory and their activation has the opposite effect. They result 
in the inhibition of adenylyl cyclase which leads to lower levels 
of cyclic adenosine monophosphate (cAMP) and promotes the 
inhibition of [Ca]++ channels diminishing cell excitability. 
In the synaptic cleft acetylcholine is broken down to its com-
ponents Acetyl-CoA and choline by the enzyme acetylcholin-
esterase (AChE). AChE is one of the most kinetically effective 
enzymes. It is able to catalyze the breakdown of 5000 molecules 
of acetylcholine per second. The choline transporter, CHT1, fa-
cilitates the uptake of choline, that is produced by the break-
down of acetylcholine by AChE, into the presynaptic neuron. 
This transporter is also the source of the choline used in ace-
tylcholine synthesis and it therefore plays a crucial role in the 
recycling of acetylcholine (Fig. 1, Ferreira Vieira et al., 2016). 
Early research into Alzheimer’s disease showed reduced activ-
ity of choline acetyltransferase in the amygdala, hippocampus 
and cortex of patients with the disease. In one such study, the 
levels of the enzyme responsible for acetylcholine synthesis in 
patients with the disease was found to be lower than 10% of the 
normal activity seen in the control group. Similarly, the levels of 
acetylcholinesterase in the same brain regions were markedly 
lower in patients with Alzheimer’s disease (Davies & Maloney 
1976).
Further studies showed that in addition to the decreased activ-
ity of the enzymes responsible for acetylcholine synthesis, the 
levels of acetylcholine uptake by neurons in the frontal cortex 
and in the hippocampus, were significantly lower in patients 
with Alzheimer’s disease. In the frontal cortex, the transport 
of choline into synaptosomes was reduced by 50% and an even 
greater reduction of 80% was seen in the hippocampus. Further 
evidence of the loss of cholinergic function in the uptake of 
Figure 1 Schematic representation of biological aspects involving 
acetylcholine neurotransmission  (Ferreira Vieira et al , 2016)
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choline in Alzheimer’s disease is seen in the lower densities of 
the presynaptic high affinity choline uptake carrier (HACU) in 
both the cortex and hippocampus (Rylett et al., 1983; Pascual 
et al., 1991). 
Other studies have shown there to be a reduction in the num-
ber of nicotinic and muscarinic M2 acetylcholine receptors in 
Alzheimer’s disease brains and there is evidence for the dis-
ruption of the M1 receptors and their G-proteins which ef-
fects the second messenger systems and transmission of signals 
(Whitehouse et al., 1988).
The cholinergic hypothesis of Alzheimer’s disease was also evi-
denced by the reduction in the amount of acetylcholine released 
from neurons in the brains of affected patients. An experiment 
conducted on brain tissue of both controls and patients with 
the disease collected with short post mortem delay, showed 
a significant reduction in tritium (3H-acetylcholine) release 
during potassium stimulation, as compared with the controls 
(Nilsson et al., 1986). 
In addition, the loss of cholinergic neurons as a result of the 
neurodegeneration caused by Alzheimer’s has further impli-
cated the cholinergic system in the etiology of the disease. In 
particular, the selective degeneration of neurons in the nucleus 
basalis of Meynert, a significant source of neurons which are 
fundamental in the cholinergic innervation of the cerebral 
cortex, explains the reduction in the levels of acetylcholine in 
individuals with Alzheimer’s disease (Whitehouse et al., 1982).
It has also been demonstrated that the cholinergic system plays 
a role in memory and in learning. The loss of the neurons in 
the nucleus basalis of Meynert has been correlated with the 
impaired memory and cognitive abilities seen in patients with 
Alzheimer’s disease. The effects on the cholinergic system has 
also been shown to result in the many behavioral and psycho-
logical symptoms seen in individuals with the disease. Emotional 
processing deficits associated with Alzheimer’s disease may 
be caused by loss of cholinergic function in the areas of the 
amygdala and frontal cortex. Apathy and depression as well as 
disturbance in sleep cycle are symptoms commonly found in 
patients with Alzheimer’s disease. It has been postulated that 
the degeneration of cholinergic neurons and the resulting loss 
of regulation of neurotransmitters, including dopamine and se-
rotonin, is responsible for the many psychiatric symptoms ob-
served. Moreover, cholinesterase inhibitors, the primary focus 
of the current pharmacologic agents available for the treatment 
of Alzheimer’s disease have shown to improve many of the psy-
chiatric symptoms. Clinical trials conducted on affected patients, 
reported reduced delusions, stress, apathy and depression in the 
treated group (Ferreira et al., 2016; Pinto et al., 2011). 
There is much research that shows the link between the cholin-
ergic system and Alzheimer’s disease. The neurodegeneration of 
neuronal cells critical in the cholinergic system, the reduction in 
the enzymes responsible for the synthesis of acetylcholine, and 
lower levels of proteins that facilitate choline uptake in neuro-
nal cells that is seen in the brains of patients with Alzheimer’s 
disease, together with the role that the cholinergic system plays 
in memory and learning have contributed to the formulation of 
the cholinergic hypothesis. However there remains some incon-
sistencies in this hypothesis that suggest the role of the cholin-
ergic system in the disease needs to be better understood. 
Although cholinergic loss seems to correlate with cognitive 
impairment, other factors such as loss of synapses and pyra-
midal cells may also be responsible for the cognitive decline. 
Additionally, some patients with Alzheimer’s disease do not 
show the large decreases in ChAT activity that would be ex-
pected. Moreover, patients with inherited olivopontocerebellar 
activity have levels of ChAT which are reduced to similar levels 
as those seen in Alzheimer’s patients yet they don’t experience 
the decline in cognition and memory that would be expected. 
An expectation of the cholinergic hypothesis would be that 
drugs that restore cholinergic function to the brain regions ef-
fected by Alzheimer’s disease would improve and reverse the 
cognitive symptoms seen in the disease. Five drugs have been 
approved by the FDA for Alzheimer’s disease. Four of these 
drugs are cholinesterase inhibitors and one is a receptor antag-
onist. The cholinesterase inhibitors have shown limited success 
in clinical trials and are mostly able to merely delay the progres-
sion of the disease. The failure of the cholinesterase inhibitors 
to cure Alzheimer’s disease was seen by some as the strongest 
evidence against the cholinergic hypothesis. 
Many researchers have continued to explore the role of neu-
rotransmission in the disease because of the acetylcholine 
dysfunction seen in the brains of Alzheimer’s disease patients. 
However, the inconsistencies with the cholinergic hypothesis 
have resulted in a shift in the focus of much of the more re-
cent research towards two of the hallmarks of the disease, the 
buildup of beta amyloid plaques in the extracellular space, and 
the intracellular formation of neurofibrillary tangles (Craig et al., 
2011; Francis et al., 1999).
Amyloid Cascade Hypothsis
The origins of the Amyloid Cascade Hypothesis lie in the se-
quencing of the Aβ extracted from cerebral blood vessels 
and the brain parenchyma of Alzheimer’s disease patients. The 
identification of the Aβ sequence led to the sequencing of the 
amyloid precursor protein gene (APP). This gene located on 
chromosome 21 encodes the holoprotein that is cleaved first by 
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the β-amyloid cleaving enzyme and then by γ-secretase to form 
the Aβ peptide. (Masters et al., 1985; Kang et al., 1987; Hussain 
et al., 1999).  The essence of the amyloid cascade hypothesis is 
that the increased production or decreased clearance of the 
Aβ peptides causes the disease. Aggregation of the hydrophobic 
Aβ40 and Aβ42 peptides results in the formation of insoluble 
plaque which triggers a cascade of changes ultimately resulting 
in cell death and the symptoms of the disease. 
Human APP belongs to a family of type I transmembrane gly-
coproteins that also includes the similar amyloid precursor like 
proteins 1 and 2 (APLP1 and APLP2). These proteins are func-
tionally the same as the APP but they lack the Aβ sequence. The 
APP gene is highly conserved and several alternatively spliced 
isoforms of APP have been identified in humans. Invertebrates 
such as the fruit fly D. melanogaster and the worm C. elegans 
contain paralogs of the amyloid precursor protein, amyloid pro-
tein precursor-like (APPL) and APP-like 1, (APL-1). The zebraf-
ish genome encodes two variants of APP, Appa and Appb. All of 
these proteins share domains that are highly conserved in both 
the large extracellular domains and in the shorter cytoplasmic 
domain (Nicolas & Hassan, 2014). 
APP can undergo two types of processing depending on the 
secretases that cleave it. In the non-amyloidogenic pathway APP 
is cleaved within the Aβ sequence by α-secretase forming the 
sAPPα extracellular protein and the membrane bound αAPP-
CT. The membrane bound protein is then cleaved by γ-secretase 
forming P3 peptide and amyloid precursor protein intracellular 
domain (AICD). 
In the amyloidogenic pathway, APP is first cleaved by β-secretase 
forming the soluble sAPPβ protein and the C-terminal mem-
brane bound fragment βAPP-CTF. The subsequent cleavage of 
the βAPP-CTF fragment by γ-secretase forms the Aβ peptide 
and the amyloid precursor intracellular domain (ACID). The 
release of the Aβ peptide by γ-secretase is thought to be fun-
damental to Alzheimer’s disease pathology, and the aggregation 
of these insoluble and toxic protein fragments results in the for-
mation of the senile plaque that is a hallmark of the disease.  In 
the earliest and most direct elucidation of the amyloid cascade 
hypothesis the aggregation of the Aβ peptide was explained as 
critical event in the development of Alzheimer’s disease. The 
accumulation of the peptide was seen as both a cause of cell 
death and as a crucial step in the hyper-phosphorylation of Tau 
proteins leading to the formation of intracellular neurofibrillary 
tangles (Hardy & Higgins, 1992).
Critical evidence for the ACH comes from human genetics. The 
observation that the Aβ peptide deposited in elderly Down’s 
syndrome patients, was the same as that found in patients with 
Alzheimer’s suggested that a gene on chromosome 21 was 
central to the development of the disease (Glenner & Wong, 
1984a). Later studies on a family with a history of early onset 
Alzheimer’s provided further evidence for a genetic link in the 
disease, and was the basis for much of the research that fol-
lowed. These studies revealed a missense mutation in the APP 
gene that resulted in a V717I amino acid substitution in the 
protein product. The position of the substitution, just upstream 
from the carboxyl terminal cleavage site of the Aβ peptide, pro-
vided further evidence for the role of Aβ peptide in the etiology 
of the disease (Goate et al., 1991). 
The link between mutations in the presenilin 1 and presenilin 2 
genes, that encode a part of the γ-secretase mutiprotein com-
plex, and the development of the disease has likewise provided 
support for the amyloid cascade hypothesis.
There are now hundreds of mutations to the PSEN-1, PSEN-2 
and APP genes that are known to cause early onset familial AD 
(FAD). These mutations effect the formation and accumulation of 
amyloid plaque in several ways. Some of these mutations result in 
Figure 2 The domain structure of APP family members in model 
organisms  All APP homologs contain the extracellular domains E2, an 
acidic domain (Ac), a copper binding domain (CuBD), and a heparin 
binding domain (HBD)  A kunitz protease inhibitor domain (KPI) is 
found only in the APP and APLP-2 forms of the protein and the Aβ 
sequence is only present in APP  The most highly conserved domain 
across species is the intracellular YENPTY domain (Nicolas & Hassan, 
2014) 
Figure 3 proteolytic processing of APP (Nicolas & Hassan, 2014) 
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the extension of the C-terminal side of the Aβ peptide, others in-
crease the overall ratio of the longer less soluble Aβ peptides to 
the shorter more soluble forms, and some are directly responsi-
ble for an increase in the aggregatory properties of the protein. 
In addition to the effects of these three genes on familial 
Alzheimer’s disease, there are also genes that are connected 
to sporadic Alzheimer’s disease (SAD). There are three major 
alleles of the APOE gene in the human population (Nickerson et 
al., 2000). These are APOE2, APOE3 and APOE4. A heterozygous 
APOE4 carrier has a four-fold increased risk for the disease 
as compared with the homozygous APOE3 genotype. The ho-
mozygous APOE4 genotype has an even more drastic 12 fold 
increase in risk. Conversely, a carrier of the APOE2 gene has 
a reduced risk of the disease (Verghase et al., 2011). The ApoE 
protein is believed to have a role in the deposition of the am-
yloid plaques. Furthermore, there are specific mutations in the 
APP gene that result in the protection against Alzheimer’s dis-
ease, with the evidence suggesting that they disrupt the ability 
to form the Aβ peptides. 
While many of the above studies have shown a link between the 
genes involved in the formation of the Aβ peptides and the de-
velopment of the disease, like the cholinergic hypothesis there 
remain some inconsistencies and unanswered questions. These 
questions have led many to believe that rather than being the 
central mechanism in the development of Alzheimer’s disease, 
the formation of amyloid plaque may just be one of several fac-
tors that contribute to its development. 
Much to the frustration of the proponents of the ACH, the amy-
loidocentric drugs have failed to produce the results that would 
have been expected according to the hypothesis. The phase three 
clinical trials of 6 of these drugs have provided disappointing 
results. Triampirosate, a small molecule drug that prevents the 
aggregation of Aβ peptide showed no significant effect on cogni-
tion and memory during the clinical trials. Similarly no significant 
effect on primary outcomes were seen in the trials of Tarenflurbil, 
a γ-secretase modulator that reduces the ratio of aggregatory 
Aβ peptide to the shorter more soluble form. The only limited 
success in this class of drug for the treatment of Alzheimer’s dis-
ease, was Solanezumab, a monoclonal antibody directed at the 
amyloid plaque protein. In its phase three clinical trials there was 
a significant improvement in cognitive abilities. In an extension 
trial, these positive effects on cognition were sustained over a 
two-year period raising hope and providing some evidence for a 
disease modifying effect (Karran & De Strooper, 2016). 
A central tenet of the amyloid cascade hypothesis is that the 
accumulation of the Aβ peptides causes both cell death and 
the intracellular neurofibrillary tangles. Tissue studies in vitro 
have shown the toxic nature of Aβ peptide and Aβ42. Many 
early studies showed that the addition of the peptide to cell 
culture resulted in neuronal death and apoptosis as well as 
synaptic and dendritic loss. In vivo studies produced similar 
results, when these deleterious effects were seen in mouse 
brains injected with the peptide. However, the relationship 
between the formation of amyloid plaque and the tangles re-
mains unclear. The aggregation of plaque initially takes place 
in the frontal cortex, before spreading throughout the cortex 
as the disease progresses. Neurofibrillary tangles first appear 
in the limbic system, in the hippocampus and dentate gyrus. 
This spatial discrepancy together with further studies that 
have shown that the tangles appear before the accumulation 
of plaque, and are more closely correlated with disease pro-
gression and severity have contributed to the re-evaluation of 
the ACH (Braak & Braak, 1998). 
An analysis conducted to determine the correlation between 
cognitive abilities and some of the neurochemical and struc-
tural measurements in 15 patients with Alzheimer’s disease 
further questions the relationship between amyloid plaque 
and cognitive impairment. In this study, there were only weak 
correlations between plaque and tangles and performance 
on psychometric tests. In contrast, the density of the cortical 
synapses was found to be strongly correlated with the psycho-
logical assessments of the patients (Terry et al., 1991). Mouse 
models of Alzheimer’s disease have shown the accumulation 
of plaques without the observed cognitive impairments. In 
addition, neuroimaging analysis have shown the presence of 
plaques in cognitively healthy people. 
The amyloid cascade hypothesis dominates the field of 
Alzheimer’s research as the most complete and evidenced 
hypothesis about the causes of the disease. However, it is not 
without its flaws, which has led to some reassessing the hy-
pothesis and to others dismissing its significance altogether. 
The genetic link to Alzheimer’s disease was considered the cen-
tral evidence for this hypothesis. Mutations in APP, PSEN1 and 
Figure 4 Amyloid precursor proteins  The diagram shows both the 
β- secretase and γ-secretase cleavage sites and protective and 
pathogenic mutations (Karran & De Strooper, 2016) 
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PSEN2 are associated with familial Alzheimer’s disease and the 
EPOE4 allele is a risk factor for sporadic AD. The fact that these 
genes are involved in the processing of APP and the formation 
of Aβ peptide has provided strong evidence for the role of am-
yloid plaque in disease progression. The mutations associated 
with APP are all located in the proximity of the cleavage sites of 
Aβ peptide, suggesting that the plaque formed by the peptide is 
central to the development of the disease. However, the muta-
tions in the presenilin genes, which encode γ-secretase, occur 
throughout the protein, and not just the sites that are involved 
with Aβ formation. This has led to the belief that defective APP 
processing may in fact be the actual cause of the disease, and 
that the formation of the Aβ peptide and plaques might just be 
a secondary effect. This belief is supported by the weak correla-
tion between plaque formation and density and cognition. While 
the ACH is the best defined and most widely accepted view, the 
data both for and against this hypothesis is significant. Many still 
strongly support the ACH and others have dismissed it entirely 
to focus on other hypotheses. 
Alternative Hypotheses
Analysis of the relationship between mitochondrial function 
and Alzheimer’s disease has resulted in the proposition of 
the mitochondrial cascade hypothesis (MCH). The funda-
mental principle of the MCH is that Alzheimer’s disease is 
a usual if not inevitable consequence of ageing. Support for 
this hypothesis comes from the undoubted evidence of mi-
tochondrial damage in the brains of patients with the dis-
ease. Mitochondria are critical in the regulation of cell death 
and mutations in mitochondrial DNA and oxidative stress 
both contribute to ageing and neurodegenerative diseases 
(Lin & Beal, 2006). Studies using flourodeoxyglucose positron 
emission tomography (PET) imaging, as a measure of oxygen 
uptake, showed deficits in the brains of Alzheimer’s disease 
patients (Jack et al., 2012). There is also strong evidence of 
free radical damage in AD brains (Sonnen et al., 2008). These 
findings suggest that dysfunctional and altered mitochondria 
is central in the disease. Experimental evidence for the MCH 
comes from studies conducted on cybrid cells- cells that 
contains mitochondria from a different cell. Studies on cy-
brid cells which were induced to take up mitochondrial DNA 
from platelets of patients with Alzheimer’s disease, showed 
increased production of beta amyloid peptide (Khan et al., 
2000). This data provides support for the MCH, by show-
ing that mitochondrial deficiency is the cause of the amyloid 
plaques and central to disease development. Despite this 
data, the MCH fails to explain the full array of Alzheimer’s dis-
ease pathology. In addition, genome wide association studies 
have failed to show links between mitochondrial genes and 
proteins and the disease. The cybrid experiments show that 
mitochondrial dysregulation in Alzheimer’s disease leads to 
increases in beta amyloid production. However, they do not 
account for the mutations in APP and PSEN which increase 
the ratio of insoluble Aβ peptide to the smaller soluble form, 
or the mutations that result in an increase in aggregatory 
properties. 
Another hypothesis that deserves mention is the metabolism 
hypothesis. According to this hypothesis, the underlying cause 
of AD is hypometabolism of glucose in the brain. The basis of 
this hypothesis was experiments on a rat model injected with 
streptozotocin, which effects insulin production, and resulted 
in decreased glucose metabolism in the brain, and learning 
and memory impairments (Lannert & Hoyer 1998). Further 
studies showed that the insulin signaling pathway is signifi-
cantly depressed in many brain regions in Alzheimer’s disease 
(Steen et al., 2005). Clinical experiments also have linked 
insulin with Aβ peptide buildup. Incretin mimetics injected 
in mice resulted in significant reductions in Aβ plaque load 
(Mcclean & Hölscher, 2014), and there is also data that sug-
gests that Aβ oligomers disrupt the insulin pathway leading 
to an increase in glycogen synthase kinase 3β (GSK 3β), a Tau 
kinase, and the formation of neurofibrillary tangles (Morgen 
& Frölich, 2015). As with the mitochondrial hypothesis, no 
data from genome wide association studies have confirmed 
this link between Alzheimer’s disease and insulin signaling. 
However, this hypothesis does provide several targets for 
possible therapeutic intervention.
A more generalized proposition is the cell cycle re-entry 
hypothesis. This view examines Alzheimer’s disease from 
the perspective of age related DNA damage. Neurons are 
post mitotic and therefore must maintain integrity long 
term. Brain cells have a very high energy requirement and 
therefore are particularly susceptible to DNA damage. 
Mitogen kinases have increased expression in the brains 
of Alzheimer’s disease patients, and have been posited to 
stimulate the neurodegenerative pathways and effect cell 
repair mechanisms (Arendt et al., 1995). Later studies on 
differentiated neurons that were infected with the on-
cogenes, c-myc and ras resulted in DNA duplication and 
hyperphosphorylated and unusually folded Tau proteins, 
similar to those observed in Alzheimer’s disease. However, 
the disrupted DNA repair mechanisms does not adequately 
explain the formation of Aβ plaques, and as before there is 
little support for this hypothesis from genome wide asso-
ciation studies.
The observation that the Alzheimer’s disease brain has a 
much-reduced capillary and vascular network has led to the 
formulation of the vascular hypothesis. There is much evi-
dence linking the brain’s vascular network and the disease. 
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Research has found that hypertension and diabetes, which 
both have vascular effects, significantly increase the risk 
of the development of the disease (Prince et al., 2014). In 
one study, it was discovered that the formation of 85% of 
the amyloid plaques in AD brains were either centered or 
proximal to vasculature (Kumar & Singh et al., 2005). A 
study of several different forms of dementia including AD 
revealed substantial reductions in microvasculature (Buee 
et al., 1994). Although there appears to be a credible link 
between the disease and the vasculature, it is not entirely 
clear if AD causes damage to the vasculature or if a vascular 
insufficiency promotes deposition of Aβ plaque (Karran & 
De Strooper, 2016). 
One final hypothesis to consider is the Aβ oligomer hypoth-
esis (AβOH). This theory is a variation of the original ACH. 
The main traction behind this theory is that it provides pos-
sible explanation as to why the density and amount of am-
yloid plaques does not correlate with the symptoms of AD. 
According to the AβOH the oligomers act at a distance from 
the plaques and mediate their effects. There is a large amount 
of data in support of this view. These include the treatment of 
cells with Aβ oligomers to induce neuronal death, the impact 
of the oligomers on insulin and nicotinic receptors, and the 
injection of these oligomers in rat brains which induced im-
paired memory and cognition. The AβOH would also explain 
why amyloidocentric drugs have had little success (Karran & 
De Strooper, 2016). 
The cholinergic hypothesis and the amyloid cascade hypothe-
sis clearly are supported by the strongest evidence. The ear-
liest experiments demonstrating the reduction in cholinergic 
function provided the basis for much of the later research 
into Alzheimer’s disease. Studies have consistently shown 
reductions in the levels of enzymes responsible for acetyl-
choline synthesis, and loss of receptor activity disrupting its 
uptake into neurons. This together with the degeneration 
of cholinergic neurons has provided the basis for this hy-
pothesis. The genetic studies into familial Alzheimer’s disease 
and the link between the disease and Down’s syndrome laid 
the path for the formulation of the ACH which is the most 
comprehensive hypothesis in Alzheimer’s disease. The cho-
linergic hypothesis fails to explain the mutations in APP in 
familial Alzheimer’s disease, the formation of the Aβ peptide, 
amyloid plaques and neurofibrillary tangles. The Amyloid cas-
cade hypothesis too has its inconsistencies and unanswered 
questions. However, rather than rejecting the undeniable data 
in support of each of these hypothesis, understanding the 
links and interactions between the two may provide a clearer 
picture of the mechanism of disease and provide a target for 
more effective therapy.
The connection between the cholinergic system and APP 
processing has been established. In one study, human em-
bryonic kidney (HEK) cell lines were transfected with mus-
carinic acetylcholine receptors. As mentioned earlier there 
are five isoforms of muscarinic receptors; M1, M2, M3, M4 
and M5. Cells transfected with M1 and M3 receptors showed 
significant increase in the release of APPα the product in the 
non-amyloidogenic pathway, when exposed to Carbachol a 
muscarinic receptor agonist. These cells also released lower 
levels of Aβ (Nitsch et al., 1992). Similar effects were seen in 
rat cerebral cortex slices that were exposed to M1 receptor 
agonists (Pittel et al., 1996). In addition to the effect the cho-
linergic system has on APP processing, Aβ peptides appear 
to modulate cholinergic function. Picomolar and nanomolar 
concentration of the beta amyloid peptide inhibit acetyl-
choline release from neurons in studies conducted on rat 
hippocampus and cortex sections. The exact mechanism by 
which the Aβ adversely effects acetylcholine release remains 
unclear. However, it appears that the Aβ peptides inhibit up-
take of choline in the presynaptic neurons. The activity of 
choline acetyltransferase (ChAT) appears to be unaffected, 
while high affinity choline uptake is decreased by 20 minutes 
after incubation with Aβ (Kar et al., 2004). Further studies on 
rat septal neurons found that Aβ42 reduces the levels of ace-
tylcholine by inhibiting the activity of the enzyme pyruvate 
dehydrogenase (PDH). The inhibition of pyruvate dehydroge-
nase results in a reduction in the biosynthesis of Acetyl-CoA, 
which is critical for acetylcholine synthesis. Aβ peptides have 
also been shown to disrupt cellular signaling and secondary 
messengers activated by muscarinic receptors. 
Aside from the disruption to the various cellular process-
es Aβ exposure is also toxic to neurons in the long term. 
Differentiated cholinergic cell lines were the most suscepti-
ble to the toxic effects of beta amyloid, while GABAergic and 
serotonergic cells were more resistant. As stated above Aβ 
peptide appears to effect choline uptake in neurons. Under 
conditions of choline depletion, cells synthesize acetylcho-
line using membrane phosphatidylcholine. Therefore, a severe 
choline depletion may result in regulated membrane turn-
over being disrupted and eventually lead to cell death. 
Aβ has also been shown to have a role in the hyper-phosphor-
ylation of Tau. Hyper- phosphorylated Tau can no longer asso-
ciate with microtubules, effecting both cell structure and vital 
mechanisms of transport. In cholinergic cell lines, aggregated 
Aβ peptide induced the phosphorylation of Tau proteins. The 
exact mechanism is unclear but it is most likely a result of an 
increase in kinase activity as Aβ peptides have been shown to 
increase the activity of both MAP kinase and GSK3β. 
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Conclusion
With the wealth of evidence in support of both the cholinergic 
hypothesis and the amyloid cascade hypothesis, an attempt at 
fully understanding the mechanism of disease will require better 
understanding of the link between Aβ peptides and the cholin-
ergic system. The cholinergic system has been shown to play a 
significant role in the regulation of APP processing. Reciprocally, 
studies have found that the accumulation of Aβ peptides disrupts 
the muscarinic and nicotinic receptors on cholinergic neurons 
while also having a downstream effect on the signaling pathway 
and secondary messengers. In addition, Aβ inhibits synthesis 
of acetylcholine in a variety of ways and cholinergic neurons 
are particularly susceptible to the toxic effects of Aβ peptide. 
Genetics provides the basis of support for the amyloid cascade 
hypothesis, and while the amyloid plaque density may not cor-
relate well with cognitive impairment in Alzheimer’s disease, its 
interactions with the cholinergic system may be responsible for 
the symptoms of AD. The exact mechanism of that interaction 
needs to be better elucidated, as that understanding provides 
the greatest potential for more effective and targeted therapy.
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Introduction
Alzheimer’s disease is the most common cause of dementia in the 
elderly (Seeley, Miller 2015) and a devastating disease for those af-
fected and their families. According to the Alzheimer’s Association, 
Alzheimer’s disease affected 5.4 million American people in 2016. 
Age is a major risk factor for developing Alzheimer’s, and the risk 
increases the longer a person lives past age 60. A person over 
the age of 65 has a one in nine chance of having the disease. 
These numbers will only increase in the future years. Because of 
advancing science and better treatments, people are living lon-
ger, therefore increasing the chances of developing this disease. 
The average cost of caring for a person with Alzheimer’s is over 
$50,000 a year, creating an emotional and financial burden on 
caregivers and family members (Seeley, Miller 2015).  
Alzheimer’s disease progresses in stages, and the first symptoms 
noted are generally memory related. The disease is usually diag-
nosed in the “mild” stage, where memory loss becomes more 
apparent and the patient exhibits other cognitive impairments 
(NIH). It is important to note that these are not symptoms of 
normal aging; this is evidence of a disease state in the brain (CDC). 
As the disease progresses to moderate and severe Alzheimer’s, 
the patient gradually loses language ability, reasoning, sensory 
processing and conscious thought. The disease culminates in the 
patient being completely uncommunicative and bedridden, wholly 
dependent on a caregiver (NIH). The disease usually lasts for 8-10 
years and ends in death from secondary factors, such as malnutri-
tion or pneumonia. This pattern of degeneration is patterned by 
the atrophy of brain tissue, which begins in the medial temporal 
lobes, then affecting the lateral parietal, medial parietal and tem-
poral lobes before spreading to the lateral frontal cortex, as seen 
by brain imaging of Alzheimer patients (Seeley, Miller 2015). 
The brain tissue of an Alzheimer patient exhibits significant shrink-
age and characteristic amyloid plaques and neurofibrillary tangles 
(Seeley, Miller 2015). Amyloid plaques consist of beta-amyloid 
oligomers that stick together. These beta-amyloid fragments arise 
from a transmembrane protein called amyloid precursor protein 
(APP). Different enzymes called alpha-secretase, beta-secretase, 
and gamma-secretase can cleave the APP protein in different plac-
es causing different results. In a healthy pathway, alpha-secretase 
will cleave off a fragment called sAPPα, which may be beneficial 
to the neuron. The rest of the APP fragment is cleaved with gam-
ma-secretase and released. In the harmful pathway, APP is cleaved 
with beta-secretase which releases sAPPβ. The residual fragment 
is cleaved with gamma-secretase and is released as amyloid-β. 
These amyloid-β fragments accumulate and become the damag-
ing amyloid plaques found in Alzheimer patients (NIH).
Another feature of Alzheimer’s disease is the neurofibrillary tan-
gles caused by the protein tau, which normally helps support the 
internal structure of the neurons. Neurons contain microtubules, 
which support them and help in transporting nutrients. Attached 
to these microtubules are the tau proteins that aid in stabilization. 
In Alzheimer’s the tau proteins are hyperphosphorylated, which 
causes the tau proteins to separate from the microtubules and 
tangle together with other tau threads. The microtubules break 
down which causes the neuron’s transport system to fail, com-
promising the neuron’s ability to communicate (NIH).
These misfolded proteins cause the degradation of neurons in 
Alzheimer’s and the subsequent brain atrophy. The causes and possi-
ble treatments for the accumulation of beta-amyloid and the neuro-
fibrillary tangles are the subjects of ongoing research. This paper ex-
plores three different current ideas as to what causes these plaques 
and tangles to form, and by what mechanism they cause disease.
Methods
Articles and studies researched in this paper were obtained 
through the Ebsco and AccessMedicine databases with access 
provided by Touro College Library. Pubmed and Google Scholar 
were used to find other research articles. Several papers were 
obtained by use of the Touro College interlibrary loan system. 
Some of the research articles were kindly provided by Dr. Zev 
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Leifer, who has an interest in the topic. In addition, references 
in these articles were used as additional sources of information.
The Effect of apoE on the Development of Senile 
Plaques
Several possible causes of Alzheimer’s disease are currently 
under investigation. Recent research has been done to study ge-
netic factors of the disease. It has been found that the apolipo-
protein E (apoE) gene exists in several alleles, and one, in partic-
ular, contributes to the biochemical mechanism of Alzheimer’s 
disease (Liraz et al., 2013). Alzheimer’s disease is characterized 
by the formation of senile plaques composed of amyloid-β, a 
40-42 amino acid long peptide derived from amyloid precursor 
protein. Another feature is the neurofibrillary tangles that arise 
from the hyperphosphorylated protein tau, which leads to a 
compromised cytoskeleton and cell death. The apoE gene en-
codes for the apoE protein, which is produced by astrocytes in 
the brain. It is an important cholesterol carrier which is involved 
in the transport of lipids and injury repair. ApoE exists as three 
alleles: apoE2, apoE3, and apoE4. ApoE is a 299 amino acid pro-
tein, and the difference between the isoforms is at amino acid 
112 and 158, where either a cysteine or arginine is present (Lui 
et al., 2013). This slight difference is enough to cause a change 
in the protein’s tertiary structure, which affects its ability to 
bind lipids, receptors, and amyloid-β. ApoE3 is the most com-
mon allele, and apoE2 is associated with a decreased risk of AD 
(Simonovitch, et al., 2016). ApoE4 is a hypolipidated version of 
the protein, and it has been linked to an increased risk of devel-
oping Alzheimer’s. A greater percentage of the apoE4 allele has 
been noted in families with late-onset and sporadic Alzheimer’s. 
In sporadic AD, the frequency of apoE4 is greater than 50%, and 
each copy of the allele decreases the disease onset 7-9 years. 
Patients with a higher percentage of apoE4 have been found to 
have a higher level accumulated amyloid-β and hyperphosphor-
ylated tau, as well as a decreased neural plasticity and neuropa-
thology (Liraz et al., 2013). The fact that amyloid-β accumulation 
is increased in apoE4 positive patients led researchers to believe 
that the two pathways interact with each other, and cross-talk 
between them causes the pathological effects. The presence of 
the apoE4 allele adversely affects the binding of apoE4 to lipids, 
leading to the proposal that the disease is caused by lipid-relat-
ed mechanisms (Liraz et al., 2013).
Impaired Autophagy in Alzheimer’s Disease
Additional research on how apoE4 is related to Alzheimer’s 
disease has shown how other factors can also play a role in 
the disease process. Besides causing the formation of senile 
plaques, the apoE4 protein can also impede the body’s means of 
removing it. Amyloid plaques and neurofibrillary tangles are usu-
ally removed from the brain through the process of autophagy 
(Simonovitch et al., 2016, p. 917). Autophagy clears out cellular 
debris such as dysfunctional organelles, old proteins, and aggre-
gated proteins. Normally astrocytes produce apoE in the central 
nervous system, which protects the brain from harmful protein 
buildup. However, the mechanism becomes faulty as the disease 
progresses, and impaired autophagy may become harmful be-
cause the accumulated protein can cause synaptic degeneration 
in hippocampal neurons. In 2016, an experiment was done to 
connect the presence of the apoE4 gene to the accumulation of 
amyloid-β buildup by the process of decreased autophagy. This 
experiment used knock-in mice with either apoE3 or apoE4 
human cell lines and 5XFAD mice to replicate the disease 
process. 5XFAD mice have a phenotype similar to Alzheimer 
disease and exhibit many comparable characteristics such as 
amyloid plaques (Alzforum). Astrocytes were isolated from the 
apoE3 and apoE4 mice and cultured with frozen coronal brain 
sections from the 5XFAD mice. The experimental results were 
based on the ability of the astrocytes to clear the amyloid-β 
plaques from the brain slices. Brain slices with no astrocytes 
were used as a control. Amino acid deprivation was used to 
induce autophagy, and results were measured at the first, sec-
ond and fourth hours of starvation. Results were calculated by 
means of the LC3 and p62/SQSTM1 proteins. LC3-I becomes 
a lipidated form, LC3-II, during autophagy and becomes asso-
ciated with the autophagosomal membrane. P62 is a protein 
that is associated with LC3 and is degraded during autopha-
gy. By looking at the LC3-II/LC3-I ratio, the rate of activation 
of autophagy can be monitored and measured. A higher ratio 
indicates greater autophagic activation, which in turn indicates 
more autophagy and more clearing of the amyloid plaques. This 
ratio was significantly higher in the apoE3 astrocytes compared 
to the apoE4 astrocytes. In addition, the levels of p62 decreased 
more rapidly in the apoE3 astrocytes compared to the apoE4 
astrocytes following starvation. This evidence suggests that the 
initiation of autophagy in apoE4 astrocytes is somehow im-
paired in Alzheimer’s disease (Simonovitch et al., 2016). 
To test this hypothesis, the researchers examined the autophagy 
levels of the astrocytes when an autophagy inducer and inhibi-
tor were added in separate experiments. Rapamycin was used 
as an autophagy inducer, and chloroquine was used as an inhib-
itor. In these sets of experiments, the apoE3 and apoE4 astro-
cytes were treated with rapamycin and chloroquine in separate 
trials. The results were measured with the LC3-II/LC3-I ratio 
and the rate of p62 degradation. The results showed that with 
treatment with rapamycin, the apoE3 cells were even more ef-
fective at clearing the amyloid-β plaques, and while it was more 
effective than the apoE4, the apoE4 was still more effective than 
the non-treated apoE4 cells. In contrast, treatment with chlo-
roquine entirely prevented autophagy in both apoE3 and apoE4 
cells (Simonovitch et al., 2016)  This research highlights how the 
apoE gene can be connected to the buildup of the amyloid-β 
18
Rochelle Rubinstein
plaques in Alzheimer’s disease. It demonstrates that the pres-
ence of the apoE4 allele affects the body’s mechanisms of natu-
rally clearing protein buildup through the process of autophagy 
and that the problem is probably at the beginning of the process 
when autophagy is first induced. This research shows that not 
only is Alzheimer’s disease caused by the buildup of misfolded 
proteins but also that the body’s normal mechanism of clearing 
it away is also adversely affected.
ABCA1 Lipidates ApoE
Knowing how the function of apoE4 is different from apoE3 
is valuable for possible therapeutic strategies. If apoE4 can be 
made to function like apoE3, many of the symptoms and pa-
thologies of Alzheimer’s disease can potentially be reversed. 
Although the full pathological process of apoE4 is not yet fully 
understood, evidence suggests that it is connected to lipid-re-
lated mechanisms (Boehm-Cagan et al., 2016). ApoE lipidation 
is controlled by the ATP-binding cassette transporters ABCA1 
and ABCG1. ABCA1 triggers the efflux of cholesterol and phos-
pholipids onto the apoE acceptor, and ABCG1 has a similar 
function. Studies have shown that apoE4 is less lipidated than 
apoE3 and is less effective at stimulating the efflux of cholester-
ol and phospholipids in a cell culture. These proteins are regu-
lated by the retinoid X receptor transcription regulating system. 
If this system can be activated by some means, the pathological 
effects of apoE4 may be alleviated.
CS-6253 Can Activate ABCA1
CS-6253 is a non-toxic peptide derived from the carboxyl ter-
minal of apoE (Boehm-Cagan et al., 2016). It has been shown to 
interact with and stimulate ABCA1 to activate cholesterol and 
phospholipid efflux. A study was done to see what effect CS-
6253 has in vivo on the neuropathology and cognitive decline 
in apoE4 mice. ApoE3 and apoE4 mice were injected intraper-
itoneally with CS-6253 every 48 hours for 6 weeks. A control 
group was injected with saline. They were then subjected to 
a series of cognitive tests to measure learning and memory. 
During the novel object recognition test, mice were placed in 
an arena with no objects. Then, two objects were introduced. 
24 hours later the mice were replaced in the arena with one 
familiar object, and one new one. Their behavior and interac-
tions with the objects were monitored and measured. During 
the Morris maze test, the mice were placed in a circular pool 
of cloudy water with a submerged hidden platform. The test 
examined the mice’s memory by measuring the time it took 
the mice to reach the platform after being placed in the pool 
previously. After the experiment, the mice were euthanized and 
the brains were removed to be stained and studied (Boehm-
Cagan et al., 2016).
The results of this experiment showed many important find-
ings on the effect of CS-6253. Treatment with CS-6253 sig-
nificantly lowered the buildup of amyloid-β in the test apoE4 
mice compared to the untreated mice. The levels of amyloid-β 
in the treated apoE4 mice brains became similar to the un-
treated apoE3 mice, who were unaffected by the treatment. 
Treatment with CS-6253 also had an effect on the buildup of 
phosphorylated tau. The tested apoE4 mice showed a marked 
decrease of phosphorylated tau compared to the untreated 
apoE4 mice. Injections of CS-6253 also affected the results 
of the cognitive tests. Before treatment, apoE4 mice took a 
significantly longer time to reach the platform in the Morris 
maze test compared to the apoE3 mice. After treatment, the 
performance of the treated apoE4 mice was similar to the 
apoE3 mice. The treated apoE4 mice also scored similarly to 
the apo3 mice during the novel item recognition test after they 
were treated with CS-6253. The experimental findings show 
that CS-6253 can successfully activate ABCA1 to reverse the 
hypolipidation of apoE4, decrease the levels of accumulated 
amyloid-β and phosphorylated tau, and reverse the cognitive 
deficiencies of apoE4 mice. These results indicate that ABCA1 
can be an important therapeutic target in treating Alzheimer’s 
disease (Boehm-Cagan et al., 2016).
Alzheimer’s Nay be Linked to Prion Diseases
Many characteristics of Alzheimer’s disease are similar to prion 
diseases, suggesting that there may be a connection between 
the two (Castellani et al., 2004). Prion diseases are charac-
terized by the buildup of misfolded prion proteins (PrP) that 
can propagate themselves by causing other healthy protein to 
misfold in the same way (Prion Alliance). Prion diseases can 
affect humans and animals. The five human prion diseases are 
Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker 
syndrome, fatal familial and sporadic insomnia, kuru, and new 
variant Creutzfeldt-Jakob disease. Alzheimer’s disease is similar 
to these prion diseases in that both have an age requirement for 
the symptoms to become apparent, both usually occur sporadi-
cally although there is a genetic component in some cases. Most 
prion diseases appear in middle age to older patients, and that 
is the age demographic that is affected by Alzheimer’s. There 
is significant overlap between the two diseases’ characteristics. 
In both diseases, there is allelic segregation, with an allele that 
makes a person susceptible to getting the disease. In prion dis-
ease, this gene is the PRNP gene, and in Alzheimer’s disease, it 
is ApoE and presenilin 1 genes. Furthermore, in a certain type 
of Gerstmann-Straussler-Scheinker syndrome, prion plaques in 
the gray matter also have tau protein with neurofibrillary tan-
gles, amyloid-β accumulation, and gradual memory loss over a 
longer span of time than typical prion diseases, more similar to 
the pattern seen in Alzheimer’s disease (Castellani et al., 2004).
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The word prion comes from “proteinaceous infectious par-
ticle” (Jeffrey 2013). These particles are neither bacteria nor 
virus, but they cause transmissible diseases. Prion diseases 
are also known as “transmissible spongiform encephalopa-
thies” because they are neurodegenerative and ultimately 
fatal. Amyloid plaques are frequently present in these diseases, 
which leads to the possibility that Alzheimer’s disease may be 
related. Prions are caused by a pathogenic form of cellular 
prion proteins (PrPc), which are encoded by the host’s PRNP/
prnp gene (Jeffrey 2013). PrPC is an endogenous, cell surface 
glycoprotein of unknown function (Elezgarei, Biasini 2016). In 
prion diseases, this normal protein undergoes a conforma-
tional change and is called a “scrapie form of PrP,” or PrPSc. 
This misfolded isomer accumulates in the central nervous 
system of affected individuals. PrPSc, or prions, are capable 
of propagating themselves by binding to normal PrPC pro-
teins and forcing their conformational change to new PrPSc, 
thereby perpetuating a cycle that leads to a buildup of misfold-
ed proteins, which causes neurodegeneration and cell death 
(Elezgarei, Biasini 2016).  PrPSc changes PrPC into prions by 
affecting the tertiary structure of the protein.  Normal PrP is 
made up of 209 amino acids and the tertiary structure is 40% 
alpha helix with minimal beta sheet. PrPSc however, is made of 
40% beta sheet and 30% alpha helix (Castellani et al., 2004). 
Research shows that the prions are formed when alpha helixes 
are converted into beta sheets. This change causes PrPSc to 
be insoluble and resistant to proteolytic enzymes (Castenelli 
et al., 2004). 
Similarities Between Amyloid-β and Prions
Amyloid-β oligomers in Alzheimer’s disease have similarities to 
prions. Soluble amyloid-β oligomers affect the neuronal synapse 
in Alzheimer’s disease, causing synaptic abnormalities and neu-
rodegeneration (Elezgarei, Biasini 2016). These oligomers are 
different from the insoluble amyloid-β that builds up in the brain. 
There is evidence that the amyloid-β oligomers bind to PrPC in 
a similar manner to prions, and cause a cascade that leads to cell 
death (Laurén et al., 2009). PrPC can act as a receptor site on 
the cell membrane of neurons, which have been shown to bind 
amyloid-β and mediate the pathological effect. Suppression of 
these receptors may, in fact, have therapeutic benefit for people 
suffering from the disease (Laurén et al., 2009) PrPC-amyloid-β 
complexes occur in the brains of Alzheimer patients, which is 
further evidence that this prion-like mechanism is implicated 
in Alzheimer’s disease. PrPC is not necessarily involved in all 
cases of Alzheimer’s; Amyloid-β can cause neural damage with-
out PrPC (Elezgarei, Biasini 2016). This fact demonstrates the 
complexity of the disease and that the cause may be due to 
several factors. There are several similarities between amyloid-β 
precursor protein (AβPP) in Alzheimer’s disease and PRNP in 
prion diseases (Castenelli et al., 2004). Mutations in both of 
these genes can cause a buildup of their respective proteins 
with increased beta sheet structure.
Disease Transmission
Classic prion diseases are transmissible from one affected in-
dividual to another. They are able to be passed from person to 
person, from animal to person, and from person to animal. PrPSc 
initially forms in sporadic diseases by nucleation. The initial for-
mation of the protein is kinetically less favorable; however, once 
it overcomes the activation barrier it is able to propagate, chang-
ing PrPC to PrPSc very easily (Beekes et al., 2014). Once you 
have an initial prion “seed,” it can quickly proliferate and corrupt 
other proteins (Figure 1). However, prions are not infectious in 
the typical sense; you cannot “catch” a prion disease through 
direct contact (Weissmann et al., 2002). Transmission of prions 
occurs perorally and perenterally. The kuru epidemic that oc-
curred in Papua New Guinea in the 1900’s was spread through 
cannibalism. A greater concern is the spread of prions to hu-
mans iatrogenically. Prion contaminated cadaver-derived human 
growth hormone gonadotrophin has caused Creutzfeldt-Jakob 
disease in people in the past, and surgical instruments that have 
been used on affected people have caused the disease in oth-
ers, even after being properly sterilized. If Alzheimer disease is 
so similar to prion diseases, can Alzheimer’s be spread through 
such means? Studies were done where amyloid-β taken from 
the brain tissue of Alzheimer’s patients was injected into mice 
(Kane et al., 2000). This resulted in the stimulation of amyloid-β 
deposition in mice that were genetically predisposed to the for-
mation of such plaques. Amyloid-β deposition was recovered 
past the site of injection, similar to prion spreading. Inoculation 
of amyloid-β in wild-type mice initiated amyloid-β build up in 
brain tissue at the site of injection, and in certain species, in 
distant areas of the brain as well. However, none of the mice 
developed cerebral neurodegeneration or cognitive decline 
(Beekes et al., 2014). Similar experiments were done with the 
protein tau (Sanders et al., 2014). The protein was able to repli-
cate itself with high fidelity in a prion-like manner and cause an 
increase of hyperphosphorylated tau in the mouse brain tissue. 
Nevertheless, this buildup of tau did not cause cognitive decline 
or severe disease in these mice. Epidemiological studies investi-
gated the transmission of Alzheimer’s disease between humans 
in real life (Beekes et al., 2014). Available data indicates that 
Alzheimer’s disease is not likely to be spread between people. 
Blood transfusions do not cause a risk of Alzheimer’s in the re-
cipient, and neither does plasma protein therapy for hemophil-
ia. Another study examined the risk associated with receiving 
cadaveric human growth hormone, derived from the pituitary 
gland of the deceased. Such growth hormone has caused over 
200 cases of iatrogenic Creutzfeldt-Jakob disease because of 
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PcPSc seeds that contaminated the hormone and caused the 
prion disease in the recipient. In this study, researchers found 
small amounts of amyloid-β in the pituitary glands of the recip-
ient. Yet, none of the recipients studied developed Alzheimer’s 
disease. Based on these studies, as similar as Alzheimer’s dis-
ease is to prion diseases, there is an essential difference when 
it comes to disease transmission. Although seeding effects of 
Amyloid-β can somewhat cause neurotoxicity, it does not cause 
the neurodegenerative a cognitive impairment characteristic of 
Alzheimer’s (Beekes et al., 2014).
Environmental Effects on Neurodegenerative 
Disease: Mystery Disease in Guam is Similar to 
Alzheimer’s
The environment can have a role in the development of neu-
rodegenerative diseases such as Alzheimer’s. On the Island of 
Guam, many of the native villagers, known as Chamorros, suffer 
from a debilitating neurodegenerative disease with symptoms 
similar to Alzheimer’s disease, amyotrophic lateral sclerosis 
(ALS), and Parkinson’s disease (Cox et al., 2016). The illness 
caused paralysis, shaking, and dementia at 50-100 times the in-
cidence of ALS worldwide (Holtcamp 2012). This disease was 
first described in the 1950’s by US Army physicians, who called 
it amyotrophic lateral sclerosis/Parkinsonism dementia complex 
(ALS/PDC). Amyloid-β plaques and neurofibrillary tangles were 
present in the brains of Chamorros who developed this mys-
tery disease. Although in some villages a quarter of adults died 
from this disease, no distinct pattern of heredity was apparent. 
Because outsiders who adopted the Chamorro lifestyle were 
also affected, the cause of this disease seemed likely to be an 
environmental toxin (Cox et al., 2016).
The BMAA Hypothesis
There was difficulty in determining the exact nature of the 
toxin because symptoms could appear years after the expo-
sure. However, researchers were able to isolate the neurotox-
in β-N-methylamino-L-alanine (BMAA) from the cycad seed, 
which the Chamorros use to make flour, a staple in their diet. In 
the 1980’s, BMAA was fed to macaques which caused acute neu-
rological symptoms. However, these results were disregarded 
when it was shown that a human would have to consume an 
inordinate amount of cycad seed flour to ingest a comparable 
dose (Cox et al., 2016). Paul Alan Cox, an ethnobotanist, arrived 
in Guam in the 1990’s and revived the hypothesis that BMAA 
causes ALS/PDC seen in the natives (Holtcamp 2012). With 
his colleague Sandra Banack, he was able to show that BMAA 
was produced by a symbiotic cyanobacteria living in specialized 
cycad roots. BMAA accumulates in the gametophytes of the 
cycad seeds that are ground and eaten by the villagers. Cox then 
showed that animals such as flying foxes, feral deer, and pigs all 
feed on the cycad seeds, which are then eaten by the Chamorro 
people. BMAA is biomagnified in these mammals 10, 000 times 
that which is produced by the cyanobacteria. This process of 
biomagnification allows a sufficiently toxic amount of BMAA 
to accumulate in the food chain that it can cause neurological 
symptoms in the Chamorro people. This problem is not limited 
to Guam. BMAA producing cyanobacteria live in many marine 
ecosystems that biomagnify BMAA up the food chain, accumu-
lating in sharks, bottom-dwelling fish, and shellfish (Cox et al., 
2016). People who eat these organisms are at risk of BMAA 
ending up in their brain tissue.
Mechanism of Toxicity of BMAA
BMAA is readily able to cross the blood-brain barrier into 
the brain and central nervous system. It is mistaken for 
L-serine by the cellular mechanism and misincorporated into 
proteins, leading to misfolding, aggregation, and apoptosis of 
the cell (Cox et al., 2016). In normal proteins, the hydrophilic 
part is on the outside of the structure and the hydrophobic 
part is on the inside. However, because of protein misfolding 
due to the incorporation of BMAA, the hydrophobic part can 
end up on the outside, exposed. These hydrophobic areas are 
sticky and tend to clump together forming the characteristic 
aggregates of neurodegenerative plaques. These small aggre-
gates end up forming larger ones that prevent the cells from 
functioning properly (Holtcamp 2012). A misincorporation 
rate of even 1 in 10,000 has been shown to have a neurode-
generative effect in laboratory animals. BMAA can also result 
in phosphorylated tau by activating mGluR5, a metabotropic 
glutamate receptor, which decreases the activity of protein 
phosphatase 2A (PP2A). PP2A is significantly decreased in 
Chamorro ALS/PDC brains, resulting in an increase of phos-
phorylated tau (Cox et al., 2015).
Neuropathology Caused by BMAA in an 
Animal Model
To further prove that BMAA is responsible for the neuro-
degenerative disease, Cox and his colleagues conducted an 
experiment in which they attempted to show that chronic 
exposure to BMAA causes neuropathology and that BMAA 
can be re-isolated from the induced organisms. Vervets, a type 
Figure 1: Mechanism of prion mediated misfolding of protein  
(Sanders 2015
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of non-human primate, were the subject of this study. The 
vervets in this experiment were exposed to L-BMAA in their 
diets for 140 days, and then the brain tissue was examined for 
tau and amyloid deposition. Sixteen juvenile vervets divided 
into 4 cohorts of 4 were used in this experiment. The first 
cohort of vervets was given a piece of fruit dosed with 651 
mg of L-BMAA. Because L-serine has been shown to prevent 
misincorporation of BMAA into proteins, a cohort was given 
was given 651mg of L-BMAA and 651 mg of L-serine. A third 
cohort was given just 651 mg of L-serine. Finally, a control 
group was given a piece of fruit with 651 mg of rice flour as 
a placebo. A second experiment was done using adult vervets, 
also using four cohorts. The first cohort was given 987 mg of 
L-BMAA. The second was given 98.7 mg of L-BMAA, a tenfold 
reduction. The third was given 987 mg of L-BMAA, and 987 mg 
of L-serine. The fourth, a control, had 987 mg of rice flour as a 
placebo (Cox et al., 2016). 
In the first experiment, the vervets that received L-BMAA 
had neurofibrillary tangles and sparse amyloid-β plaque 
buildup in many areas of the brain. In contrast, the cohort 
that received L-serine and the control cohort did not show 
signs of amyloid-β or tau inclusions. The cohort that received 
an equal amount of L-BMAA and L-serine showed an 80-90% 
reduction in amyloid-β plaques and neurofibrillary tangles. 
In the second experiment, all BMAA exposed vervets de-
veloped hyperphosphorylated tau proteins and neurofibril-
lary tangles. The density of the neurofibrillary tangles in the 
brain was clearly related to the dose of BMAA administered. 
Besides for the control cohort, the low dose cohort had 
the lowest median count of neurofibrillary tangle density; the 
median density of the high dose cohort was more than twice 
the levels of the low dose cohort. The cohort that received 
both high dose BMAA and L-serine had a 50% decrease of 
neurofibrillary tangles compared to the high dose cohort. 
Exposure to BMAA also increased the chances of developing 
amyloid-β deposits, which were not found in any of the con-
trol vervets (Cox et al., 2016).
This study shows that dietary exposure to BMAA can cause 
the formation of neurofibrillary tangles and deposition of 
amyloid-β (Figure 2).  BMAA-producing cyanobacteria live 
worldwide and can have an important effect on human 
health. BMAA may possibly act as an initiator for sporadic 
Alzheimer’s disease by triggering the formation of amyloid 
plaques and neurofibrillary tangles. This study also indicates 
that L-serine is able to reduce the risk of formation of the 
characteristic plaques and tangles in the brains tissue of af-
fected individuals, and that L-serine may have a possible ther-
apeutic role in the treatment of mild cognitive impairment 
and early Alzheimer’s disease (Cox et al., 2016).
Conclusion
This paper investigated three seemingly unrelated mechanisms 
that have been proposed to cause the neuropathology seen in 
Alzheimer’s disease. Although the means of each method re-
viewed are very different, they have all been studied as a po-
tential cause of the buildup of the characteristic plaques and 
tangles present in the disease. Alzheimer’s disease is a public 
health problem; it is the sixth-leading cause of death in the 
United Stated, and fifth among people 65 and older (Alzheimer’s 
Association). Therefore it is important to study various models 
of the mechanism of the disease in the hope of gaining a better 
understanding of it, and eventually finding a cure. These three 
models may seem disconnected from each other, but in reality, 
Alzheimer’s disease is a complex disease. There are multiple fac-
tors involved that cause a person to develop Alzheimer’s related 
neurodegeneration; there is no one “correct” model. The three 
mechanisms discussed are only part of the multipart picture, 
and yet they are important to understand to get a complete 
understanding of the various pathways that lead to this disease. 
Figure 2: Theoretical pathways of development of ALS/PDC and 
Alzheimer’s disease neuropathology from dietary BMAA exposure 
causing neurofibrillary tangles and amyloid-β plaques  (Cox et 
al ,2016)
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By examining different routes, hopefully some light will be shed 
on questions like; why, if two people have a genetic predisposi-
tion, does one develop Alzheimer’s and one does not? Only by 
studying the causes will we ever discover a cure to the disease 
that affects so many.
References
Alzforum. Research models: 5XFAD. http://www.alzforum.org/
research-models/5xfad. Accessed January 3, 2017.
Alzheimer’s Association. 2016 Alzheimer’s disease latest facts 
and figures. http://www.alz.org/facts/. Accessed January 4, 2017. 
Boehm-Cagan A, Bar R, Liraz O, Bielicki J, Johansson J, Michaelson 
D. ABCA1 Agonist  Reverses the ApoE4-Driven Cognitive and 
Brain Pathologies. Journal Of Alzheimer’s Disease [serial online]. 
September 29, 2016;54(3):1219-1233. Available from: CINAHL  
Complete, Ipswich, MA. 
Beekes M, Thomzig A, Schulz-Schaeffer W, Burger R. Is there 
a risk of prion-like disease transmission by Alzheimer- or 
Parkinson-associated protein particles? Acta Neuropathologica 
[serial online]. October 2014;128(4):463-476. Available from: 
PsycINFO, Ipswich, MA. 
Castellani R, Perry G, Smith M. Prion disease and Alzheimer’s dis-
ease: Pathogenic overlap. Acta NeurobiologiaeExperimentalis 
[serial online]. 2004;64(1):11-17. Available from: PsycINFO, 
Ipswich, MA. 
CDC. Alzheimer’s disease. Centers for disease control and 
prevention. https://www.cdc.gov/aging/aginginfo/alzheimers.htm. 
Accessed December 27, 2016.
Cox P, Davis D, Mash D, Metcalf J, Banack S. Dietary exposure 
to an environmental toxin triggers neurofibrillary tangles and 
amyloid deposits in the brain. Proceedings.Biological Sciences 
/ The Royal Society [serial online]. January 27, 2016;283(1823)
Available from: MEDLINE, Ipswich, MA. 
Elezgarai S, Biasini E. Common therapeutic strategies for prion 
and Alzheimer’s diseases.Biological Chemistry [serial online]. 
July 6, 2016;Available from: MEDLINE, Ipswich, MA. 
Holtcamp W. The emerging science of BMAA: Do cyanobac-
teria contribute to neurodegenerative disease? Environmental 
Health Perspectives. 2012;120(3):A110-A116. https://ehp.niehs.
nih.gov/120-a110/. 
Jeffrey M. Review: Membrane-associated misfolded protein 
propagation in natural transmissible spongiform encephalopa-
thies ( TSEs), synthetic prion diseases and Alzheimer’s disease.  
Neuropathology & Applied Neurobiology [serial online]. June 
2013;39(3):196-216. Available from: Academic Search Complete, 
Ipswich, MA. 
Kane M, Lipinski W, Walker L, et al. Evidence for seeding of beta 
-amyloid by intracerebral 
infusion of Alzheimer brain extracts in beta -amyloid precur-
sor protein-transgenic mice. The Journal Of Neuroscience: The 
Official Journal Of The Society For Neuroscience [serial on-
line]. May 15, 2000;20(10):3606-3611. Available from: MEDLINE, 
Ipswich, MA. 
Laurén J, Gimbel D, Nygaard H, Gilbert J, Strittmatter S. Cellular 
prion protein mediates 
impairment of synaptic plasticity by amyloid-β oligomers. 
Nature [serial online]. February 26, 2009;457(7233):1128-1132. 
Available from: Academic Search Complete, Ipswich, MA. 
Liraz O, Boehm-Cagan A, Michaelson D. ApoE4 induces Aβ42, 
tau, and neuronal pathology in the hippocampus of young target-
ed replacement apoE4 mice. Molecular  Neurodegenerat ion 
[serial online]. May 17, 2013;8:16. Available from: MEDLINE, 
Ipswich, MA. 
Liu C, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer 
disease: risk, mechanisms  and therapy. Nature Reviews. 
Neurology [serial online]. February 2013;9(2):106-118.  Available 
from: MEDLINE, Ipswich, MA. 
NIH. Looking for the causes of AD. National Institute of Aging. 
https://www.nia.nih.gov/alzheimers/publication/part-3-ad-re-
search-better-questions-new- answers/ looking-causes-ad .
Accessed December 27, 2016.
Prion Alliance.What are human prion diseases? 2013, December 
2, Retrieved December 25, 2016, from http://www.prionalliance.
org/2013/12/02/ what-are-human-prion-diseases/
Sanders D, Kaufman S, Diamond M, et al. Distinct tau prion 
strains propagate in cells and mice 
and define different tauopathies. Neuron [serial online]. June 18, 
2014;82(6):1271-1288. Available from: MEDLINE, Ipswich, MA. 
Sanders L. Alzheimer’s acts like prion disease. Science News 
[serial online]. October 17,  2015;188(8):12. Available from: 
MAS Ultra - School Edition, Ipswich, MA. 
Seeley WW, Miller BL. Alzheimer’s Disease and Other 
Dementias. In: Kasper D, Fauci A,  Hauser S, Longo D, 
Jameson J, Loscalzo J. eds. Harrison’s Principles of Internal  
Medicine, 19e. New York, NY: McGraw-Hill; 2015. 
Simonovitch S, Schmukler E, Pinkas-Kramarski R, et al. 
Impaired Autophagy in APOE4  Astrocytes. Journal Of 
Alzheimer’s Disease: JAD [serial online]. 2016;51(3):915-927.  
Available from: MEDLINE, Ipswich, MA. 
Weissmann C, Enari M, Klöhn P-C, Rossi D, Flechsig E. 
Transmission of Prions. Journal  Of Infectious Diseases 
[serial online]. December 2, 2002;186:S157. Available from:  
Academic Search Complete, Ipswich, MA. 
23
Introduction
Alzheimer’s and Type 2 Diabetes are two of the most common 
diseases afflicting the elderly population today. A 2016 Report 
by the Alzheimer’s Association found that of the 5.4 million 
Americans with Alzheimer’s, an estimated 5.2 million people 
are age 65 and older (Alzheimer’s Association, 2014).  Similarly, 
the American Diabetes Association reported that in 2012, of 
the 29.1 million Americans with Diabetes, an estimated 11.8 
million people were age 65 and older (American Diabetes 
Association, 2012). The two conditions have traditionally been 
treated as independent disorders.  However, recent studies link-
ing Alzheimer’s to Type 2 Diabetes have led to the proposal that 
Alzheimer be referred to as “Type 3 Diabetes”. Discoveries of 
common pathological mechanisms between these two diseas-
es have given rise to novel clinical trials incorporating diabetes 
therapies to treat Alzheimer’s disease.
Methods
A variety of literary reviews and research papers on the subject 
were collected through use of the PubMed database. Keywords 
such as Alzheimer’s disease, insulin resistance and Type 2 Diabetes 
were used to search for relevant material. Access to PubMed was 
provided by the Touro College online library system.
Pathophysiology of Alzheimer’s and Type 2 
Diabetes
Alzheimer’s disease is a neurodegenerative condition, which 
results in nerve cell death and tissue loss throughout the brain 
(Li, Z et al., 2015).  Scans of brains of individuals suffering from 
Alzheimer’s demonstrate severe shrinkage of the hippocampus 
and cerebral cortex, as well as the enlargement of the ventricles 
(Querfurth et al., 2010).
The pathophysiology of Alzheimer’s disease is described by 
the amyloid cascade hypothesis. Cleavage of amyloid precur-
sor protein (APP) leads to the formation of the protein amy-
loid beta.  Excessive cleavage of APP coupled with inefficient 
removal of amyloid beta can lead to the formation of amyloid 
beta plaques in the brain.  These plaques damage and destroy 
brain cells by blocking cell-to-cell signaling at synapses (Reitz, 
2012). Amyloid beta plaques have also been shown to cause 
apoptosis.  The presence of amyloid plaques in the brain gener-
ates the production of harmful oxidative free radicals which in 
turn activates the c-Jun N-terminal kinase (JNK) pathway. The 
JNK pathway stimulates the transcription of several key target 
genes, including the death inducer Fas ligand. The binding of 
Fas ligand to its receptor Fas then induces a cascade of events 
that lead to caspase activation and ultimately neuronal cell 
death. (Yoshiyuki et al., 2001).
The tau protein also plays an important role in Alzheimer’s dis-
ease (Lasagna-Reeves CA et al., 2012). This protein is integral 
to maintenance of internal support and transport systems be-
tween brain cells. Hyperphosphorylation, which is the addition 
of phosphate to too many amino acids, leads to the collapse of 
tau proteins into twisted strands referred to as neurofibrillary 
tangles (Jack et al., 2013). Without the support of the tau pro-
tein, the transport system in the brain collapses. Consequently, 
essential nutrients are unable to reach brain cells and cell death 
ensues (Gong and Iqbal, 2008).
Diabetes is a metabolic disorder which develops when the body 
does not make enough insulin or is unable to use insulin effec-
tively. (Yarchoan and Arnold, 2014). If left untreated, diabetes can 
cause many complications, including kidney failure, diabetic ke-
toacidosis, heart disease and stroke (Schnell et al., 2016).  Type 
2 Diabetes is characterized by an insulin resistant state which 
is most commonly caused by obesity (Smith and Kahn, 2016). 
In insulin resistance, muscle, fat, and liver cells do not respond 
properly to insulin and thus cannot easily absorb glucose from 
the bloodstream. As a result, the body needs higher levels of 
insulin to help glucose enter cells. The pancreatic beta cells ini-
tially increase their insulin output but fail over time to keep up 
with the body’s increased demands for insulin. Type 2 diabetes 
develops when insulin production is inadequate to overcome 
insulin resistance, resulting in the drastic rise in blood glucose 
levels (Yarchoan and Arnold, 2014). 
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Discovery of Insulin Resistance in Alzheimer’s 
Disease
Insulin receptors are widely distributed in brain regions known to 
be involved in memory function, including the hippocampus, cere-
bral cortex and cerebellum (Werther et al., 2015).  Clinical studies 
have found evidence for central insulin resistance in Alzheimer’s 
brains. Post-mortem studies of brain tissues from people with 
Alzheimer’s disease have discovered extensive abnormalities in 
insulin and insulin-like growth factor signaling mechanisms in 
the brain (Steen et al., 2005).  A study of post-mortem human 
hippocampus Alzheimer’s tissue was done by exposing the tissue 
to different concentrations of insulin. This allowed researchers 
to study the activation of insulin pathways in the brain tissue of 
people with Alzheimer’s compared to the brain tissue of those 
with normal cognitive function. In normal brains, activation of 
the insulin receptor initiated a signaling cascade which led to the 
production of many downstream insulin signaling proteins. The 
blunted insulin response observed in the Alzheimer’s brain tissues 
was similar to the insulin resistance observed in Type 2 diabetes 
peripheral tissues (Talbot et al., 2012).
The formation of amyloid beta plaques has been implicated as 
a possible impetus for the removal of insulin receptors in brain 
cells.  Studies of Alzheimer’s brains have demonstrated that the 
binding of amyloid beta oligomers to hippocampal neurons trig-
gers the removal of dendritic insulin receptor substrates from 
the outer membrane of the cell (Xie et al., 2002). These studies 
prove that elevated amyloid beta levels induce the removal of cell 
surface insulin receptors, thereby furthering insulin resistance.
A molecular model has been proposed to explain how the am-
yloid beta plaques found in Alzheimer’s disease promote insulin 
resistance (Dineley et al., 2014).  This model is based on the in-
flammatory pathway observed in Type 2 Diabetes, where inflam-
matory cytokines play an important role in establishing insulin 
resistance.  Signaling from the inflammatory cytokine Tumor 
Necrosis Factor (TNF) stimulates JNK (Hoeks et al., 2012). 
Activation of the JNK pathway by TNF results in serine phos-
phorylation of the insulin receptor (Zhao et al., 2008). In order 
to be activated, phosphorylation of the insulin receptor must 
occur at a tyrosine residue.  Addition of the phosphate group at 
the serine amino acid in individuals with Type 2 Diabetes results 
in inhibition of the insulin receptor (Bomfim et al., 2012).
In a similar fashion, inflammatory cytokines induced by the pres-
ence of amyloid beta in the brain can lead to insulin resistance in 
Alzheimer’s.  Recent work suggests that soluble misfolded amy-
loid beta can induce inflammatory cytokines through an inflam-
matory pathway known as NF-κB-inducing kinase (NIK). The 
resulting inflammatory state induces insulin resistance through 
feedback inhibition of the insulin receptor (Carrero et al., 2012). 
In this case the many signaling chemicals produced by the in-
flammatory pathway stop the activity of the insulin receptor 
(Talbot et al., 2012).
Insulin resistance may promote Alzheimer pathology through 
several mechanisms.  Firstly, abnormal insulin signaling may 
promote amyloid beta and hyperphosphorylated tau formation 
through the kinase GSK-3.  The activity of GSK-3 is normally 
regulated through inhibition by the protein AKT, which is an im-
portant kinase in the insulin signaling cascade referred to as the 
IRS-1 –AKT pathway (Yarchoan and Arnold, 2014).  Therefore, 
dysfunctional insulin signaling caused by disturbances in the 
IRS-1 –AKT pathway leads to increased GSK-3 activity.  Studies 
of GSK-3 found that its activity increases tau protein phosphor-
ylation (Li, X et al., 2006) and that it is involved in amyloid beta 
production (Takashima, 2006).
Abnormal insulin signaling also interferes with memory and 
learning pathways.  Insulin is a direct regulator of the ERK/MAP 
kinase pathway.  This pathway is essential to the induction of 
longer term potentiation (LTP) and memory consolidation in 
the hippocampus (Winder 1999).   LTP is responsible for the 
maintenance of long term memory, which is the ability to recall 
episodes which are not part of the immediate past (Kelleher et 
al., 2004).  Disruptions of LTP and memory consolidation con-
tribute to the impaired cognitive function typified by Alzheimer’s 
disease (Dineley et al., 2014).
Discussion: New Role for Diabetes Drugs as a 
Treatment for Alzheimer’s
Given the role of insulin resistance and deficiency in the patho-
genesis of Alzheimer’s disease, it is possible that a drug current-
ly prescribed for Type 2 Diabetes may able also be useful for 
Alzheimer’s.  Various diabetes drugs are under study to test for 
their potential activity in Alzheimer’s.  This section provides an 
overview of the various clinical studies which assess the po-
tential prospects of using the diabetes drugs insulin and amylin, 
as well as the weight loss hormone leptin, to treat Alzheimer’s.
Insulin
The administration of exogenous insulin has predictably become 
a prime focus of the effort to treat insulin signaling dysfunction 
in Alzheimer’s.  Clinical trials have demonstrated that insulin ad-
ministration acutely affects behavior and cognitive performance 
in both healthy individuals and those suffering from Alzheimer’s. 
A 2001 study assessed the effects of peripherally administered 
insulin infusion in non-impaired individuals (Kern et al., 2001). 
Two groups were infused with insulin for 6 hours, one at a high 
rate and the other at a low rate. Any effects of the insulin ad-
ministration on blood glucose concentrations were counteract-
ed by constant glucose infusions.  Comparison of the results 
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of the high rate insulin and low rate insulin treatment groups 
indicated an improvement in the cognitive function of the high 
rate insulin group.  Subjects exposed to higher insulin infusion 
rates demonstrated changes in auditory-evoked potentials, had 
enhanced memory as evidenced by improved word recall and 
improved cognitive flexibility as measured by the Stroop test. 
Similar benefits of peripheral insulin administration on cogni-
tive function were observed in individuals with Alzheimer’s. In a 
1999 study, Alzheimer’s patients showed improved story recall 
and attention during insulin infusion relative to saline infusion 
(Craft et al.,2012).
Despite the results of these clinical trials, there are two main 
concerns that must be addressed with regards to utilizing pe-
ripheral insulin administration as a treatment for Alzheimer’s. 
Firstly, peripherally administered insulin cannot bypass the blood 
brain barrier in order to enter the central nervous system (CNS) 
and is therefore unable to affect and improve brain function. 
Secondly, peripheral insulin infusions can induce hypoglycemia. 
Hypoglycemia is a condition characterized by abnormally low 
blood glucose which can lead to a seizure or unconsciousness 
if left untreated. Although hypoglycemia was mitigated by simul-
taneous glucose infusions in both studies involving peripheral 
insulin administration, this solution is highly impractical outside of 
a research setting (Yarchoan and Arnold, 2014).
In light of these concerns, intranasal insulin is considered to be 
the best method for insulin delivery in Alzheimer clinical trials. 
Insulin that is delivered nasally bypasses the blood brain barrier 
and is rapidly delivered into the cerebrospinal fluid from where 
it can easily enter the CNS (Mao et al., 2016).  Additionally, be-
cause intranasal insulin is preferentially delivered to the CNS, it 
is possible to achieve clinically relevant insulin concentrations 
in the CNS without causing systemic hypoglycemia (Yarchoan 
and Arnold, 2014).
Pilot clinical trials using intranasal insulin have had successful re-
sults. A 2008 clinical trial reported that delivery of intranasal insulin 
for 21 days improved story recall, attention and caregiver-rated 
functional status in cognitively impaired subjects or individuals with 
Alzheimer’s (Reger et al., 2008). In another clinical trial subjects 
given insulin spray over a placebo demonstrated improved delayed 
memory and cognitive function (Craft et al., 2012). 
One study sought to illustrate the underlying mechanisms 
through which intranasal insulin ameliorates Alzheimer’s pathol-
ogy (Mao et al., 2016).  APP/PS1 mice possessing the patholog-
ical features of Alzheimer’s disease received intranasal insulin 
treatments for a total of 6 weeks, while a control group re-
ceived saline treatments. Tissue samples were harvested from 
both groups upon the conclusion of the treatment period.  
In order to determine whether intranasal insulin enhances brain 
insulin signaling, the respective levels of key components of the 
insulin signaling pathway, such as the insulin receptor beta-sub-
unit (IRB) and protein B kinase (AKT), were measured through 
Western Blot analysis.    Tissue from healthy wild type mice was 
also analyzed to serve as a reference marker of normal levels. 
The total levels of IRB and AKT were significantly decreased 
in the saline treated APP/PS1 mice compared with wild-type 
controls. However, the levels of IRB and AKT in the mice which 
received intranasal treatment were closer that of the wild-type 
mice, indicating that intranasal insulin treatment can partially 
protect APP/PS1 mice from brain insulin signaling deficits.
Intranasal insulin was also shown to reduce the activation of 
JNK in APP/PS1 mice.  Activation of the JNK pathway results 
in serine phosphorylation of the insulin receptor and induces 
apoptosis.  The level of phosphorylation of JNK was significantly 
increased in the hippocampus of saline-treated mice compared 
with wild-type controls, signifying that intranasal insulin reduces 
JNK activation.  
Immunohistochemical analysis of the tissue samples measured 
the amounts of amyloid beta plaque deposits in the brains of 
the APP/PS1 mice.  The number of amyloid plaques in the APP/
PS1 insulin-treated mice was significantly reduced in both the 
hippocampus and cortex compared to the saline control group. 
It was also discovered that the area of amyloid beta plaques 
was significantly decreased in both the hippocampus and cortex 
of the insulin treated mice.  Additionally, quantitative analysis 
revealed substantially reduced soluble amyloid beta oligomers 
in insulin-treated APP/PS1 mice.  This revelation is especial-
ly significant considering that soluble amyloid beta oligomers 
are considered the most neurotoxic form of amyloid beta. 
Enhanced neurogenesis was also observed in the insulin-treated 
APP/PS1 mice. It was shown that intranasal insulin significantly 
increased levels of DCX, a marker of neurogenesis.  The overall 
conclusions of the study were that intranasal insulin treatment 
improves cognitive deficits, ameliorates defective brain insulin 
signaling, strongly reduces amyloid beta plaque formation, inhib-
its JNK activation and promotes neurogenesis in APP/PS1 mice.
Despite the successful results observed in studies involving 
intranasal insulin treatment, there is concern that chronic hy-
perinsulinemic conditions in the brain may actually promote 
brain insulin resistance.  Excessive exposure to insulin in mice 
has been shown to lead to abnormal phosphorylation of key 
components of the insulin signaling pathway, such as AKT and 
GSK-3, in a manner consistent with insulin resistance (Kim et 
al., 2011).  It may therefore be beneficial to explore avenues 
of diabetes treatments which restore the byproducts of insulin 
signaling without directly affecting insulin levels.
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Amylin 
Amylin is a metabolic hormone which is co-secreted with insu-
lin by pancreatic beta cells (Adler et al., 2014). Amylin’s systemic 
effects in diabetic patients include the lowering of blood glucose 
levels through delayed gastric emptying, increased satiety, and 
decreased secretion of glucagon, which is an antagonist of insu-
lin (Yarchoan and Arnold, 2014).  
Amylin’s signaling activity has the potential to alleviate the 
detrimental effects of insulin resistance in Alzheimer’s dis-
ease. Amylin binds to independent receptors in the brain to 
activate signaling pathways that converge with insulin signaling. 
Amylin activates the production of the protein AKT, which is 
needed for the proper regulation of GSK-3, a protein which 
can lead to increased production of amyloid beta plaques and 
hyper phosphorylated tau (Moon et al., 2011).  Amylin is also 
a known modulator of the ERK signaling cascade, a pathway 
significant in the maintenance of long term memory and mem-
ory consolidation (Adler et al., 2014).  An advantage of using 
amylin as a medication is that it poses no risk of hyperinsulin-
emia, as it can activate the insulin pathway without interfering 
with the concentration of insulin in the body (Yarchoan and 
Arnold, 2014).  
One study investigated the potential outcomes of using amylin 
as a treatment for Alzheimer’s.  The first part of the study com-
pared plasma human amylin levels between individuals with 
Alzheimer’s or mild cognitive impairment and individuals with no 
cognitive impairments (Adler et al., 2014).  The results showed 
significantly lower amylin levels among subject with Alzheimer’s 
and mild cognitive impairments compared to individuals with no 
cognitive deficits.  With this correlation between amylin levels 
and cognitive function established, a follow-up study was con-
ducted in order to investigate the effects of amylin administra-
tion on Alzheimer’s pathology.  A senescence-accelerated prone 
(SAMP8) mouse was selected as a model of Alzheimer’s related 
dementia, because it displays multiple features known to occur 
early in the pathogenesis of Alzheimer’s including cortical atro-
phy, amyloid beta alterations, tau phosphorylation and severe 
deficits of learning and memory.  The SAMP8 mice were treated 
with either amylin or saline infusions for a total of 5 weeks.  Due 
to the tendency of amylin to aggregate into brain plaques in its 
natural form, a soluble analog of amylin called pramlintide was 
used in the study.  
The object recognition test was performed on the mice during 
the last week of the 5-week treatment period in order to assess 
the effects of amylin on cognitive function. The object recog-
nition test is a behavioral assay that is based upon the natural 
tendency of mice to investigate a novel object instead of a fa-
miliar one, as well as their innate tendency to restart exploring 
when they are presented with a novel environment.  The mice 
were placed in an open field box filled with different objects of 
various shapes and sizes.  After a series of trials, during which 
the mice habituated to the configuration and properties of 
the different objects, some of the objects were replaced with 
new ones to evaluate novel object recognition.  The pramlin-
tide-treated SAMP8 mice spent a greater proportion of time 
exploring the novel objects as compared with the familiar ob-
jects, whereas the saline-treated SAMP8 mice did not differ in 
time spent with the novel and familiar objects.  The behavior of 
the pramlintide-treated mice signified a marked improvement in 
their cognitive function.
Hippocampal tissue samples were harvested from the SAMP8 
mice in order to assess the effect of amylin on oxidative 
stress, an important pathologic feature of Alzheimer’s.  The 
protein levels found in the pramlintide-treated SAMP8 mice 
indicated a decrease in the molecular markers associated 
with oxidative stress and neuro-inflammation.  The pramlin-
tide-treated SAMP8 mice had significantly decreased expres-
sion of the protein H0-1 in the hippocampus compared with 
saline-treated mice.  HO-1 is a cellular stress protein that is 
activated during high oxidative stress and inflammatory states, 
and is also known to be increased in the cerebral cortex of 
Alzheimer’s brains.  The pramlintide-treated SAMP8 mice also 
had decreased levels of the lipid peroxidation adduct HNE 
and the enzyme COX-2.  HNE is a protein that is known to 
be an early and abundant cellular stress marker in Alzheimer’s 
brains, while C0X-2 is a classic marker of inflammation which 
is increased in Alzheimer’s brains.
The pramlintide-treated SAMP8 mice expressed high amount of 
proteins associated with synaptic activity and dendritic growth. 
Amylin was found to increase expression of hippocampal syn-
apsin I, a protein located in neuronal synaptic vesicles that is 
involved in synapse formation, neurotransmitter release, and 
learning and memory.  A robust increase in CDK5 was also ob-
served in the hippocampus of the pramlintide-treated SAMP8 
mice. CDK5 is a kinase which plays an intimate role in synaptic 
plasticity, learning and memory in adult brains. 
The overall conclusions of the study were that chronic infusion 
of amylin in SAMP8 mice was found to improve memory per-
formance in object recognition tests, increase neural synaptic 
activity and decrease inflammatory markers in the hippocam-
pus. Amylin treatment improved both the cognitive status and 
Alzheimer’s pathology features of the SAMP8 mice.  
Another study also assessed the results of amyloid treatment 
on behavioral impairment and brain amyloid pathology in 
mouse models of Alzheimer’s disease (Zhu et al., 2015). The 
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study utilized 5XFAD Alzheimer mice which exhibit significant 
neuron loss.  The 5XFAD mice were treated with intraperito-
neal injections of either pramlintide or saline once daily for 10 
weeks.
The 5XFAD mice were tested for improvements in cognitive 
functions by going through a Morris water maze.  The Morris 
water maze test is used to determine hippocampal spatial 
memory deficits.  The test consisted of placing the rodent in a 
circular tank filled with cloudy water, which is used to motivate 
the animal to escape the water by swimming to a hidden plat-
form located in one quadrant of the pool. Over several days the 
rodent learnt to find the hidden platform by using spatial cues, 
such as posters or taped objects strategically placed on the walls 
outside of the water maze, in the testing room.  The pramlintide 
treatment improved the performance of the mice in the Morris 
water maze test, reducing the time necessary for memory ac-
quisition and retention during maze training as compared to 
the saline-treated control group.  The improved performance of 
the pramlintide-treated groups over the saline-treated groups 
in the Morris water maze test demonstrated that peripheral 
treatments with pramlintide improves learning and memory in 
the 5XFAD mice.
Pramlintide treatment was shown to have an effect on amy-
loid beta levels, one of the prime pathological hallmarks of 
Alzheimer’s. Immunoassays of brain tissue from the 5XFAD 
mice revealed that pramlintide-treated 5XFAD mice experience 
a reduction in both size and intensity of amyloid beta plaques 
in the cortex, hippocampus and thalamus and had decreased 
numbers of amyloid beta plaques in all areas of the brain with 
the exception of the hippocampus. Furthermore, comparison 
of amyloid beta serum levels from before and after the intra-
peritoneal pramlintide infusion revealed a significant increase in 
serum amyloid beta after the infusion.  These results indicate 
that pramlintide enhances the removal of amyloid beta from the 
brain and its transfer into the blood. 
The successful outcomes of these separate studies assessing the 
effect of pramlintide treatment on different Alzheimer’s mouse 
models indicate that amylin has potential to become a promis-
ing new avenue for the treatment of Alzheimer’s.  Amylin was 
shown to improve cognitive function, reduce oxidative stress 
markers, increase synaptic activity and enhance clearance of am-
yloid beta from the brain.
Leptin
Leptin is a chemical produced by fat tissues which activates the 
central nervous system to regulate food consumption and en-
ergy expenditure (Oomura et al., 2006). Although leptin has tra-
ditionally been studied in the context of obesity, recent studies 
have examined its neurological effects.  Leptin receptors are 
highly expressed in areas of the brain that are involved in learn-
ing and memory, such as the hippocampus (Li, X-L et al., 2002).  
A study was designed in order to assess leptin’s role in the 
regulation of hippocampal functions and the control of learn-
ing and memory processes (Li, X-L et al., 2002).    The study 
focused on leptin receptor-deficient mice.  The behavioral 
and molecular data obtained from the leptin receptor-defi-
cient mice was compared against a positive leptin receptor 
control group.  Both groups of mice were put through the 
Morris water maze task.  The leptin receptor-deficient mice 
swam greater distance than their positive controls before 
they found and climbed onto the hidden platform.  When 
the platform was removed, the leptin receptor-deficient mice 
crossed the original platform location fewer times than the 
positive control group. The hippocampus was removed from 
the leptin receptor-deficient rodents and the control group. 
Electrophysiological analysis of the hippocampal tissue of the 
leptin receptor-deficient mice showed impairments of long 
term potentiation (LTP) and long term depression (LTD).  The 
decreased cognitive behavior and impaired LTP and LTD pro-
cessing observed in the leptin receptor-deficient mice support 
the conclusion that leptin enhances LTP and regulates mecha-
nism involved in both learning and memory 
Leptin also appears to regulate a number of defining features 
of Alzheimer’s disease.  AMP- dependent kinase (AMPK) is 
known to regulate glycogen synthase kinase-3B (GSK-3B), a 
kinase which is crucial in the regulation of tau phosphorylation 
(Nikolaos et al., 2009).  It has been shown that leptin directly 
activates AMPK and thereby possesses the ability to modulate 
tau phosphorylation (Yu et al., 2004).  Leptin also facilitates the 
uptake of amyloid beta complexes via its regulation of the lipo-
protein receptor-like protein (Fewlass et al., 2004).  Thus, leptin’s 
activity directly affects the regulation of amyloid beta uptake 
and tau phosphorylation, two of the impaired pathophysiological 
features of Alzheimer’s disease. 
One study assessed the effects of leptin treatment on CRND8 
Alzheimer’s mouse models (Greco et al., 2010). The CRND8 
mice received daily treatments of leptin for a total of 8 weeks 
with a control group receiving saline infusions.  Leptin-treated 
mice spent statistically more time with the novel object com-
pared to the saline-treated control group during the object 
recognition test, indicating an improvement in working memory 
performance after leptin treatment.  Analysis of brain tissue from 
the CRND8 mice revealed that the leptin-treated group had 
reduced  amyloid beta levels in both brain and serum.  Staining 
of the brain tissue for amyloid fibers showed a significant de-
crease in amyloid burden in the hippocampus of the leptin 
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treated CRND8 mice, which was associated with a decrease 
in the average size of amyloid plaques.  There was no significant 
increase in the levels of the inflammatory molecule C-reactive 
protein, tumor necrosis factor or cortisol in the plasma of the 
leptin-treated group compared to the saline-treated group, in-
dicating that leptin does not induce an inflammatory reaction. 
The results of the study fully support the ability of leptin to 
ameliorate Alzheimer’s like pathological pathways, strengthening 
leptin’s potential of becoming a novel therapeutic treatment for 
Alzheimer’s disease.
Synergistic Effects of Amylin and Leptin
Leptin and amylin activate overlapping signaling cascades and 
ultimately converge on the insulin signaling pathway by activat-
ing AKT and increasing insulin sensitivity (Yarchoan and Arnold, 
2014). Recent studies have indicated that leptin and amylin sig-
naling appear to have synergistic properties.  
One study profiled hypothalamic neurons in order to deter-
mine the effects of amylin and leptin on hypothalamic activity (Li, 
Z et al., 2015).  It was discovered that hypothalamic expression 
of lapp, a precursor to amylin, was markedly decreased in mice 
with mutations in the gene regulating the production of amylin, 
but was normalized after infusions of leptin. The decrease of 
amylin expression in mice that had mutated leptin genes showed 
that hypothalamic amylin is a neuropeptide that is leptin regulat-
ed.  Additionally, AC187, an amylin antagonist, was found to blunt 
the activity of leptin and decreased its effects on neurons in the 
hypothalamus.  The presence of the amylin antagonist signifi-
cantly inhibited the effects of leptin on both leptin depolarizing 
and hyperpolarizing neurons.  The ability of an amylin antago-
nist to blunt the response of leptin suggests that amylin can 
modulate leptin’s effects.  Leptin and amylin were also found to 
have synergistic effects on hypothalamic neurons.  Patch clamp 
recordings demonstrated that the presence of either leptin or 
amylin elicited similar excitatory and inhibitory effects on hy-
pothalamic neurons.  Leptin excited 65% and inhibited 35% of 
the neurons, while amylin excited 62% and inhibited 38%.  The 
significant correlation between the effects of individual neurons 
exposed to both treatments indicates that amylin depolarizes 
the same neurons that are depolarized by leptin and hyperpo-
larizes the same neurons that are hyperpolarized by leptin. This 
suggests that the response of the neuron would be amplified 
upon simultaneous presentation of amylin and leptin.  
The synergistic potential of these two treatments has been 
explored with regards to treating obesity.  Stand-alone obesi-
ty treatments have proven unsuccessful because diet-induced 
obese (DIO) rats and obese humans are only minimally respon-
sive to even high pharmacological doses. Nonetheless, amylin 
possesses the ability to heighten leptin’s effects.  For this reason, 
one study found that doses of exogenous leptin that was high-
ly effective in lean rats had minimal effects on weight or food 
intake in DIO rats.  However, the results of the study showed 
that administration of amylin together with leptin resulted in a 
synergistic, fat-specific reduction in body weight in two inde-
pendent experiments (Roth et al., 2008). 
In light of this discovery, a clinical trial was designed in order to 
evaluate the weight-lowering effect of combined amylin/leptin 
(using pramlintide/mertreleptin) treatment in human obesity. 
A 24-week, randomized, double-blind, study was conducted in 
obese or overweight subjects. Subjects receiving pramlintide/
metreleptin lost almost 13% of their initial body weight over 
24 weeks, compared with only ~8% in subjects receiving ei-
ther pramlintide or metreleptin. Towards the end of the study, 
weight loss plateaued in subjects treated with monotherapy, 
but not in subjects treated with the combination. The overall 
results of the study showed that weight loss caused by the 
combination of leptin and amylin in humans was greater than 
the additive weight loss of each drug used alone (Ravussin et 
al., 2009).  
Thus far, there have been no studies to examine the efficacy of 
combination therapy of leptin and amylin to treat Alzheimer’s. 
The successful results observed in weight loss clinical trials sug-
gest that even greater improvements in memory in Alzheimer’s 
patients may be possible by using amylin and leptin as a com-
bined therapy.  
Conclusion
The discovery of insulin resistance in Alzheimer’s has given 
way to a growing interest in restoring insulin signaling in 
Alzheimer’s with therapeutic agents originally developed for 
the treatment of Type 2 Diabetes.  Intranasal insulin, amylin 
and leptin are examples of hormones typically associated with 
obesity and diabetes which have shown promise for treating 
Alzheimer’s disease.  An advantage of using amylin and leptin 
as medications for Alzheimer’s is that unlike with insulin, treat-
ment using these hormones pose no risk of inducing hyperin-
sulinemia, as they activate the products of the insulin signaling 
pathway without interfering with the concentration of insulin 
in the body.  Furthermore, weight loss studies have discovered 
that amylin and leptin are synergistic substances which pro-
duce significantly enhanced results when used in combination. 
This unique synergy suggests that achieving even greater im-
provements in memory may be possible by using amylin and 
leptin as a combined therapy for Alzheimer’s.  Further research 
will need to take place before the proposed combined therapy 
can be tested in a clinical trial and ultimately be distributed 
pharmaceutically. 
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Part I-Introduction:
The last three decades have witnessed an enormous increase 
in childhood obesity in the United States. It is estimated that at 
least 17% percent of children are currently overweight accord-
ing to the Centers for Disease Control and Prevention (CDC), 
and certain demographics like Hispanic and Black Americans 
display more alarming percentages.  As more children become 
classified as overweight, those already at risk for extreme obe-
sity are becoming even heavier. This becomes a grave concern 
because an adolescent develops an acute probability of becom-
ing an obese adult.  Consequently, childhood obesity has evolved 
into the most widespread predominant nutritional disorder af-
fecting American children that pediatricians address (Childhood 
Overwieght, 2014).
Contributors to Childhood Obesity
The factors that contribute to this serious health concern are 
numerous. The most obvious ones are food choices consumed 
in an individual’s diet, and average physical vs. sedentary activ-
ity. Less obvious but still pertinent are hereditary and genetic 
factors. There are numerous genetic alterations, or single gene 
mutations that are responsible for weight gain, although this is 
rarer (Childhood Overwieght, 2014). Parental obesity is a very 
significant indicator of a child’s potential for being overweight. 
Specifically, parental BMI preceding and during pregnancy is a 
dominant early‐life risk factor influencing BMI of offspring in 
adulthood. BMI is an acronym for body mass index which is a 
figure that relates weight to height and is obtained by dividing 
a person’s weight in kilograms by his or her height in meters 
squared (Definition of Body mass index, 2016).
In the Australian pregnancy cohort study, offspring of mothers 
who had not received a college education, smoked and gained 
excessive weight during pregnancy or had high BMIs preced-
ing pregnancy, had a higher chance of being obese at age 22. 
Paternal obesity, bottle fed babies and those who had a high 
birth weight had an increased risk of childhood but not neces-
sarily adult obesity (Rath et. al. 2016).
Physical Consequences of Childhood Obesity
Adolescents who suffer from extreme overweight issues are 
prone to a host of severe medical issues at every stage of life, 
amongst them problems that normally afflict only the senior 
population. A well-documented study indicates that the lifetime 
risk of being diagnosed with type 2 diabetes (a disease brought 
on by excess weight) is estimated at 30% for boys and 40% 
for girls. Other publicized studies of the health issues directly 
or indirectly caused by obesity include cardiovascular disease, 
hypertension, high cholesterol, and in some rare but disturbing 
incidents, heart attacks in children as young as 5 (Bagchi, 2011).
Children who suffer from these contributing factors to heart 
disease may be suffering from Metabolic Syndrome (MS), which 
refers to a group of risk factors that increases the danger of 
developing heart disease and other health problems, such as 
diabetes and stroke. (What Is Metabolic Syndrome?, 2016).
In a study to determine MS prevalence, 201 obese subjects aged 6 
to 18 were studied. The subjects in the study were diagnosed with 
MS if they had a BMI above the 97th percentile and met two or 
more of the following conditions: triglyceride level ≥ 1.7 mmol/L, 
HDL ≤ 1.03 mmol/L, fasting glucose ≥ 5.6 mmol/L, and arterial hy-
pertension (systolic blood pressure ≥ 130 mmHg and/or diastolic 
blood pressure ≥ 85 mmHg).   Of the 201 children and adolescents, 
110 (54.7%) subjects were moderately obese and 45.3% were cat-
egorized as severely obese. The frequency of MS was 24.5% in the 
group of moderately obese and 37.4% in severely obese subjects. 
The majority of children and adolescents in the study had one or 
two components of MS. This discovery highlights the significance of 
recognizing degrees of obesity in children and adolescents, which 
could theoretically influence different rates of displaying cardiovas-
cular risk factors (Šimunović et. al. 2016).
The obese pediatric population is also prone to developing 
nonalcoholic fatty liver disease (NAFLD). In a Japanese study 
conducted on NAFLD, researchers determined that more than 
10% of all obese children had at least modest increases in serum 
transaminases, which indicates liver damage, even if they hadn’t 
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developed full NAFLD. Other consequences of obesity include 
cholelithiasis, pseudotumor cerebri, obstructive sleep apnea, 
polycystic ovary syndrome, and orthopedic conditions such as 
slipped capital femoral epiphysis (Allcock., 2009).
Psychological Impact
Aside from the many alarming medical conditions these chil-
dren grapple with, the detrimental impact their circumstance 
can have on their emotional wellbeing can be devastating. Obese 
and overweight children often develop depressive symptoms 
that can lead to negative body image and put them at risk for de-
veloping an eating disorder. Consequently, these children suffer 
from low self-esteem, which can instigate behavior issues that 
may develop into learning difficulties (Childhood Overwieght, 
2014).  A well detailed study on the psychological effects of 
childhood obesity found that children aged 5 to adolescents 
aged 18 shockingly compared their quality of life to individuals 
undergoing chemotherapy treatment for cancer (Bagchi, 2011).
A study involving young school age girls was conducted to de-
termine how much behavior is impacted by weight. The study 
observed behavioral problems in 17%, 27%, and 2% of obese, 
overweight, and normal weight children, respectively. Cultural 
differences between varying countries didn’t impact the cor-
relation between the two factors and similarities were observed 
in most of the emotional-behavioral problems related to over-
weight and obesity. Internal emotional baggage, which includes 
anxiety, depression and withdrawal were seen in 11%, 15%, 
and 2% respectively, and external indicators of emotional dis-
turbance, including aggression and delinquent behaviors, were 
observed in 8%, 17%, and 2% in obese, overweight, and normal 
weight children, respectively. (Seyedamini, et. al. 2012) 
The data we have concerning childhood obesity and its correla-
tion to significant impact on the physical and emotional health 
of the child is concerning enough. But the consequences on 
health later in life also requires study. Thus, the essential ques-
tion in this field is: What effects will adolescent obesity have on 
the health of the child when s/he becomes an adult?
This paper will examine the various health issues that can sur-
face for individual who continue to suffer from extreme over-
weight into adulthood, in addition to proposing some solutions 
for those who fall into that category. 
Methods 
Information was obtained online with access to online publi-
cations through the Touro college library. Additional references 
were obtained through Pubmed. 
Part 2- Results and Discussion:
Correlation Between Childhood Obesity and 
Adult Obesity
Before determining what the medical impacts on adult health 
are due to childhood obesity,we need to answer a fundamental 
question: Do obese children become obese adults? According 
to the response of test subjects, roughly twice as many individ-
uals who reported that they were “considered a fat child” were 
more than 155% larger than what their ideal body weight should 
have been as young adult women, compared with women who 
did not report that they were “considered a fat child” (Rimm, 
1976).  Corpulence in infants leads to a twofold increase for risk 
of subsequent obesity. Another study concluded that the odds 
ratio for the persistence of obesity rises with age among obese 
children; endurance of obesity for overweight children hovered 
at 50%. Considering that this study was conducted before the 
enormous surge in childhood obesity in recent years, the cur-
rent figure would be even higher (Allcock et. al., 2009).
A study was conducted where 1,355 participants from the 
Australian Pregnancy Cohort were analysed. This represented 
an Australian birth group born between 1989 and 1991. There 
were 12 periodic intervals where mothers and children were 
surveyed starting from early pregnancy: birth, 1, 2, 3, 5, 8, 10, 14, 
17, 18, 20 and 22 years. The data collected provided researchers 
with an opportunity to track BMI patterns from birth to ma-
turity and to examine the significance of early-life contributing 
factors to obesity.
Factors that were investigated as possible causes of being ex-
tremely overweight were: sex, most advanced level of education 
of the mother (paternal education level not available), mater-
nal and paternal pre‐pregnancy BMI (based on recalled weight 
recorded at 18 weeks of pregnancy), maternal smoking during 
Figure 1 A diagram of a child’s obese body with labels on the parts 
of the body that can be affected by obesity (Williams, 2010)   
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pregnancy, maternal anemia and diabetes during pregnancy 
(pre-existing or gestational), and excessive pregnancy weight 
gain (change in weight from pre-pregnancy to 18 weeks and 
34 weeks’ gestation). These factors all represent pre-birth con-
ditions. Post-partum, other factors of influence were observed 
to be cesarean delivery, early birth, birth-weight, first-year 
growth and extent of breast-feeding.
BMI of the participants was recorded; to eliminate any gender 
discrepancy the BMI was standardized using z scores and stan-
dard deviations. A BMI higher than the 85th percentile was con-
sidered overweight and obesity was declared above the 95th 
percentile. In adulthood, these would correlate to BMIs of 25 
and 30 respectively. 
The results indicated that maternal and paternal BMI produced 
the strongest effect on offspring BMI, particularly in adolescence 
and early adulthood. Compared to children whose parents were 
not overweight, children at ages 14 and 22 with overweight 
mothers had more than 4 times the risk of developing obesity. 
This paled in comparison to children of obese mothers which 
predicted a 7to10-fold increase of risk. Paternal overweight al-
most tripled obesity risk at age 14 although it was determined 
to be non-impacting at age 22. But paternal obesity resulted in 
an almost fourfold increased risk of offspring obesity at both 
ages (Rath, 2016).
In an attempt to clarify the correlation between childhood and 
adult obesity, statistics were assembled from four longitudinal 
studies conducted between 1929 and 1960. The studies com-
pared the BMI at the target adult age of 35 to the BMI between 
1 and 18 years. BMI at age 13 usually predicted the BMI at 35 and 
the BMI at 18 was usually extremely accurate in predicting adult 
size. One study tracked the BMI of infants until the age of 21. At 
the study’s completion, 41% of the individuals that were lean at 
one year remained in the lean category and 41% of the fat infants 
remained in the fat category.  Further studies have projected that 
up to 81% of overweight (BMI greater than 85th percentile) ado-
lescents will become obese young adults. (Whitaker, 1997)
Researchers have also had to determine which BMI should be 
the cutoff point that ascertains obesity. They established that 
the likelihood that obesity will continue in 50% of adolescents 
identified by a BMI ≥95th percentile, or by a weight-for-height 
of 130%, which is slightly larger than a BMI ≥95th percentile, 
suggests that a BMI ≥95th for children of the same age and 
sex signifies a realistic cutoff point to identify lasting obesity. 
After establishing these percentage guidelines, researchers then 
had to establish the number adolescents that fall into these 
categories. The CDC has determined contemporary data that 
demonstrates that 31.9% of youth aged 2-19 are at or above the 
85th percentile, 16.3% are at or above the 95th percentile and a 
shocking 11.3% are at or above the 97th percentile of the 2000 
BMI-for-age growth charts. This indicates that approximately 
one in three individuals between the age of 2 and 19 years is 
either overweight or obese (Allcock., 2009).
Health Implications for Obese Adults
Now that we have determined the immense likelihood that 
obese children will morph into obese adults, we need to examine 
the health consequences this correlation presents. Individuals 
who suffer from childhood obesity are at risk for higher rates of 
developing disease as an adult as well as dying earlier.  This can 
be referred to as the impacts on adult morbidity and mortality, 
which is defined in the following way: Morbidity describes the 
unhealthy state of an individual while mortality occurrence of 
death in a population (Morbidity vs. Mortality, n.d.).
A 1988 follow up on the Third Harvard Growth Study of the 
early 1930s that tracked school-age youth into adulthood pro-
vided some insight into the effects on adult health and quality 
of life. Overweight participants were determined to be ado-
lescents who had more than two measurements of their body 
mass index (BMI) above the 75th percentile during high school. 
Subjects with a BMI between the 25th and 50th percentile 
throughout high school were classified as slim. The follow-up 
data was collected when the subjects were 55 years of age, 
and the results were modified to represent smoking status and 
reported weight. There was an extremely high correlation be-
tween disease and their excess childhood weight. Both males 
and females had increased rates of the classic diseases that 
afflict the obese population: diabetes, coronary heart disease, 
atherosclerosis, hip fracture and gout. The risk of these diseases 
was only slightly diminished after adjustment for smoking and 
adult weight. Only the risk of diabetes became insignificant after 
adjustment for lower adult weight; type 2 diabetes is known to 
be directly correlated to high weight  (Dietz, 1998).    
A Dutch study similarly sought to observe the impact of a high-
er BMI at age 18 on premature adult mortality from all causes. A 
group of over 78,000 Dutch men at the age of 18 were studied 
and tracked over a 32-year period. They found a higher inci-
dence of all-cause deaths in those individuals with a BMI >25 
(classified as overweight) compared to individuals with a BMI 
between 18 and 25 (Hoffmans, 1988).
Cardiovascular Disease and Risk Factors
Of all the diseases mentioned, the most severe are arguably 
cardiovascular. How does childhood obesity impact adult heart 
health, or lack thereof? With rising evidence to help conclude 
that childhood obesity is linked to adult obesity, the medical 
world has been grappling with the question as to whether obese 
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adults’ risk of cardiovascular disease (CVD) is increased by their 
pediatric obesity or just similar to weight-matched peers. 
The precise connection between obesity in youth and adult 
development of cardiovascular disease was researched in the 
Princeton Follow-up Study. As expected, the group that present-
ed symptoms of MS in childhood due to obesity had a dra-
matically increased risk of developing cardiovascular disease 25 
years down the road, compared with the group that didn’t suffer 
as children. In fact, MS in childhood was a stronger determinant 
of future cardiovascular disease in adulthood than was gender 
or even genetic history of cardiovascular disease. The youth in 
their initial study exhibited an adolescent incidence of MS of 4%. 
In the follow-up study, this had risen to 27.2% for adults. This 
study also demonstrated that risk of CVD increased by more 
than 24% for each 10 % increase of BMI (Allcock, 2009).
Researchers also wanted to establish the connection between 
weight change or maintenance from youth to adulthood and the 
subsequent development of MS. 
From 1993-4, a population study examining participants born 
between 1947-57 was implemented in Finland. Records of the 
7-year-old height and weight were obtained for 439 subjects. 
Obesity was delineated as the top third BMI measure and MS was 
diagnosed based on observations in the following areas: a systol-
ic blood pressure ≥140 mm Hg and a diastolic blood pressure 
≥90 mm Hg. If a patient was receiving treatment of antihyperten-
sive drugs they were considered to have high blood pressure as 
well. Other factors were:  dyslipidaemia (hypertriglyceridaemia 
≥1.70 mmol/l, low HDL cholesterol levels <1.00 mmol/l (<1.20 
mmol/l in women), insulin resistance (abnormal glucose metab-
olism according to the World Health Organization’s criteria or 
hyperinsulinaemia (≥78 pmol/l), or both). 
The number breakdown amongst the 439 subjects was as 
follows: 75 were obese as both adults and children, while 219 
weren’t obese for either age. Of these, 71 were obese adults 
who hadn’t been fat as children, and another 74 were over-
weight in their youth but not as adults. Eight per cent of men 
and 5% of women displayed symptoms of MS, which amounted 
to 30 individuals in total. Of  those people, 21% were obese 
adults and 21 had also suffered from childhood obesity. The 
study found that risk of MS was 2.9% for adults who had been 
obese as children but this figure increased to 26.7% for people 
who continued to obesity into adulthood. Interestingly there 
was a zero incidence of MS in the 74 people who had formerly 
been overweight but had since slimmed down.
The study concluded that ultimately childhood obesity augment-
ed the dangers for developing MS as an adult and that obese 
youth who grew to be obese adults had a particularly high risk 
of MS. Incredibly, the risk was lower in obese adults who had 
not been that way as children. This reinforces the theory that 
obesity determined prior to adulthood is more detrimental 
than late onset obesity. The probable explanation for this is that 
unceasing obesity serves as a “generator” for protracted insulin 
resistance, which is directly correlated to and causes hyperten-
sion and metabolic irregularities. The study results indicate that 
prevention of adult obesity and consequent MS and CVD risk 
is dependent on the earliest possible intervention for obese 
children to ensure they lose the weight (Vanhala, 1998).
One of the  indicators of CV.  is carotid artery intima-media 
thickness (IMT) and is recognized as an important predictive 
measure of clinical coronary atherosclerosis health issues in 
middle-aged and elderly populations.  Carotid artery IMT mea-
sures the thickness of the inner two layers of the carotid artery, 
the intima and media. A thickening of both is a measure used to 
diagnose the extent of carotid atherosclerotic vascular disease 
(Carotid Intima-Media Thickness Test, n.d.).
From September 1973 to December 1996, a study that inves-
tigated the effect of childhood adiposity on adult heart health 
examined a cohort of 486 participants from a community in 
Bogalusa, Louisiana. Surveys were conducted approximately 
every 3 to 4 years; 7 surveys examined children from the ages 
of 4 to 17 years while 5 surveys followed up with young adults 
aged 18 to 38 years, who had participated as children and re-
mained available. The premise of the study (observing children 
into adulthood over a 20-year span) enabled the researchers 
to measure the collective and snowballing effect of risk factors 
since childhood. The purpose of the study was to observe the 
link between carotid IMT in young adults and traditional cardio-
vascular risk factors measured since childhood.
Participants experienced the following procedure for each ex-
amination: Height and weight were obtained within a .1% range 
of error after the subject fasted for half a day. These measures 
were used to calculate BMI. Next, duplicate blood pressure 
measurements were taken. Systolic and diastolic blood pressure 
levels were evaluated 6 times and these levels were averaged for 
the final observation. 
The results found strong correlation coefficients between CVD 
risk factors measured since childhood and the carotid IMT in 
young adults: Overweight adolescents with high levels of LDL 
cholesterol (“bad” cholesterol) in childhood, high BMI and sys-
tolic blood pressure were interrelated with carotid IMT in young 
adults, with LDL-C level showing the highest correlation. As men-
tioned previously, this is concerning as high carotid IMT levels are 
strong indicators of developing cardiovascular disease. (Li S 2003)
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Prostate Cancer and Obesity
Prostate cancer has also been linked to obesity. When the pro-
longed nature of this disease is considered, it can be assumed 
that adolescent health may be an early life contributor. A num-
ber of studies of the correlation between prostate cancer and 
early life obesity. It is important to note that the results of the 
studies provided conflicting data: some observed a direct link 
between childhood BMI and prostate cancer risk, while others 
actually determined that increased BMI served as a protective 
measure against the disease.
A contemporary study that tracked 950,000 men for a 20-year 
span was conducted in Norway. The study determined that a 
BMI larger than 30 amplified the risk of prostate cancer by only 
9%. Conversely, the 50 to 59 age group of obese men had a 58% 
increased risk of prostate cancer but no younger age group pre-
sented a substantial risk. Another study that incorporated data 
from the Health Professionals Follow-up Study by Giovannucci 
and colleagues, discovered that an increased BMI was actually 
correlated to a decreased risk of prostate cancer among men 
younger than 60 years or those with a family history of the 
disease (Freedland and Aronson, 2004). 
Psychological Ramifications of Childhood 
Obesity into Adulthood
Aside from the obvious physical implications obesity presents, 
the Harvard Growth study also determined that additional 
psychological repercussions resulted when adult morbidity was 
linked to childhood obesity. In a large sample studied during the 
National Longitudinal Survey of Youth, surveyors revealed that 
obesity present in adolescent females had grave social conse-
quences several years later as an adult. Amongst them were: low 
marriage rates, decreased years of education, inferior net in-
comes and compounded poverty levels. The prevalence of these 
results, (after adjustment for the income and educational levels 
of the individual’s family as well as self-esteem) indicated that 
female obesity actually triggered these socioeconomic links, as 
opposed to being a result of these socioeconomic associations. 
This further demonstrates the detrimental impacts of adoles-
cent obesity on adult quality of life. (Dietz, 1998)
Part 3: Future- Preventions and Treatment
Youth Intervention Studies
Looking forward, it is incumbent on us as a society to prevent 
and treat obesity given all the severe and often fatal maladies 
obesity causes. So far, exploration of obesity prevention was 
conducted in only a limited number of studies. This may be for 
a host of reasons including a dearth of funding for public health 
and obesity investigation; insufficient prevention tactics, and 
overall inadequate training in medical education programs.  The 
prevention tactics targeting obesity on a small community-wide 
scale that have been used are the following: Targeting a com-
munity wide population with the goal of reducing the average 
BMI collectively, which is known as an intervention strategy. If a 
strategy narrows the scope to target only individuals already at 
high risk (offspring of obese parents) it is a selective prevention. 
This kind of program seeks to educate and imbue these people 
with the necessary skills to avoid weight gain. Finally, a targeted 
prevention tactic assists those who are already overweight or 
obese in their attempt to lose weight. One example of how this 
was implemented was in the North Carelia Project which in-
corporated media education, as well as programs specifically de-
signed for schools and work places. The program saw the most 
success in a ten year follow up when children were treated in 
conjunction with their parents. Weight changes and decreased 
incidence of obesity proved the efficacy of the family based and 
lifestyle mediations.
Researchers on the subject believe that primary intervention 
for youth is better than attempting to treat already obese adults. 
There are established periods that have been identified as cru-
cial to preserving healthy body weight: the prenatal stage, the 
period between 5 and 7 years of age (which is referred to as 
the adiposity rebound) and the teenage years. Although a large 
percentage of individuals may only experience weight gain as 
adults, there is a substantial correlation between childhood and 
adult BMI. Childhood obesity persevering into adulthood ap-
pears to rise linearly as a child get older. Precursors of adult 
diseases such as hypertension are increasingly affecting obese 
children. As demonstrated earlier, childhood obesity is a strong 
predictor of adult morbidity and it has therefore been suggest-
ed that an effective treatment of adult obesity may be youth 
intervention. Based on this assumption, researchers developed 
the KOPS (Kiel Obesity Prevention Study) which inaugurated 
in 1996.  A cohort of 5 to 7 year old children was gathered in 
a the city of Kiel, Germany and the study was supervised with 
cooperation from school physicians and teachers, in addition to 
the formation of a new sports program for heavy children. Basic 
information gathered at the beginning of the study included: 
evaluation of the nutritional state and dietary habits of the child, 
review of lifestyle (active vs. sedentary) social status, physical 
fitness compared to a subgroup of children, muscle strength, 
and preexisting health factors that increased risk, such as blood 
pressure, glucose levels and cholesterol. The cohort (which 
amounted to 25,338 children in total) had their BMIs record-
ed in comparison to the norms of the total group of 5-7 year 
olds born in 1998. Overweight and obese BMIs were designated 
based on the following criterion: triceps skinfold thickness (TSF) 
as a parameter of fat mass. The 90th TSF percentile was used 
as the value to determine obesity. The study was designed to 
conduct a follow up session with the participants every 4 and 8 
years. The study was implemented by introducing a nutritional 
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awareness and health promotion program for children and their 
parents in three intervention schools every year. Corresponding 
data from demographically similar schools were designated as 
the control groups. This reversed every alternate year. Family 
assistance and a structured sports program were offered to 
families with overweight or obese children, as well as families 
with normal-weight children with obese parents.
The premise of the study was that preventing obesity is depen-
dent on healthy lifestyle.  Lifestyle changes can only be imple-
mented by augmenting knowledge and self-awareness as well as 
harnessing self-esteem and personal independence.  The rigorous 
intervention methods included a panoply of directives, amongst 
them: eat fruit and vegetables daily, reduce the intake of high fat 
foods, keep active at least 1 hour a day, and decrease TV consump-
tion to less than 1 hour a day. These messages were delivered to 
pre-school age children within their first year. Teachers working 
in conjunction with skilled nutritionists offered 8 hour courses 
on nutrition for the students as well as parents, who were asked 
to attend school meetings to address the issue. Aside from the 
programs offered in school, families with obese children or par-
ents were provided with counseling and support programs for 
the family as a whole. This consisted of home visits arranged by 
a nutritionist who visited on between 3 to 5 times in a span of 3 
months to assist with shopping, cooking and ‘resetting the family 
table’. The counseling instructed parents to screen food ingestion 
and physical activity. A half year program of structured sports bi-
weekly was also offered to overweight youth. Assessment of the 
results were collected with the intention of determining the fol-
lowing outcomes: primarily, a change in BMI and second, change in 
health-related comorbidity, or the presence of diseases caused by 
obesity. The differences were examined in both the intervention 
and the control schools. 
In the first 4 years of the study, school interventions were directed 
at 414 children, their parents and teachers. 92 out of 368 eligible 
families partook in the family intervention program and 25% of the 
families finished the program. The short-term effects were studied 
for all children within 3 months after the end of the interventions. 
Due to the interventions, 60% of the children exhibited adequate 
nutrition recognition (as opposed to the original 48%), 65% of chil-
dren related that their physical activity had increased (while time 
spent in TV watching had diminished) and 28% of them had joined a 
sports group. Families as whole had a 50% increase in their produce 
consumption and low fat food was also consumed more frequent-
ly, increasing from 20% to 50%. The nutritional state of children 
in the intervention schools was reevaluated after 1 years’ time. 
Compared to the nutritional states of children in control school, 
the intervention school group showed drastically improved results: 
the control groups had higher increases in TSF as well as percent-
age of fat mass. (Müller et al. 2001)
Another study was conducted to evaluate various methods of 
intervention for adolescents ranging from behavioral, which 
consisted of introducing simple intervention methods, to phar-
macological treatments which consisted of a drug regimen, and 
finally, surgical interventions for the morbidly obese sector. 
Behavioral interventions were incorporated in schools or spe-
cialty health care settings to target youth aged 5 to 18 years and 
introduced behavioral modifications similar to the Kiel Obesity 
Prevention study: education about healthy dietary habits and 
augmented physical activity. The data collected from the school 
interventions described a 0.4 to 2.07 difference in mean BMI 
change between those that were treated and the controls at 6 to 
12 months, with a collective estimate of .82 lower BMI in those 
treated. This would mean a loss of 3 pounds for an 8-year-old 
boy or girl, (assuming growth of 2 inches or less), and a 4-pound 
loss for a 12-year old boy or girl. For a 16-year-old adolescent, 
this would mean a weight loss of 4.5-6 pounds, depending on 
gender. Specialty health care setting proved to be much more ef-
fective, displaying a 1.9 to 3.3 BMI difference, compared to control 
groups, for 6–12 months post-treatment. This would mean a 12-
13-pound weight loss for an 8 year old (again, assuming 2 inches 
of growth), and a 16.6 to 17.75 pound weight loss for a 12 year 
old. 16 year olds enrolled in the program could experience up to 
a 23-pound weight loss (Whitlock EP et al. 2008).
It is important to acknowledge that the trial results would not 
necessarily translate well to helping individuals in a real world 
setting. The studies utilized media advertisements for enroll-
ment; it follows that those participants may have been more 
inspired to lose weight, and had a surplus of free time. Parental 
alarm, multiple failed attempts at weight loss or other such fac-
tors may have produced skewed results. 
Pharmacological aides in addition to behavioral interventions 
have been investigated only in obese youth aged 12 to 18 years 
that meet adult criteria for class II obesity, which is a mean BMI 
of 35 to 40 the beginning of the trial. Drugs incorporated into 
the weight loss regimen such as sibutramine and orlistat were 
administered in conjunction with behavioral interventions for 
a 6-12 month span. Unfortunately, longer term impacts after 
treatment termination are not presented for any of the phar-
macological trials (Whitlock EP et al. 2008).
A sizable trial consisting of 498 people tested 12 months of 
sibutramine in combination with a behavioral intervention 
plan. The control group received the same behavior modifica-
tion plans but a placebo pill. Sibutramine is a medication that 
supports weight-loss by altering neurotransmitters within the 
brain. Nerves need to correspond with other nerves and neu-
rotransmitters are what nerves produce to accomplish the 
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process. When neurotransmitters are sent out, they either at-
tach to other nerves or they may experience reuptake, which 
is when the same nerve reabsorbs it. Sibutramine obstructs the 
reuptake of the neurotransmitters dopamine, norepinephrine, 
and serotonin. Preventing reuptake of neurotransmitters modi-
fies the balance of neurotransmitters within the nerve cells and 
thus affects nerve function and interaction. 
After 12 months, the subjects who took the 10-15 mg dosage of sub-
atramine lowered their BMI by almost 3 units, which corresponds 
to a 14-pound weight loss. Astonishingly, the participants of the 
control group experienced a 4.2-pound weight gain. Interestingly, it 
seems the decrease in weight that occurs over a year with intense 
and successful behavior intervention rivals the achievements of the 
pharmacological interventions in the same time span, but more 
direct comparison would be necessary to substantiate the claim. 
(Whitlock, et al. 2008) Although this drug proved to be successful, 
it’s important to note that it’s no longer available in the U.S. for fear 
of heart attack or stroke (Eni Williams, 2015).
Conclusion
Childhood obesity is increasing with alarming frequency and 
can be attributed to a number of factors including diet, health 
education, and parental BMI. The impacts can be devastating; 
obese children battle with deadly diseases that can severely 
compromise their quality of life. This issue only gets amplified if 
obesity persists into adulthood. Numerous studies have demon-
strated the adult health ramifications caused by childhood obe-
sity, including diabetes, metabolic syndrome and cardiovascular 
disease. Overall mortality for adults also increases when they 
have a BMI above 25 (overweight range). Although the present 
seems bleak, various studies have investigated prevention and 
treatment for obesity, amongst them community wide behavior 
interventions that have been very successful. If obesity is effec-
tively conquered in childhood, the individual’s adult health and 
quality of life can be immeasurably improved.
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Introduction
Current methods of treatment for various ocular ailments in-
clude both oral medications and topical eye drops. There are 
significant downsides to both. Orals are often not the first line of 
treatment both because, they take a circuitous route to the eye 
and cause many more negative systemic side effects (Kim, et al., 
2014). Next, in the case of eye drops, there are multiple barriers 
to overcome. First, much of the dispensed eye drop is inhibited 
by pre-corneal factors which include nasolacrimal drainage, tear-
ing, and blinking. These factors significantly lower the bioavailabil-
ity of the medication. Research indicates that only a fraction of 
the precious medication, a mere one percent to seven percent, 
reaches its required destination, thereby reducing the drug’s ef-
fectiveness (Schultz and Mint, 2002). Furthermore, the drops are 
often administered by the patient, and sometimes are required 
multiple times a day. This commonly leasds to low patient com-
pliance, and doses are frequently forgotten or skipped purposely 
(Ciolino et al., 2011). Given the above, there exists an impetus to 
develop alternate methods of delivering ocular medications, thus 
enabling effective treatment. Researchers are currently working 
on developing a contact lens that will also dispense nanoparticles 
of medication directly into the eye while correcting refractive 
error. In patients who don’t have refractive error, the contact 
lenses can simply be worn for the purpose of delivering the 
needed medication into their eyes. The use of contact lenses for 
ocular drug delivery can solve many of the issues associated with 
eye drops. First, the space created by the lens with the cornea 
has limited tear mixing, and potentially a greater amount of con-
tact time between the drug and the cornea.
This causes greater bioavailability. Additionally, there is an 
added benefit of eliminating the need for multiple doses a day, 
which will increase the amount of patient compliance. Under 
ideal kinetics, the drug will release in a time dependent man-
ner, extending the therapeutic effects of one dose (Phan et al., 
2014). Research with a drug dispensing contact lens (DDCL), is 
currently underway for a number of ocular conditions. In this 
work specifically, a DDCL for the diseases of glaucoma, fungal 
keratitis, and hay fever are discussed.
Glaucoma
Glaucoma, a group of conditions that damages the eye’s 
optic nerve, usually results from increased intraocular pres-
sure (IOP) which can result in vision loss and blindness. The 
two main forms are open-angle glaucoma and angle-closure 
glaucoma. Both forms, involve clogging of the eye’s drainage 
canals, leading to elevated ocular pressures and subsequent 
nerve damage. In open-angle glaucoma this leads to a gradual 
increase in IOP because, the angle between the iris and cornea 
is wide and open. In angle-closure glaucoma there is a sudden 
increase in IOP because, the angle between the iris and cornea 
is either very narrow or closed. Current methods of treatment 
include surgery, oral medications, and eye drops, depending on 
the classification and extent of the disease. When surgery is 
warranted however, it usually does not resolve the increased 
IOP completely and generally a regimen of eye drops are pre-
scribed as well post operatively. Additionally, surgery can cause 
negative side effects including, cataract formation, inflamma-
tion, ocular infections, corneal issues, and low IOP. Negative 
side effects caused by oral medications can include irritation, 
stinging, redness, blurred vision, itchiness, low blood pressure, 
fatigue, shortness of breath, headaches, dry mouth, frequent 
urination, upset stomach, and memory problems, depending 
on the class of drug prescribed. In general, topical eye drops 
are the first line of treatment. However, due to the issues 
posited above, a contact lens that can dispense anti-glaucoma 
drugs is currently being developed.
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Research for Anti-Glaucoma Drug Dispensing 
Contact Lens
Joseph B. Ciolino, MD, at the Massachusetts Eye and Ear, con-
ducted an in vivo study on the effectiveness of a Latanoprost-
dispensing contact lens for female monkeys with induced 
glaucoma. Latanoprost is currently on the market as a topical 
anti-glaucoma eye drop. It belongs to a class of anti-glaucoma 
medications knows as prostaglandin analogues, which work to 
lower the IOP by increasing uveoscleral flow (although more re-
cently research suggests that it may occur through a trabecular 
pathway) and it is prescribed for cases of open-angle glaucoma 
(Lindén and Alm, 1999, Winkler and Fautsch, 2013). In Ciolino’s 
research, a thin latanoprost-polymer film was introduced into 
a methafilcon hydrogel contact lens. Both a low-dose contact 
lens (CL), and a high-dose CL were synthesized. The intraocular 
pressure of the glaucomatous monkeys was monitored after a 
period of the following cases:
1. Treatment with Latanoprost eye drops
2. Treatment with CL-low
3. Treatment with CL-high
4. No treatment
The results demonstrated that the latanoprost eye drops suc-
ceeded in reducing IOP approximately 5 mmHg, the CL-lo by 
about 6.5 mmHg, and CL-hi by about 11 mmHg. 
Evidently, “Sustained delivery of latanoprost by contact lenses is 
at least as effective as delivery with daily latanoprost ophthal-
mic solution. More research is needed to determine the opti-
mal continuous-release dose that would be well tolerated and 
maximally effective. Contact lens drug delivery may become an 
option for the treatment of glaucoma and a platform for ocular 
drug delivery (Ciolino et al., 2016)”
Additional anti-glaucoma contact lenses that are currently being 
researched, synthesized, and patented are those that contain 
timolol maleate or brimonidine tartrate within a polymeric hy-
drogel. Timolol maleate belongs to a class of anti-glaucoma drugs 
known as beta-adrenergic blockers and brimonidine tartrate is 
an alpha agonist. Both are prescribed for cases of open-angle 
glaucoma. Specifically, in the case of beta blockers, systemic side 
effects can be pretty severe such as, cardiac arrhythmias, bron-
chospasm, and stroke and is therefore prescribed based on a 
patient’s complete medical history. The aim of the study was 
to develop contact lenses that maintain normal hydration and 
comfort, and will dispense lower doses of drug for extended 
periods of time. This will lead to increased patient compliance, 
decreased negative side effects, and efficacious treatment 
(Schultz and Mint, 2002). 
Etafilcon contact lenses (hydrogels) were washed in a saline 
solution and briefly dried. Then they were immersed in either a 
dilute solution of brimonidine tartrate (0.02%), or a dilute solu-
tion of timolol maleate (0.05%). (Topical ophthalmic solutions of 
the above drugs are commercially available as 0.2% solutions for 
brimonidine, 0.25% for timolol, and 0.5% for timolol ophthalmic 
gel forming solution). The lenses were subsequently tested on 
multiple patients as a replacement for their current regimens of 
eye drops. Instead of the patient administering their daily eye 
drop, he wore the contact lens for 30 minutes each day. In all 
cases, this method allowed for IOP to remain below the nec-
essary value of 20 mmHg, with no evidence of ocular toxicity.  
An additional study was conducted on glaucomatous beagle 
dogs. NIGHT & DAY™ silicone hydrogel contact lenses were 
immersed in timolol and phosphate buffered saline solution. 
Then, one lens was inserted into one of the dog’s eyes, while 
the other eye served as the control, and no lens was inserted. 
The lenses with similar dosing to timolol eye drops led to an 
IOP reduction of about 5 mmHg (which is slightly greater than 
the IOP reduction resulting from timolol eye drops). However, 
lenses with a third drug loading as the eye drops led to a similar 
reduction in intraocular pressure, suggesting increased bioavail-
ability. Finally, the eye without the contact lens remained unaf-
fected by its proximal lens, which suggests reduction in systemic 
absorption of the drug released by the lens (Peng et al., 2012).
Fungal Keratitis
Fungal keratitis is an infection of the cornea (the clear, round 
dome covering the eye’s iris and pupil) which causes pain, re-
duced vision, light sensitivity, and tearing or discharge from the 
eye. Resulting from infection from contact lens use, or from 
injury to the eye, fungal keratitis usually develops very quickly, 
and if left untreated, can cause blindness (Boyd, 2015). Fungal 
keratitis is also prevalent in tropical and subtropical climates 
(Ciolino et al., 2011).
Current treatment options for fungal keratitis vary depending 
on the severity of the condition. Topical eye drops are often 
the first line of treatment (Ciolino et al., 2011). Once again the 
above drawbacks to eye drops are present:
“The failures of topical antimycotic treatments may be 
related to the limitations of eye drops as a form of drug 
delivery. Eye drops generate a transiently high concen-
tration on application followed by a short period of ef-
fective therapeutic concentration and then a prolonged 
period of underdose. Furthermore, each drop is diluted 
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and washed away by reflex tearing and dispersed by 
blinking. As a consequence, only 1% to 7% of drug in a 
drop is absorbed in the eye. The cornea absorbs only 
a fraction of this dose, in part due to the tissue’s short 
contact time with the topical drops (Ciolino et al., 
2011).”
Currently there is only one drug available on the market, na-
tamycin, as a topical ophthalmic antifungal. However, this drug 
specifically is shown to have poor corneal penetration and is 
mainly effective with superficial corneal infections caused by 
Fusarium species (Singh, 2015). Depending on the severity and 
identity of the disease, often subconjunctival injections of an 
antifungal agent are prescribed and the dosage times are not 
infrequent, (twice every hour for the first 24 hours, then once 
every hour for the next 24 hours etc). “Successful antifungal 
therapy for fungal keratitis requires frequent drug administra-
tion for prolonged periods (ie, at least 12 weeks) (Singh, 2015).” 
Sometimes antifungals in an oral form are prescribed. However, 
15 to 27 percent of patients with fungal keratitis require surgical 
intervention (Boyd, 2015). Even after surgery, a course of topical 
drops is often prescribed as well. Finally, surgery is not effective 
in all cases, and a patient may be rendered significantly visually 
impaired (Singh, 2015).
Research for an Anti-Fungal Contact Lens
The ineffectiveness of the topical regiment arises from low 
penetrance of the drug to the corneal epithelium as well as 
inadequate contact time between drug and tissue. Additionally, 
low patient compliance is common due to the frequency with 
which the drug needs to be administered. A contact lens that 
dispenses antifungal particles could resolve all these issues. A 
prototype antifungal contact lens (Ciolino et al., 2011) was syn-
thesized using the following method: 
Econazole, an antifungal drug, was added to a film of poly (lac-
tic-co-glycolic) acid (PLGA). PLGA is desirable because of its 
biocompatibility and biodegradability, and its effectiveness at 
controlling drug release kinetics. Various film sizes were syn-
thesized and all were encapsulated into polyhydroxymethacry-
late (pHEMA), a common contact lens material. Contact lenses 
were synthesized with different concentrations of econazole. 
A control lens was created as well which contained the PLGA 
film inside the pHEMA hydrogel without the econazole. The 
contact lenses were tested against the fungus C. albicans, a 
common agent of fungal keratitis. First the lenses were placed 
directly onto a rich medium, a culture plate containing 1 mL of 
the Candida suspension. After a number of cycles of incubation 
and refreshing the medium, the culture was diluted, incubated, 
and counted for viable colonies. This was done to determine 
the effect of the contact lenses in direct contact with the fungi. 
The lenses were also tested for their drug-releasing capabilities. 
The testing was conducted by immersing the lenses in a yeast 
nitrogen base medium and incubated. Then they were immersed 
in fresh medium every 24 hours. The yeast nitrogen base drug 
release medium was collected at different intervals, and diluted 
with new medium containing C. albicans. Once again after a pe-
riod of dilution and incubation, the suspension was plated and 
counted for viable colonies. 
The results showed that both methods were capable of killing 
100% of fungi for extended intervals. The release medium which 
contained contact lenses with 16 mg of econazole (PLGA-16) 
killed 100% of fungi for 21 days! The mediums from contact 
lenses, containing lower concentrations of econazole, killed fun-
gus for shorter amounts of time. In the cases where the contact 
lenses came directly in contact with the fungal suspension, 100% 
of fungi were killed for 8 to 10 days (with PLGA-16). Studies 
show that C. albicans is more difficult to kill than Fusarium 
species. Therefore if Candida was killed by econazole, Fusarium 
should be as well (Ciolino et al., 2011). (Currently econazole is 
not FDA approved for ophthalmic use, although many ophthal-
mologists would prefer to treat fungal infections with some-
thing other than Natamycin, currently the only available drug). 
Contact lenses that could elute the drug natamycin have also 
been synthesized (Phan et al., 2013). The study focused specifi-
cally on manipulating various contact lens materials. Hydrogels 
were composed of: 
1. 100 % pHEMA, 
2. 85% pHEMA and 15% [Tris(trimethylsiloxy)silyl]-propyl 
methacrylate (TRIS)
3. 75% pHEMA and 25% TRIS 
4. N,N-dimethylacrylamide (DMAA), 
5. 85% DMAA and 15% TRIS
6. 75% DMAA and 25% TRIS 
The lenses were monitored by their uptake and release of two 
forms of natamycin. The first form was Natamycin dissolved in 
deionized water, and the second form was Natamycin encap-
sulated within poly(D,L-lactide)-dextran nanoparticles. Results 
indicated that the optimal materials to use were those contain-
ing DMAA. Furthermore, all gels had a greater uptake with the 
nanoparticles of natamycin versus natamycin alone. Finally, the 
release of natamycin within nanoparticles was greater than the 
natamycin alone. Also, the first hour of release was noteworthy. 
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The lenses with regular natamycin released 28-82% within the 
first hour. In the nanoparticle lenses this was reduced to 21-54% 
(Phan et al., 2013). 
Hay Fever and Allergic Conjunctivitis
“Spring allergies are triggered as trees start blooming and bil-
lions of pollen grains are released into the air, causing suscep-
tible individuals to develop allergic rhinitis… In these patients, 
the pollen causes degranulation of mast cells, which contain 
inflammatory mediators, ie, histamine and other allergy-causing 
chemicals. This process is clinically represented by sneezing; red, 
tearing eyes; postnasal drip; sinus headaches; feelings of sinus 
fullness; and itchy, scratchy throat (Medscape, 2016).”
As the conjunctiva of the eye is a mucosal membrane, it too is 
subjected to the inflammatory responses of allergic rhinitis. Per 
the CDC (Center for Disease Control and Prevention), approx-
imately 19 million adults and another 6 million children suffer 
from hay fever in the U.S. alone. For the ocular symptoms of rhi-
nitis, also known as allergic conjunctivitis, eye drops containing 
anti-histamines and/or mast cell stabilizers can be prescribed or 
recommended. Another class of treatments are corticosteroids 
and glucocorticoids, which also work to reduce the allergic 
reactions which affect the eye and relieve the negative symp-
toms. These can be prescribed as an ophthalmic suspension for 
topical use. Once again due to inhibitive pre-corneal factors, an 
alternate drug delivery mechanism is currently being researched 
in the form of a drug dispensing contact lens. 
Research for DDCLs for Allergic Conjunctivitis
The Kingston University London conducted an in vitro experi-
ment to synthesize a contact lens that could dispense nanopar-
ticles of a synthetic glucocorticoid, prednisolone, into the eyes 
of patients with allergic conjunctivitis. (Currently prednisolone 
is on the market as prednisolone acetate ophthalmic suspension 
for topical use.) The main purpose of the experiment was to 
consider the effects of the encapsulated drug on the contact 
lenses’ functionality and safety as well as the drug’s bioavailabil-
ity (ElShaer et al., 2016). 
Prednisolone nanoparticles (PNP) were synthesized using an 
emulsion-solvent evaporation method. The experiment was de-
signed to maximize three key nanoparticle features: small parti-
cle size (increased surface area/bioavailability), highest encapsu-
lation efficiency, and maximum surface charge (no coagulation 
of particles; increases stability). To obtain the smallest particle 
size, four variables were manipulated: PLGA (poly-lactic-co-gly-
colic acid), PVA (polyvinyl alcohol), API (amount of prednisolone 
used), and homogenization time. Through optimization of these 
components a particle size of about 295 nm was obtained. To 
form the contact lens molds, HEMA (2-hydroxymethacrylate), 
MAA (methacrylic acid) and a small amount of EGDMA (eth-
ylene glycol dimethacrylate) were mixed together along with 
the PNPs. These four hydrogel materials were allowed to polym-
erize thermally for 4 hours at 80°C in molds of polypropylene. 
The in vitro drug release pattern of the contact lens with 0.4 
grams of PNP was observed to be a two-phase process: an ini-
tial burst, followed by a period of slower release. The lens was 
placed in a release medium of phosphate buffered saline for 24 
hours. 10.8% of drug was released in that time. The slow release 
of the drug can be due to the need for the drug to get past its 
nanoparticle barrier and through the contact lens as well. One 
of the issues with eye drops is that all of the drugs are released 
within a few hours. Nanoparticles of medication embedded in 
contact lenses can provide a longer lasting therapeutic regimen 
(ElShaer et al., 2016). 
Method of Drug Release from Contact Lens
Although some studies for drug-eluting contact lenses pre-soak 
the contact lenses in drug, to allow for eventual diffusion into 
the eye, to achieve a more controlled method of release, other 
methods are being researched. The human tear film contains an 
enzyme called lysozyme. In a study on anti-glaucoma contact 
lenses, timolol maleate was encapsulated in nanodiamond (ND) 
particles. The NDs were coated in both polyethyleneimine (PEI) 
and chitosan. Chitosan is an enzyme-cleavable polysaccharide 
and PEI enables a more effective cleavage. The drug release of 
these impregnated lenses was monitored in vitro. In the absence 
of lysozyme, no release of timolol maleate was detected. In the 
presence of lysozyme the lens released 9.41 micrograms in 24 
hours (Kim et al., 2014).
Addition of Drug to Contact Lens Material and 
Subsequent Hydration and Oxygen Permeability
This feature was monitored in the prednisolone study cited 
above. Contact lenses lacking the PNPs had an average hy-
dration of about 36%. Lenses containing a smaller volume 
of drug nanoparticles (0.2 g) had a decreased hydration 
by about 31%, whereas the lenses with a higher volume of 
PNPs (0.4 g) had a further reduction in hydration to about 
30.5%. 
Surface wettability determines comfort of the lens, and was 
measured as well. A good surface wettability is identified by a 
contact angle less than 90 °C. Unmodified lenses have a con-
tact angle of 85 °C. The prednisolone encapsulated lenses had 
further reduced angles which should increase ocular comfort 
(ElShaer et al., 2016). Similarly, contact lenses containing nano-
diamond particles of timolol maleate demonstrated acceptable 
hydration values (Kim et al., 2014).  
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Transparency/light Transmission Capability of 
Drug-Impregnated Lens
Ideally a contact lens should have a light transmittance of 
above 90%, so vision is unobstructed. The control contact 
lenses (lacking PNP) in the prednisolone study had a high 
transparency of 94.5%. The lenses containing 0.2 grams and 
0.4 grams of PNP had a reduced transparency of 86.23% and 
83.1% respectively. However, this amount contributes to low 
or no opacity, and as long as the correct amount of nanopar-
ticle is added to the lens, vision should not be compromised 
(ElShaer et al., 2016). Similarly, addition of nanodiamond par-
ticles of timolol maleate to a pHEMA lens did not cause any 
discernable changes to the lens’ optical clarity. The lens with 
a higher concentration of NDs maintained a transmittance of 
84.5% (Kim et al., 2014).
Dimensions/measurements of Drug-Eluting 
Contact Lenses Compared to Commercially 
Available Lenses
In the study done on antifungal contact lenses, when syn-
thesizing the econazole-laden lenses, parameters of an 8.05 
base curve and a 15.5 mm diameter were measured, which 
are consistent with commercially available lenses (Ciolino et 
al., 2011).
Preservation of Contact Lens through 
Lyophilization (to prevent drug elution/
degradation) Effect on Lens Capability
Depending on the method used to impregnate the lenses with 
drug, there exists a risk of the drug eluting out of the lens during 
storage. In order to combat this, anti-fungal contact lenses were 
lyophilized, a preservation process involving the freeze drying of 
a substance and subsequent removal of water by a vacuum caus-
ing the water to go from an ice state directly to a gaseous one. 
The fungicidal activity of the lyophilized lens was then assessed 
and found to be intact, although the duration of its effectiveness 
was reduced by 1 to 2 days (Ciolino et al., 2011).
Risk Factors and Drawbacks Associated with a DDCL
Although there is a lot of potential is this innovative drug deliv-
ery system, several potential downsides should be noted. There 
are many consumers who do not wear contact lenses because 
they find them uncomfortable or haven’t found the proper fit. 
Others do not wear contact lenses because they have no re-
fractive error and would thus need a special fitting session just 
to wear a short-term lens. Additionally, glaucoma often affects 
the geriatric population. Individuals of this population could also 
have difficulty inserting and removing the lenses, however this 
issue could be aided by an eye-care professional. These factors 
could potentially minimize the market for such lenses. Another 
problematic feature involves the drug-eluting property of the 
lenses. Once removed by the patient any remaining drug may 
continue to diffuse out. In the case of anti-fungal drugs, this 
could have an effect on the development of resistant strains 
while in the case of other drugs this may simply pose as a hazard 
for children. (It should be noted though that with lenses con-
trolled by lysozyme presence this undesired drug-elution may 
be minimized).
Conclusion and Further Applications
Contact lenses for the treatment of glaucoma, fungal keratitis, 
and allergic conjunctivitis have been synthesized and demon-
strate much potential in effective treatment. However, the lens-
es are far from having a clinical relevance. Much more animal 
and human testing is required prior to the necessary FDA-type 
approvals. Although in this paper glaucoma, fungal keratitis, and 
allergic conjunctivitis were discussed, research is also under-
way for additional ocular conditions such as, chronic dry eye 
and bacterial infections (Legett, 2009), (ElShaer et al., 2016). 
Additionally, the studies are working on embedding various drug 
nanoparticles into lenses without obstructing optical transpar-
ency. Potentially, instead of drugs, various ocular-necessary vita-
mins and supplements can serve as the embedded nanoparticle. 
As salt is iodized to promote proper thyroid function, perhaps 
macular degeneration could be prevented by infusing contact 
lenses with nanoparticles of lutein and zeaxanthin, two nutrients 
vital to a healthy macula.
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Introduction
One of the most widely studied biological topics is the field 
of morphology. Specifically focusing on embryonic morphology, 
much research has been done to link genetics with the various 
formations and stages of embryonic development. Throughout 
the years, genetics has been used to explain and account for 
countless aspects of development patterns and pathways found 
in embryonic development. Many genes and signaling molecules 
have been identified and used to formulate blueprints of mor-
phogenic pathways in a developing embryo.
In recent years, there has been a shift in the study of embryonic 
development. New studies are beginning to focus on the pos-
sible role of mechanical and physical forces in morphogenesis. 
There are numerous physical forces found within the embryo 
during the stages of development. This review focuses on con-
tractions of cells, fluid forces, shear stress, and surface tension, 
and their impact on cardiac morphogenesis. Breakthroughs and 
new technology in mechanical biology allowed for advanced 
studies of these forces.
Finally, the data will be analyzed to determine if these physical 
forces that are involved in cardiac development can potential-
ly be linked to genetic factors. Recent studies have begun to 
attempt to relate the mechanical factors affecting heart mor-
phology with the genetic factors which have been studied for 
many years. By bridging the gap between genetic and mechanical 
forces, we will have a better understanding of the control of the 
development of cardiac tissue and the heart within an embryo.
Methods
Critical analysis of peer reviewed journal articles and original 
clinical research papers was used to write this review. The ar-
ticles and papers from which the research was gathered were 
obtained by using the PubMed search engine found on the gov-
ernment’s National Center for Biotechnology Information web-
site. Additional references were obtained from those sources. 
Keywords used were heart morphology, heart development, 
mechanical forces, and hemodynamics.
Heart Fields and the Heart Tube
Before analyzing mechanical factors involved in embryonic car-
diac morphology, it is essential to have a solid understanding 
of the stages of heart development in an embryo. The current 
accepted model of cardiogenesis was first discovered during the 
last decade. Heart morphogenesis begins with cells with myo-
cardial potential that are located in a specific region, known as a 
heart field (Buckingham et al., 2005). This was the first research 
done which classified two individual heart fields, both of which 
participate in cardiac development. Before this, there were 
others who identified a second heart field (Kelly et al., 2001). 
However, Buckingham was the first to explain the process by 
which the two different fields give rise to distinct portions of 
the human heart.
Much of this research was done with chick embryos and mouse 
embryos. Comparisons of gestation timelines of chicks or mice 
to humans can be made using the formulas outlined by Srivastava 
(Srivastava, 2006). The anterior lateral plate mesoderm gives 
rise to cells in the first heart field. A crescent shape is formed 
by the first heart field. This occurs at approximately the second 
week during human gestation. By the third week the ends of 
the crescent merge with each other, forming a basic heart tube. 
This heart tube is considered basic because it is simply made up 
of two layers: an interior endothelial cell layer, and an exterior 
myocardial cell layer (Srivastava, 2006).
Simultaneously, the second heart field is expanding in a for-
mation which appears to encircle the first heart field. The first 
heart field in the basic heart tube acts as a platform upon which 
the second heart field is able to settle and begin the process of 
becoming the various chambers found in the heart (Buckingham 
et al., 2005). Figure 1 labels the heart fields and shows how each 
field ultimately gives rise to a different portion of the heart. 
Abstract
For years, the genetic element of heart morphogenesis has been studied. This review focuses on a relatively new area of 
study, namely, mechanical factors influencing heart morphogenesis. To understand the context of the role of mechanical 
factors in heart development, an extensive review of the stages of heart morphogenesis is provided.
It is found that shear stress, surface tension, fluid forces, and contractions of certain cells play a role in various stages 
of heart development. Numerous studies have shown that in cases where these mechanical forces were modified, 
abnormal heart defects were produced. These studies prove that the mechanical forces are essential for normal heart 
morphogenesis.
Although attempts have been made to define the mechanisms involved in these pathways, most of the research done so 
far has been inconclusive. While it has been proven that the mechanical forces play a role in heart development, it is still 
unclear exactly how the forces are involved in the developmental pathways, and what initiates them to proceed. As of 
current studies, it is also still unclear if there is any correlation between the genes and the mechanical factors involved 
in heart morphogenesis.
Mechanical Factors Affecting Heart Morphogenesis
Moshe Fenster
Moshe Fenster will graduate with a BS in biology in June 2017.
45
Mechanical Factors Affecting Heart Morphogenesis
It also gives a clearer understanding to the anterior/posteri-
or positioning of the first heart field (labeled “FHF”) and the 
second heart field (labeled “SHF”) at two and three weeks of 
human gestation. It depicts how the second heart field (shown 
in yellow) uses the first heart field (shown in red/pink) as a sup-
port in the initial stages of morphogenesis. Figure 1 also clearly 
illustrates how the second heart field completely surrounds the 
first heart field by three weeks of human gestation.
It is unclear what exactly causes the crescent shaped first heart 
field to bend into a heart tube. It is theorized that contraction 
of the crescent, caused by microfilaments in the apical regions 
of the epithelial cells results in the production of the tube. The 
contractions force the cells to assume a wedge-shape, causing the 
plane of the cell sheet to begin to bend into a tube-like forma-
tion (Taber, 1998). Unrelated research supported this theory by 
reporting that administering pharmacological agents that inhib-
ited actin filament function prevented the heart tube formation 
and resulted in the persistence of the crescent shape (Ettensohn, 
1985). Because no experimental work has definitively linked con-
tractions of the actin microfilament with the crescent bending 
and heart tube formation, it would be inappropriate to say that 
this is definitely the mechanism which forms the heart tube. 
Nonetheless, the research provided is enough to strongly suggest 
that this is the correct method of heart tube formation.
Dextral Looping
Before the heart can fully develop into its various components 
and chambers, it must go through an event known as looping. 
Looping produces the c-shaped structure present in the third seg-
ment of Figure 1. There are various stages of this looping process, 
also known as “dextral looping.” To analyze this process research 
was performed using chick embryos. Before looping begins, in a 
stage referred to as the prelooping stage, the heart tube is essen-
tially bilaterally symmetrical. As the heart tube undergoes rapid 
elongation, interventricular grooves are formed. These grooves 
ultimately become the bending points upon which the bottom 
curve of the “c” looping is established. Upon the completion of 
c-looping, three bended bands are easily noticeable: the truncus 
arteriosus (which will later develop into the aorta, its branching 
arteries, and the pulmonary trunk), the primitive atria region, and 
the primitive ventricular region (Manner, 2000). Figure 2 gives de-
tailed pictures of the process of dextral looping.
It can be seen clearly in Figure 2 that throughout the process 
of dextral looping, the heart loses the symmetry and linearity it 
possessed during the previous stages of the heart tube (Manner, 
Figure 1  Mammalian Heart Development (Srivastava, 2006) 
Figure 2  Stages of Dextral-Looping  Slides A and B represent the 
prelooping stage  In Slide B, “1” and “2” represent the interventricular 
grooves  Slides C – G show the incremental changes in the heart tube 
as it proceeds through the process of dextral looping  In Slide H, upon 
completion of dextral-looping, “c” represents the conus, “v” represents 
the primitive ventricular region, and “a” represents the primitive atria 
region (Manner, 2000) 
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2000). The conus will ultimately give rise to the aorta, the left and 
right subclavian arteries, the left and right carotid arteries, and the 
pulmonary trunk. The primitive ventricular region will ultimately 
give rise to the left and right ventricles. The primitive atria region 
will ultimately give rise to the left and right atria (Srivastava, 2006).
While the slides in Figure 2 show actual images of the stages 
of dextral looping, the third segment in Figure 1 diagrams how 
the developing heart appears after dextral looping of the heart 
tube is completed. Upon completion of looping, the aorta and 
its various branching arteries are not fully developed. The aorta 
appears as a simple structure known as the aortic sac (labeled AS 
in Figure 1). At this stage of development, the branching arteries 
of the aorta (left and right subclavian arteries and left and right 
carotid arteries) are bilaterally symmetric branches (labeled “III” 
and “IV” in Figure 1) stemming off of the aortic sac. As Figure 1 
illustrates, following dextral looping, the aortic sac and its branch-
es are not yet positioned between the atria (Srivastava, 2006).
Transformation of C-Shape to S-Shape
Following dextral looping, the heart goes through another mor-
phogenic process, converting the c-shaped heart loop (created 
by dextral looping) into an s-shaped heart loop, resulting in the 
placement of the ultimate locations of the chambers and mod-
ifying the position of the craniocaudal axis. This process pushes 
the right atrium to be positioned superior to the right ventricle, 
and drags the left atrium towards the right atrium, aligning the 
left atrium almost directly above the left ventricle. This process 
causes the aortic sac and its branches to become positioned 
between the atria. Because the ultimate location of the aorta 
will be parallel to what will eventually be the interatrial septum, 
this positioning of the aortic sac and its branches between the 
atria is essential for the process of heart morphogenesis to 
proceed (Manner, 2000). Figure 3 shows the resulting s-shaped 
heart loop with the aortic sac positioned between the atria, 
which have become aligned superiorly to the segment destined 
to be split into the left and right ventricles.
Blood Flow during Heart Formation
By the time that looping is completed, there is already blood 
flow present in the developing heart. At this point, septation of 
the atria into right and left components has not yet occurred. 
The blood flows from the portion of the primitive atria region 
destined to be the left atrium down into the primitive ventric-
ular region. It flows through an area known as the AV canal, 
the walls of which will ultimately give rise to the region of the 
atrioventricular valve. Because septation of the ventricles has 
also not yet occurred, the blood must flow through the primi-
tive ventricular region with enough force to navigate the entire 
ventricular loop. The blood enters the primitive ventricular 
region via the inlet tract, ultimately destined to become the 
left ventricle, and exits the ventricular loop via the outlet tract, 
ultimately destined to become the right ventricle. The inlet and 
outlet tracts are delineated by the interventricular foramen, 
which is an opening separating what will ultimately be the left 
and right ventricles. As will be described later, septation of the 
ventricles occurs by the closing of the interventricular foramen 
(Moorman et al., 2003).
Development of the Cardiac Chambers 
(Septation)
Changes in the atria and ventricles occur over the same period 
of time. As the developing lung forms, a network of vessels sur-
rounds the lung buds. This network of vessels connects with the 
primary atrium (the unseptated atria) and attaches at a point on 
the left portion, in its inferior region. (This network of vessels, 
ultimately destined to become the pulmonary veins, does not 
expand and become fixated on the roof of the left atrium until 
after septation is completed.) In the right portion of the primary 
atrium, the sinus venous, the small cavity where the superior and 
inferior vena cava drain, attaches to the right atrium.
As this group of vessels attach to the primary atrium, the left 
and right atrial appendages begin to grow out of the walls of 
the primary atrium. The appendages are sacs which form in the 
muscular walls of the left and right atria. While the right atrial 
appendage is quite large and expands distally in a continuous 
path parallel with the right atrium, the left atrial appendage is 
narrower, and positioned in the superior portion of the left atri-
al wall. This is because the formation of the left atrium consists 
of a much larger portion of the primary atrium. The appendages 
are notably the first appearance of morphological differentiation 
Figure 3  S-Shaped Heart Loop  The left and right atria are 
represented by “la” and “ra”, respectively, the ventricles are 
represented by “v”, and the aortic sac is represented by “c” and “t” 
(Manner, 2000) 
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between the left and right atria. Known as morphological sided-
ness, this development is controlled by a pathway governed by 
the Pitx2 gene (Moorman et al., 2003).
As all of this is occurring, septation of the atria is also progress-
ing. Cardiac jelly found in the edges of the region of the septum 
begin to fuse into ridges, eventually giving rise to an almost 
complete atrial septum dividing the primary atrium into the left 
and right atria. Blood resists entering into pulmonary circulation 
because the lungs do not become inflated until the baby is born. 
The foramen ovale is an opening found in the atrial septum. The 
foramen ovale allows for the blood in the right atrium to shunt 
into the left atrium, avoiding pulmonary circulation. It is formed 
by the overlapping of the two bands of the septa, resulting in a 
unidirectional valve (Bressler, 1990). At birth, the foramen ovale 
closes, and is represented in the adult heart as the fossa ovalis. 
Figure 4 shows a drawing of the embryonic heart with the fora-
men ovale. It is clear from the diagram how the foramen ovale is 
formed by the overlapping of the two bands of the septa.
Simultaneously, development of the interventricular septum is 
occurring. By the time that heart tube looping finished, the pri-
mary interventricular foramen (which connects the left and right 
ventricles before the interventricular septum develops) becomes 
noticeable (Moorman et al., 2003). The dextral loop is made up of 
an inner curve and an outer curve. The outer curve balloons out, 
extending the ventricular wall and increasing the size of the lumen 
(Davis, 1927).
Numerous studies have attributed ventricular development to 
consolidation of myocardial trabeculae found in the primitive 
ventricular region. Myocardial trabeculae are spongy jagged folds 
of endocardium running along the circumference of the primary 
heart tube (Icardo, Fernandez-Teran, 1987). As these jagged edges 
become more compact and consolidated, the ventricular walls are 
formed (Moorman et al., 2003). Unfortunately, due to the geomet-
ric randomness and inconsistencies of the folding and compacting 
of ventricular trabeculae, so far no one has been able to successfully 
produce an accurate and definitive model of the methods involved 
in ventricular trabeculation (Taber, Perucchio, 2000).
Valvulogenesis
As the heart chambers undergo morphological pathways to 
attain their final shape, sizes, and orientations, the atrioven-
tricular valves are forming. In the right side of the heart, the 
atrioventricular canal expands in order for the right atrium to 
become continuous with the right ventricle. During this pro-
cess, the muscle tissue found in the right half of the atrioven-
tricular canal becomes integrated with the right atrium, forming 
the region where the tricuspid valve will develop. In the left 
side of the heart, the left atrium is already continuous with the 
left ventricle due to a mechanism which occurs during looping. 
Similar to the right side, the muscle tissue found in a portion 
of the atrioventricular canal becomes integrated with the left 
atrium, forming the region where the mitral valve will develop 
(Moorman et al., 2003).
The function of the heart valves is to prevent backflow of blood 
from the ventricles into the atria. The valves are often described 
as multileaflet structures (Bartman, Hove, 2005). There is an 
abundance of a gelatinous substance known as cardiac jelly 
found in between the endocardium and the myocardium. It 
is believed that as the cardiac jelly in specific regions of the 
heart begins to swell, endocardial bulges are formed. These 
cushions are further enhanced by migrating cardiac endothelial 
cells, changing the cardiac jelly into cardiac mesenchymal cells, 
causing the endocardial bulges to begin to grow. Once their 
growth is completed, they are referred to as endocardial cush-
ions (Markwald et al. 1977). These endocardial cushions then 
proceed through another stage of growth, ultimately forming 
heart valves made of fibrous tissue. The fibrous tissue found in 
the heart valves allows for them to open and close as the heart 
pumps blood throughout its chambers (Bartman, Hove, 2005).
The pulmonary valve and aortic valve have similar functions to 
the atrioventricular valves. They prevent backflow into the right 
ventricle and left ventricle, respectively. The mechanism for their 
morphogenesis is very similar to the growths of endocardial 
cushions described above in the formation of the atrioventricu-
lar valves (Bartman, Hove, 2005).
Development of the Arterial Trunks
Throughout heart development, the aortic sac undergoes 
changes to become the outflow tracts of the heart. As the dis-
tal outflow portion of the original ventricular loop begins to 
Right Atrium
Right Ventricle
Left Atrium
Left Ventricle
Foramen
Ovale
Figure 4  Diagram of Foramen Ovale Shunting Blood from the Right 
Atrium to the Left Atrium
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extend out of the pericardial cavity, it is divided into two, form-
ing the ascending aorta and the pulmonary trunk. The ascending 
aorta and the pulmonary trunk are two separate tubes, divided 
by the aorticopulmonary septum. Figure 5 shows a scanning 
electron micrograph image of the bend formed in the tube. The 
edge of the distal outflow portion of the original ventricular 
loop completely extends to the edge of the pericardial cavity. 
The distal outlet portion of the aortic sac develops into the dis-
tal portions of the aorta and its branching arteries, completing 
the systemic circulation path. The pulmonary trunk extends and 
attaches to the lungs to complete the pulmonary circulation 
path (Moorman et al., 2003).
As can be seen in this image, the dog-leg bend produced by the 
outflow tract helps align the aorta with aortic arches III and IV, 
and the pulmonary trunk with arch VI (Moorman et al., 2003).
Mechanical Forces Involved in Heart Morphogenesis
When analyzing mechanical factors affecting heart morphogen-
esis, the initial, and probably most striking piece of data, is that 
the heart begins to function before it is completely developed. 
Blood begins to flow through the primitive heart chambers by 
the time that initial stages of heart looping are completed. This 
suggests that the actual pumping of the heart, along with other 
forces produced by blood flowing through the heart chambers, 
might actually be the cause of later steps of heart morphogene-
sis (Bartman, Hove, 2005).
One of the accepted mechanisms of heart tube formation in-
volves forces caused by contracting actin microfilaments. The 
forces caused by the contractions mold and bend the crescent 
into a tube shape, forming the heart tube (Taber, 1998).
Many theories have been produced to try to link biomechanics 
with heart looping. As early as 1970, a theory was suggested 
that looping is caused by differential growth of portions of 
the heart tube. Differential growth is when cells of the same 
structure grow at different rates, causing the structure to un-
dergo a physical change of shape and other physical properties 
(Stalsberg, 1970). Others suggested that heart looping is caused 
by pressures placed on the heart tube due to the expanding 
cardiac jelly (Manasek et al., 1984). Later scientists proposed 
that looping is caused by residual stress which causes the dorsal 
mesocardium to shorten and bend (Taber, 1995). Although these 
theories give possible mechanisms for the cause of heart loop-
ing, they do not provide a clear explanation for what causes the 
heart tube to bend in a specific orientation.
Additionally, all of these theories are based on the assumption 
that the forces controlling heart looping are forces from within 
the heart tube (Bartman, Hove, 2005). In 2002, an experiment 
was run to attempt to prove that heart looping is caused by 
forces placed on the heart tube from external adjacent tissues 
pressing on the embryo. The splanchnopleure is an extraem-
bryonic membrane which presses against the heart tube on its 
ventral side. Because heart looping involves ventral bending and 
rightward rotation, the forces applied by the splanchnopleure 
assist the heart in rotating in the rightward direction. In an 
experiment, the splanchnopleure was removed from 24 chick 
embryos. In all 24 cases, abnormal heart looping was reported, 
proving that forces applied by the splanchnopleure have a direct 
effect on heart looping. In most of the cases, slightly skewed 
ventral bending was reported, along with reports of minimal 
rightward rotation of the heart tube.
In most ex vivo experiments that analyze heart development, 
such as this one, conditions required to analyze the growth 
are dependent on factors which cause surface tension. Under 
normal in vivo conditions, surface tension forces have not been 
found to affect heart looping. It is interesting to note that in 
a parallel experiment, it was found that by placing the chick 
embryos in a liquid medium and thereby eliminating standard 
ex vivo surface tension forces, some abnormalities were found 
with respect to heart looping. This suggests that there are in fact 
surface tension forces present in vivo which play a role in heart 
looping (Voronov, Taber, 2002).
Another pathway regulating heart looping begins with secreted 
proteins flowing through the heart tube. Although very little is 
known about this pathway and the forces involved, it is known 
that it in some manner provides the forces required to initiate 
rightward rotation of the heart tube. This pathway is controlled 
by the Pitx2 gene, the nodal gene, and the lefty gene (Moorman 
et al., 2003).
Figure 5. Bending of the distal outflow portion of the ventricular 
loop (Moorman et al , 2003) 
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Myocardial trabeculae are known to have many effects on 
the developing heart. While they are mainly known for their 
assistance in helping blood flow in the appropriate direction 
prior to formation of the atrial and ventricular septa, myo-
cardial trabeculae also produce peristaltic contractions within 
the myocardium. These contractions help the trabeculae to 
become more compact and to fold along each other, there-
by producing the ventricular walls (Thompson et al., 2000). 
A result of producing and solidifying the ventricular walls is 
that the intramyocardial blood flow increases. This increase in 
blood flow will cause an increase in the fluid forces affecting 
heart morphogenesis, and will also cause these stresses to be 
more evenly distributed within the portions of the heart upon 
which they are working (Taber, 1998).
The role of hemodynamics in septation has been debated for many 
years. The “flow molding” hypothesis suggests that cardiac septa 
form due to opposite pressure gradients formed by two antiparallel 
streams of blood flowing through the heart simultaneously (Jaffee, 
1963). Scientists who support the flow molding hypothesis believe 
that the cells lining the heart tube are able to detect changes in 
pressure caused by different flow velocities and directions. When 
such changes are detected, morphological changes are induced, 
causing the septa to form. Using this biomechanical mechanism as 
a springboard, they also suggested that these fluid forces assist in 
shaping and molding the cardiac jelly into firm structures in order 
to form the walls of the heart chambers (Dewey et al., 1981). 
Furthermore, experiments proved that modifying the fluid veloci-
ties in developing chick hearts can result in many heart malforma-
tions, including deformed ventricular septum formation (Clark et al., 
1989). Challengers of the flow molding theory argue that the whole 
foundation of the theory is incorrect. They have used advancements 
in imaging technologies to show that the initial blood flow through 
the heart chambers does not appear as two antiparallel streams. 
This data suggests that perhaps septa formation is not at all affected 
by fluid forces. Possibly, it is the formation of the septa which may 
actually create and direct the streams of fluid; the heart septa might 
be the initial cause of formation of certain fluid forces found in the 
heart (Yoshida et al., 1983).
The frictional force caused by fluid flowing along the surface of 
a cell is known as shear stress. In the developing heart, shear 
stress is caused by the blood which is being pumped throughout 
the developing chambers. Shear stress is known to play a very 
major role in valve formation. In a study done with zebrafish, 
reduced fluid forces resulted in complete prevention of valve 
formation (Hove et. al., 2003).
In a recent study, a positive displacement pump was used to 
simulate the fluid forces and shear stress produced in the devel-
oping heart. Because the experiment focused on valvulogenesis, 
embryonic chick hearts with endocardial cushions were iso-
lated. They were placed inside a tubular collagen scaffold, and 
remained there untouched for 72 hours. The purpose of this 72 
hour period was to guarantee that the cells adhered to the in-
side of the tube (Tan et al., 2012). It is known that hemodynamic 
forces increase as heart development progresses (Biechler et al., 
2010). Therefore, the forces applied by the pump were divided 
into two periods, one of a low force, followed by one of a higher 
force. Obviously, the actual level of fluid forces and shear stress 
found in vivo could not be completely replicated, for had these 
forces been applied, the cushions would have been pushed out 
of the tubular scaffold. The forces used in the experiment were 
based on formulas used to determine the highest magnitude 
of force that the cushions would be able to withstand without 
being dislodged from the tube. Initially, through the use of a pos-
itive displacement pump, a force with a frequency of 5.38 x 10-2 
Hz with an average velocity of 0.07mm/s was applied in the tube 
for a period of three days. The shear stress calculated based on 
these numbers is 7.6 x 10-4 Pa and a positive pressure of 4.3 x 
10-3 Pa. After this three day period, the flow rate was raised to 
a force with a frequency of 0.29 Hz with an average velocity of 
0.86mm/s, and was applied for an additional four days. The shear 
stress calculated based on these numbers is 9.4 x 10-3 Pa and 
a positive pressure of 0.053 Pa. The shear stress in the second 
flow phase is equivalent to a 92% increase. Control groups were 
set up in tubes where no pump was attached. The control tubes 
were attached to bioreactors to ensure a closed loop would 
exist, thereby maintaining comparable oxygen levels and other 
conditions with the flow tubes.
Figure 6. Comparison of flow and no-flow cushions (Tan et al., 2012).
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Following the first (days 1-3) and second (days 4-7) phases of 
pumping forces, the “flow” cushions and the “no-flow” cushions 
were analyzed. After the first phase, no significant differences 
were found between the flow and no-flow cushions. However, 
analysis after the second phase revealed amazing results. The 
no-flow cushions formed a scattered network of cells in the 
lumen of the tube. This network was very loose, and did not 
exhibit signs of the rigidness or compactness normally found 
in heart valves. In contrast, the flow cushions formed a very 
compact mass of cells. The mass was wedge-shaped, and had 
leaflet-like structures extending off of it (Tan et al., 2012). 
Figure 6 shows confocal laser scanning microscope images 
comparing the cushions.
A signaling molecule, rhoA was also studied in this exper-
iment.  rhoA regulates the stiffening of the AV cushions, a 
prominent characteristic.  The flow cushions were found 
to be much stiffer than the no-flow cushions.  It was found 
that rhoA message levels were increased by flow forces. 
In addition to that, it was also reported that inhibiting a 
downstream effector of rhoA, rhoA coiled-coil containing 
kinase (ROCK), caused a decrease in stiffness of the fibers 
in the AV cushions.  Figure 7 shows a graph comparing the 
expression of rhoA in flow and no-flow cushions (Tan et 
al., 2012).
This study was a major breakthrough in relating biomechan-
ical forces to heart development.  Even though the shear 
stress and fluid forces applied in this study were significant-
ly below values found in vivo, the cushions and proteins 
still responded appropriately.  The flow cushions still devel-
oped into wedge-shaped stiff masses, and rhoA was clearly 
upregulated.
Discussions
Formation and development of the human heart involve many 
precise and intricate steps.  New studies have analyzed how 
many of these steps are initiated by mechanical factors.  A 
major element of this hypothesis is that the heart begins to 
pump blood before it is completely developed.  The fluid rush-
ing through the developing heart causes shear stress, flow 
pressure, and surface tension.  With experiments, these forces 
have been proven to play a role in propagating various stages 
of heart development, with specific focuses on heart looping 
and valvulogenesis.  
Other mechanical factors, such as contractions and expansion 
of cardiac jelly, have also been linked to heart development. 
With regard to all of these forces, studies have been done to 
show abnormal heart development in experiments where the 
forces have been eliminated.  This provides a strong basis for 
theories suggesting that these mechanical forces play a major 
role in heart development.
Because the study of mechanical factors affecting heart 
development is relatively new, much of the research is still 
inconclusive.  While in many cases it has been proven that 
mechanical factors play a role in specific stages of heart de-
velopment, much of the research has not been able to spec-
ify exactly which mechanical factors affect which steps of 
heart development.  Additionally, the research done to date 
has not been able to prove, in many cases, if the mechani-
cal factors involved are causes or effects of certain stages. 
Specifically with regard to septation, it has been debated for 
years whether the blood flow paths cause the septation to 
occur, or is a result of septation.  Nonetheless, it has been 
documented that mechanical factors are definitely present in 
heart development, and regardless of whether they are the 
cause or effect of one step, they definitely affect propagation 
of further steps of heart development.
An interesting facet of studying the role mechanical forces 
play in heart development is to attempt to link these forces 
to the genes and genetic pathways which have already been 
discovered.  Due to the relative novelty of studying mechani-
cal forces in heart development, minimal breakthroughs have 
been made with respect to linking these forces to genetics. 
Although a few genes have been recognized as working si-
multaneously with mechanical factors, it is unclear whether 
these genes are influencing the mechanical factors, or are 
merely present at the same time and only affecting other, 
non-mechanical, elements of heart morphogenesis.  Future 
studies need to be performed in order to determine wheth-
er or not these mechanical force are linked to genetic fac-
tors.  If they are proven to be linked, future studies will be 
necessary to determine to what extent they are linked and 
to determine the exact mechanisms relating the genes to the 
mechanical forces.  Relating mechanical factors to genetics 
could lead to major breakthroughs in diagnosing and pre-
venting heart developmental abnormalities.
Figure 7. rhoA expression in flow and no-flow cushions (Tan et al., 2012).
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Introduction
Sports drinks were initially created for the purpose of rehy-
dration and electrolyte replacement for athletes during intense 
physical activity. (Mathew et. al. 2002) The drinks have proven 
to increase concentration, stimulate metabolism, and eliminate 
harmful substances from the body (Pinto et. al. 2013).  However, 
sports drinks have become popular today among amateur ath-
letes and ordinary exercisers looking for a drink after a work-
out. With the push for a healthier lifestyle, more people have 
begun to exercise and many drink sports drinks on a regular 
basis. In 2000, the sports drink market was estimated at 1.2 
billion dollars and has been growing since (Hooper et. al. 2005). 
Current research has demonstrated that these drinks have neg-
ative effects on teeth and can eventually lead to teeth rotting. 
With the growth in the sports drinks industry, it is critical to 
understand the effects sports drinks have on the body. This 
paper attempts to examine sports drinks from the perspective 
of oral health and review the current knowledge on the effects 
of sports drinks on teeth.
Tooth structure
Teeth are composed of three different types of tissues: enamel, 
cementum, and dentin. The enamel is the most superficial of 
all three and is the hardest substance in the entire body. The 
enamel is composed of 96% minerals with the rest being water 
and organic content. The hardness and density of enamel both 
decrease further from the surface (Lussi et. al. 2011). Because 
the enamel comes into contact with the outside, it is the most 
affected by acid producing bacteria, which can cause dental car-
ies. The cementum, which is avascular, is the part of the tooth 
that covers the root of the tooth. Collagen fibers project out 
of the cementum, forming most of the periodontal ligament, 
which keeps the tooth attached to in its socket. Deep to both 
the enamel and cementum is the dentin  (Ross et. al. 2003). 
The dentin makes up most of the tooth and is in contact with 
the dental pulp. The dentine is made up of 47% minerals and 
33% organic content (Lussi et al. 2002).  This dental pulp is both 
highly vascularized and very innervated (figure 1).
Effects of Acid on Teeth
Dental erosion is the dissolution of tooth mineral caused by 
external sources and not from bacteria, like plaque (Arnauteanu 
et. al. 2015). It is characterized by initial softening of the enamel 
surface.  This leads to further dissolution of the enamel crystals, 
which will cause permanent loss of tooth volume and a softened 
surface layer  (Lussi et. al. 2002). Erosion, as opposed to tooth 
decay, leads to a widespread thinning of the tooth surface with-
out causing dental caries (Milosevic 2004.) Erosion occurs when 
the pH of the solution around the enamel is lower than 5.5. 
At this low pH, the hydrogen ions dissolve the minerals which 
allows the calcium and phosphate ions to diffuse out of the 
teeth  (Adhani et. al. 2015). In dentine only the mineral portion 
dissolves in acid while the organic component remains (Lussi et. 
al. 2011)(figure 2).
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Figure 1. The anatomy of a tooth. The enamel being most superficial 
and moving deep, the cementum, dentine, and pulp  (https://
medlineplus gov/ency/images/ency/fullsize/1121 jpg)
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Figure 2   The different stages of dental erosion  On the left the 
softening of the enamel without tooth material loss  In the middle 
there is partial tooth material loss and softening of the underlying 
surface. On the right is significant tooth material loss. (Lussi et. al. 
2011)
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A study was done in which tooth samples were incubated in 
two different solutions, one at pH of 7 and the other at a pH of 
4. Both showed a decrease in the minerals of calcium, zinc, and 
phosphate, with the solution at pH of 4 showing a greater de-
crease. This demineralization is characteristic of teeth in acidic 
conditions (Adhani et. al. 2015).
While erosion affects all teeth, the extent of erosion will differ 
for each type of tooth. A study was conducted using different 
types of teeth to compare the effects of acid and also to exam-
ine how the buccal/labial and lingual/palatal sides are affected 
(figure 3). The results showed that the lingual/palatal surface of 
the teeth showed greater loss due to acid dissolution than the 
buccal/labial side of the corresponding tooth. The palatal side 
of all maxillary teeth showed greater susceptibility than the lin-
gual surface of the mandibular teeth. The teeth in the mandible 
showed great variation among teeth and based on surface, while 
the maxillary teeth showed similar dissolution for the palatal 
side and little variation among the buccal/labial sides. The dif-
ference can be due to the fact that the lingual/palatal sides of 
the teeth generally are observed have more wear due to being 
exposed to food for longer periods of time than the buccual/
labial sides (Tucker et. al. 1998). 
Acidity of Sports Drinks
The acidity of many sports drinks is much lower than the critical 
pH of 5.5, which has been shown to cause dental erosion.  
Product  pH
Monster Assault 3.49
Red Bull 3.37
Gatorade Fruit Punch 3.27
Propel Mango 3.23
Gatorade Lemon-Lime 3.07
Full Throttle Energy Drink 2.94
Gatorade Cool Blue 2.92
5-Hour Energy 2.81
Powerade Red 2.77
Rockstar 2.53
Figure 3  The pH of many common sports drinks  (http://www 
sheltondentistry com/patient-information/ph-values-common-drinks/)
Erosion Caused by Sports Drinks
A study was performed to determine if there is an association 
between drinking sports drinks and dental erosion. Seven hun-
dred and ninety-five patients filled out a self-administered ques-
tionnaire, which included their background, dietary habits, and 
frequency of tooth brushing. The patients then were checked 
for dental erosion, checking twenty surfaces in total among 
fourteen different teeth for each patient. A patient with three or 
more surfaces exhibiting erosion was considered to be affected. 
Of the people who had a low consumption of sports drinks, 
less than 0.24 liters/day, 26 percent were affected. Of those with 
moderate consumption, 0.25-0.75 liters/day, 41 percent were 
affected and of those with high consumption, more than 0.75 
liters/day, 77 percent were affected. An athlete during training 
will drink at least 1.5 liters/day, which is much higher than those 
considered in the high consumption group for this study, and 
would therefore be highly susceptible to dental erosion due to 
these sports drinks. This study showed that there is an associa-
tion between drinking sports drinks and dental erosion  (Sovik 
et. al. 2015).
In a two-part experiment the erosive potential of 5 sports 
drinks was first checked in vitro for erosive potential and then 
the most erosive drink was tested to determine how it affect-
ed teeth in situ.  The in vitro part took Gatorade, powder and 
liquid, Isotar, powder and liquid, and Isotar liquid and immersed 
six enamel samples for each solution for a total of four hours, 
checking the erosion every hour. The Gatorade liquid was the 
most erosive and therefore was used for the in situ part. In this 
experiment ten adults wore intraoral appliances that contained 
two teeth. The adults were then put on a drinking regimen of 
the Gatorade for ten days. Upon completion the samples were 
checked for erosion. The results showed marked erosion in 
three, mild erosion in two, and slight erosion for the remain-
ing five. This showed how there is variability among individual 
susceptibility to enamel erosion. This variation can be due to 
many components including drinking habits, amount of saliva, 
and biological variation in tooth specimens. It also showed that 
individuals that are susceptible can have major erosion due to 
sports drinks (Hooper et. al. 2005).
In another experiment, Sting, a sports drink with citric acid 
with a pH between 2-3, was investigated for its effects on tooth 
enamel.  Anterior teeth were submerged in Sting for five min-
utes every six hours for fifteen days.  The results showed surface 
irregularities, pitting and structural loss of enamel. This exper-
iment confirmed previous studies that beverages with “higher 
concentrations of citric acid have an aggressive effect on the 
enamel surface leading to its dissolution” (Kazmi et. al. 2016).
In another study, three sports drinks were tested for their ero-
sive potential. The three drinks were Gatorade Citron, 5-Hour 
energy, and Powerade Cherry. Fourteen premolars were chosen 
for the study and were divided into groups for each drink. The 
teeth were exposed to the specified drink for four times for 
two minutes each over a one hour span every day for fourteen 
days. Compared to the control group held in artificial saliva, the 
Gatorade was the most erosive with an average loss of 10% of 
calcium ions and 8% of phosphorous ions. The Gatorade was fol-
lowed by Powerade in erosive potential, having an average loss of 
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9% of calcium ions and 6% of phosphorous ions. The least erosive 
of the three drinks was 5-hour Energy, which showed an aver-
age loss of 5% of calcium ions and 3% of phosphorous ions. The 
results showed that each of the drinks caused erosion of the 
enamel and loss of calcium and phosphorous ions, with Gatorade 
showing the most erosive potential (Arnauteanu et. al. 2015).
In a study, three beverages and medicated cough syrup (Johnson 
and Johnson) were tested on teeth with and without resto-
rations. The drinks were a carbonated drink (The Coca-Cola 
Complany), a non-carbonated drink (Parle Agro), high-energy 
sports drink (Red Bull). The sports drink had a pH of 3.26 but 
also compared to the other drinks had the highest neutralizable 
acidity. The specimens were in the high-energy sport drink for 
350 hours over fourteen days, equaling fourteen years of normal 
beverage consumption. The teeth without restorations showed 
erosion and the restored teeth showed microleakage, due to the 
erosive effects of the sports drink. The drink contained citric acid 
which can “bind to calcium and phosphorous thereby promot-
ing increased titratable acidity levels.” The citric acid added to 
the drinks for flavoring agents leads to an increase in the sports 
drinks erosive potential. The microleakage caused by long term 
use of the sports drinks can eventually lead to restoration failure 
or secondary caries  (Trivedi et. al. 2015).
Another problem for people who drink sports drinks is the hy-
posalvation that occurs during exercise. Due to the strenuous 
activity, an athlete can lose up to 1.5 liters of liquid from perspi-
ration. This leads to a decrease in saliva resulting in xerostomia, 
dryness of the mouth. Saliva normally acts as a buffer and can 
neutralize the acidity of consumed liquids or foods. The saliva will 
also clear the liquids and foods quicker from the mouth there-
by lessening the harmful effects of the acid. Even as acids cause 
ions to release from the teeth, the saliva can provide calcium and 
phosphorous to replenish the teeth. However, when there is less 
saliva in the mouth during an exercise the sports drinks’ acidity 
will have an even greater effect than normal and cause more ero-
sion than during rest. Also, because of this dryness in the mouth 
a person will usually drink more and therefore will have more 
acidic drink with less buffer (Noble et. al. 2011).
In the future drink companies are looking for ways to combat 
the erosive potential of sports drinks. By adding calcium, com-
panies can see a pH adjustment which will reduce the erosive 
potential of the sports drinks, as it has been done for soft bev-
erages (Arnauteanu et. al. 2015). This concept of adding calcium 
has also been tried with Ribena ToothKind. Compared to regu-
lar Ribena, the Ribena Toothkind showed significantly less enam-
el loss. (Milosevic 2004). If these results can be duplicated with 
sports drinks then their erosive potential will be decreased and 
be healthier for athletes.
Conclusion
Originally developed for professional athletes, sports drinks 
have become increasingly popular among the general popula-
tion as well. However, studies indicate that the acidity levels 
found in sports drinks can cause dental erosion. Sports drinks 
have a pH well below the critical pH of 5.5 and therefore have 
harmful effects on teeth. The low pH of the drinks causes the 
minerals to diffuse out of the tooth and cause a loss in tooth 
volume. The acid also causes a loss in hardness, which can lead 
to further tooth damage. New ways of making these drinks may 
help mitigate the adverse negative effects of sports drinks on 
dental health.
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Introduction
The immune system is incredibly complex in its means of main-
taining health and protecting the body against foreign invasion. 
It is a network of cells, tissues, and organs that work together 
to defend the body against “invaders” known as antigens. If the 
body recognizes a cell as being “non-self”, it triggers an immune 
response against the antigen. The immune response includes 
different cells that the body stores in preparation for attack 
(Storey, Jordan, 2008). 
All immune cells begin as immature stem cells in the bone mar-
row. They respond to cytokines (which are proteins involved 
with immune system cell communication) and other signals to 
develop into B cells, T cells, and phagocytes. B cells’ main role is 
to secrete antibodies. When B-cells encounter an antigen, they 
create plasma cells for that antigen, which then secretes hun-
dreds of identical antibodies that are specific to that antigen. 
Antibodies, also known as IG- immunoglobin, are highly specific 
proteins found in body fluids that identify antigens and connect 
to them with its specific shape and mark them for destruction. 
They neutralize the antigen and prevent it from attacking a host 
cell. Phagocytic cells then destroy the antigen (Storey, Jordan, 
2008).
Another type of immune cell is called a T-cell. There are two 
different types of T cells; Helper T cells (CD4’s) contribute by 
directing immune responses, and Killer T cells (CD8’s) attack 
infected cells. The Major Histocompatibility Complex (MHC) 
are proteins on cell surfaces and code for the specific unique 
proteins that the cell contains. MHC protein bind to the sur-
faces of antigenic cells and help T-cells distinguish other cells as 
being self or nonself (Adar, et. al. 2015). 
This leads to the concept of transplantation. If foreign tissue 
is implanted in the body, the T-cells will recognize the tissue’s 
MHC as being nonself and will therefore attack it. A fetus has 
the distinction of being a tissue alloantigen in the mother’s body. 
This is because it is impossible for a mother and child to be 
genetically identical since the fetus inherits a set of genes from 
each parent so the paternal genes are going to be considered 
foreign to the maternal immune system (Mellor, Munn, 2007). 
Furthermore, if the fetus is a boy, then they are certainly genet-
ically different due to the presence of the Y chromosome in all 
males (Simpson, et. al. 1997). Consequently, one would assume 
that the maternal immune system would identify the fetus as 
being a foreign tissue and reject it. However, nature proves that 
this is not the case. Additionally, pregnant women do not seem 
to be more susceptible to infection. This proves that the ma-
ternal immune system is functioning and carrying out all other 
appropriate immune responses (Sacks, et. al. 1999). The purpose 
of this review is to explore this unusual relationship, and by sur-
veying the recent literature, gain insight into the complexities 
of the immune system and explain this seemingly paradoxical 
relationship.  The first to have raised the question of the mater-
nal-fetal immunological paradox was Peter Medawar. His initial 
1953 lecture and essay on this topic led to extensive research 
till this day. Retrospectively, scientists give him the distinction as 
the father of reproductive immunology. Upon doing pioneering 
research on skin graft rejection, Medawar wondered why a fetus 
is different than any other foreign transplant if the body clearly 
tolerizes its presence. He proposed three possible explanations; 
the mother and fetus have a physical anatomical separation, the 
antigenic immaturity of the fetus, and the immunological inert-
ness of the mother (Billington, 2003).
Methods
Research was compiled from original journal articles, accessed 
through Touro’s online library (www.tourolib.org) which has a 
subscription to the EBSCO and ProQuest databases. Key phras-
es such as maternal fetal immunology, rejection of fetus, and 
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tolerization of fetal allograft were searched to find relevant in-
formation. These were the basis for this comprehensive review 
of the topic. 
Discussion
The first to have raised the question of the maternal-fetal im-
munological paradox was Peter Medawar. His initial 1953 lec-
ture and essay on this topic led to extensive research till this 
day. Retrospectively, scientists give him the distinction as the 
father of reproductive immunology. Upon doing pioneering re-
search on skin graft rejection, Medawar wondered why a fetus 
is different than any other foreign transplant if the body clearly 
tolerizes its presence. He proposed three possible explanations; 
the mother and fetus have a physical anatomical separation, the 
antigenic immaturity of the fetus, and the immunological inert-
ness of the mother (Billington, 2003).
T cell Awareness of Fetal Presence
In response to Medawar’s first hypothesis, research was done 
to test if the maternal immune system is aware of the fetus’s 
presence. The trophoblast is a tissue layer that surrounds the 
embryonic cells. It supplies that embryo with nutrients, and its 
outer layer separates the fetal and maternal circulatory system 
throughout the entire pregnancy (Bonney, Matzinger, 1997). 
Researchers performed an experiment to discover if there are 
fetal MHC molecules at the extraembryonic tissues and if so, 
if the paternal genes are present in equal proportion to the 
maternally inherited genes. They implanted an embryo with pa-
ternal (foreign) and maternal (identical) MHC class 1 genes in a 
mouse and tracked them. On day 13 of gestation, fetal cells had 
low levels of MHC class 1 genes, yet equivocally high levels of 
both paternally and maternally derived genes were present at 
the interface of the extraembryonic and uterine tissues . Since 
the paternally derived genes are present in high numbers at the 
interface, it is unlikely that the paternal antigens are not acces-
sible to the maternal immune cells. This study proves that the 
maternal tolerance cannot be contributed to a lack of paternal 
gene expression or to a lack of contact between the mother’s 
immune system and fetal cells (Philpott, et. al. 1988).
Another study which strengthens this point was done on mice 
in which H-2K females were mated with H-2B males. For com-
parison purposes, they also mated these females to H-2K syn-
ergic mice and a third party, H-2s bearing mice. When tested 
mid-pregnancy, mice bearing H-2B conceptuses had reduced 
numbers of T cells with high expression of the clonotype and 
6-9 times more clonotype positive cells that were missing CD4 
and CD8 than the control mice. This reaction proves that the 
maternal T cells are exposed to and recognize the paternal allo-
antigen (Tafuri, et al. 1995).
They tested the mice further to determine if the T cell changes 
were still present after delivery of the fetus and found that the 
T cells were restored to the same levels as the control mice. 
However, that could just indicate that there is only tolerization 
when the paternal alloantigen is present in the body. To test this, 
after delivery, they introduced grafts of the H-2KB gene and 
the mice rejected it. They have also tried transplanting paternal 
grafts and have found that the mother’s immune system only 
accepted it if the MHC peptide complexes on the graft were 
identical to that of the fetus. After the pregnancy, however, the 
maternal immune system did reject the graft. This study proved 
that pregnancy induces a transient state of tolerance for the 
paternally derived genes of the fetus (Tafuri, et. al. 1995).
These studies indicate that Medawar’s first two hypotheses 
were wrong. The maternal tolerance is clearly not due to lack of 
exposure, and must be contributed to some mechanism which 
occurs during pregnancy that protects the fetus from rejection. 
As for his argument that the fetal antigenic cells are immature, 
we do see that fetal cells may lack high levels of MHC expres-
sion during gestation. However, he was assuming that the only 
exposure the maternal immune system has is from the fetal 
cellsf. As the above experiments proved, the trophoblast, which 
is definitely in contact with the mother’s immune cells, had 
MHC genes at high levels from the beginning of gestation. Thus, 
it cannot be that the tolerization is due to antigenic immaturity. 
Another study was done to test Medawar’s third hypothesis 
which is that the mother is in an immunological tolerant state. 
They found that the T cells in the spleen and lymph node dis-
played characteristics that were typical of functionally unre-
sponsive T cells and are not typical for antigen-experienced T 
cells (Zhou, Mellor, 1998). Researchers conclude from this data 
that maternal T cells are exposed to the paternal alloantigen’s 
and this exposure somehow induces a tolerant state. Scientists 
are now focused on trying to figure out what exactly causes this 
tolerant state. However, it is clear that the mother’s immune 
system is not suppressed, because it is responsive to all other 
antigens. Therefore, it would be inaccurate to describe the ma-
ternal immune system as being inert. 
Indoleamine 2,3-dioxygenase (IDO) Mechanism
There is a mechanism discovered by Drs. Mellor and Munn 
which is currently the most well accepted explanation for this 
immunological contradiction. They attribute this tolerance to 
the fetus shutting off the mother’s natural defenses. Their hy-
pothesis is that the embryotic cells in the placenta, known as 
syncytiotrophoblasts, produce an enzyme called indoleamine 
2,3-dioxygenase (IDO) which destroys an amino acid, trypto-
phan, that is necessary for the maternal T cells to protect the 
maternal body effectively (Munn, et. al. 1998).
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In order to test this hypothesis, an experiment was done in which 
they had four groups of female mice. Two groups (A and B) were 
mated to mice that were genetically identical to them and two 
groups were mated to mice that were genetically different (C and 
D). Levels of IDO were first assessed in all groups. IDO transcrip-
tion were present in all mice from 7.5 to 9.5 dpc (days post co-
itus). At later gestation times, such as on days 10.5 and 13.5, IDO 
was present in the placenta but not in the uterus or embryonic 
tissue. This data proves that IDO is only found in synctytiotro-
phoblasts and not in other tissue (Munn, et. al. 1998). 
1-methyl-tryptophan, a pharmacologic agent that inhibits IDO 
enzyme activity was then inserted under the skin of mice from 
groups A and C. Groups B and D were used as a control. On 
6.5 dpc, mice from all groups were carrying normal numbers of 
concepti and development was normal as well. However, from 
7.5 to 8.5 dpc, the number of concepti in mice from group C 
(mice that were mated with allogenic males and treated with 
the IDO inhibitor) decreased significantly and there was hem-
orrhaging around the concepti that were left. At 8.5 and 9.5 
dpc, all concepti showed signs of inflammation and deteriora-
tion. After 9.5 dpc, no concepti that were treated with the IDO 
inhibitor remained. To contrast, the concepti from groups A and 
B, fetuses whose parents were genetically identical, all survived 
and showed signs of normal development. This is despite group 
A having received treatment of the IDO inhibitor. Group D, 
which included the mice mated with synergetic partners, were 
not given IDO inhibitor and the pregnancy progressed normally 
and all concepti survived (Munn, et. al. 1998).
To test if a single paternal MHC class 1 difference will also lead 
to rejection, the scientists altered one gene and mated the mice. 
They found that the mice treated with IDO inhibitor all lost 
their concepti. The results of this experiments clearly indicate 
that IDO is an important factor in preventing the maternal im-
mune system from rejecting the fetus (Munn, et. al. 1998).
A closer look at this data sheds some light on the mechanism 
that is likely to be responsible for protecting the fetus from re-
jection. Data showed that fetal rejection happened very early on 
in gestation, which does not give enough time for B cells to have 
produced the appropriate antibodies. This leaves it to T cells to 
have taken the active role in rejecting the fetus. Furthermore, it 
would be impossible to attribute the fetal loss to toxic effects 
of 1-methal-tryptophan, because the synergetic mice that did 
receive the inhibitor displayed no symptoms, indicating that it 
must have been an immunological effect of the inhibitor. This 
groundbreaking study indicates that it is the fetal allograft that 
protects itself from being rejected (Munn, et. al. 1998).
Many studies have since been done to test this hypothesis. Due 
to obvious ethical considerations, it is impossible to do com-
plete experiments on humans, because of the rejection results 
that will likely occur. However, another research group tested 
for presence of the IDO enzyme in the human placenta. They 
first detected IDO at around week 14 and then levels increased 
rapidly and remained high throughout the pregnancy. When 
studying pregnancies with retarded intrauterine development, 
the IDO levels were significantly lower. This suggests that IDO 
enzyme is protecting the fetus from the maternal immune sys-
tem (Sedlmayr, et. al. 2002).
Because tryptophan is an amino acid and cannot be synthesized 
by the body, the body’s only source of it is from dietary intake. 
When placing golden hamsters on a high tryptophan diet, exper-
imenters found that there was reduced embryonic survival and 
it influenced pregnancies adversely. This seems to link tryptophan 
levels with maternal rejection of the fetus (Meier, Wilson, 1983).
Another finding which seems to give credence to Mellor and 
Munns findings is the progressive decrease of tryptophan levels in 
serum from the beginning of human pregnancy until delivery. This 
shows a distinct inverse relationship between tryptophan levels 
and successful pregnancy in humans (Schröcksnadel, et. al. 1996). 
In addition to the discovery of the role of IDO enzyme, further 
experiments indicate that there is another enzyme, Tryptophan 
2,3-dioxygenase (TDO), which also contributes to tryptophan de-
grading activities. While establishing a time course, they have found 
that on days 9.5 to 12.5, IDO enzyme was at its peak expression. 
This phase coincides with the days of placental appearance and 
growth. In this experiment, IDO levels did decrease after this small 
phase, but tolerization lasted throughout the pregnancy which can 
indicate that once tolerance is established, it lasts despite contin-
ued tryptophan activity. However, on days 5.5 to 10.5, at the early 
stages of gestation, TDO enzyme was found at high levels. It is clear 
that during this early stage, IDO enzyme is not there, as 1-me-
thal-tryptophan (an IDO inhibitor) was administered and did not 
inhibit the tryptophan degrading activities. This study suggests that 
early tryptophan inhibiting activities is due to TDO enzyme and 
during placental formation, IDO enzyme is responsible for inhibit-
ing the T cell proliferation (Suzuki, et. al. 2001).
Th-2 Bias Mechanism
Many researchers contribute the tolerization to mechanisms 
other than the IDO enzyme.  
Another mechanism that is now being researched is based on 
the link between successful pregnancy and a bias of Th2 cells. 
There are two types of helper T cells, Th1 and Th2. Th1 cell 
secretes pro inflammatory cytokines such as IFN-y and TNF-
a. Th2 cells secrete anti-inflammatory cytokines such as IL-4, 
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IL-10, and IL-13. IL-4, which is produced by Th2 inhibits the 
growth of Th1 cells. IFN-y, which is produced by Th1 inhibits the 
growth of Th2 cells. Dr. Wegmann, hypothesized that in success-
ful pregnancies, there is a strong bias of Th2 cells circulating at 
the maternal-fetal interphase. Because Th2 is anti-inflammatory, 
a significantly strong presence of Th2 cells will protect the fetus 
from th1 cells that cause inflammation and will allow fetal tol-
erization. In order to test this hypothesis, he injected pregnant 
mice with IFN-y and found that it resulted in pregnancy loss. 
This indicates that Th2 cells may promote maternal tolerance 
(Wegmann, et. al. 1993) .
Similar experiments done on both humans and mice have in-
dicated this mechanism. Several studies showed that in normal 
human pregnancies there were increased levels of Th2 cell ration 
bias and at fetal loss there was a Th1 cell ratio bias (Ng, 2002). 
Furthermore, after examining samples from pregnant women, 
they found increased expression of IL-4 mRNA and decreased 
expression of IFN-y mRNA (Tranchot-Diallo, et. al. 1997).
A study of the th1/th2 cell levels in peripheral blood of women 
showed further links. Researchers examined the blood of 
women who have a history of recurrent miscarriages which is 
assumed to have been caused by maternal rejection. Within that 
group, they had a subgroup of women who were currently in 
middle of a healthy pregnancy and a subgroup of women who 
just had a miscarriage. They found that the women in the middle 
of a normal pregnancy had a strong bias of th2 compared to the 
women who just had a miscarriage and that the women who 
just miscarried had a strong bias of th1 cells (Makhseed, et. al. 
2001). This implicates that th1/th2 cell ratio may play a signifi-
cant role in the maternal tolerization of paternal alloantigens. 
Nonconcurrent Theory
There have been suggestions that the fetal cells migrate to the 
maternal circulatory system: the lymph node, spleen, and thymus, 
where they will proliferate and then inactivate the potentially 
reactive T-cells. Several studies prove this to be the case with 
tolerized organ transplants. However, later research proved that 
it is highly unlikely that fetal cell migration can account for ma-
ternal tolerization. They found that, in fact, this scenario of fetal 
cell migration occurred in 1 out of 5 pregnant mice and at a 
level of 1-5 fetal cells per every 100,000 maternal cells. Because 
this event occurs so rarely, it doesn’t seem rational to list fetal 
cell migration as a likely mechanism that protects the fetus from 
being rejected (Bonney, Matzinger, 1997).
Clinical Implications
Recurrent Spontaneous Abortions
As the experiments on mice indicated, fetal rejection resulted 
in the death of concepti. The death was caused by the maternal 
immune system’s rejection of the placenta, which led to severe in-
flammation and hemorrhaging of the embryo, causing it to choke 
and die. This scenario can present in human pregnancy as well. 
Clinicians now wonder if the underlying explanation behind a lot of 
the miscarriages that occur is really the maternal immune system’s 
rejection of the foreign paternal alloantigen (Mellor, Munn, 2000). 
Furthermore, if it is indeed the cause of recurrent miscarriages, 
then discovering the mechanism that induces maternal tolerance 
has clinical relevance as it is essential for proper treatment. 
In order to test the IDO enzyme explanation for fetal tolerization, 
and to uncover if failure or dysfunction of this mechanism can lead 
to a miscarriage, researchers tested the cervical mucous, placental 
villi and decidua tissue. They surgically removed the tissue samples 
and mucus from women with recurrent miscarriages and divided 
the group into those that exhibited normal chromosomal group-
ings and those that did not. They compared the level of IDO en-
zyme presence to samples from women who had normal pregnan-
cies and delivery.  In samples of cervical mucous and decidua tissue 
they did not find a significant difference among levels of IDO in any 
group. However, when comparing villi from miscarried pregnan-
cies of normal chromosome analysis and abnormal chromosome 
analysis, they found that the tissue from the normal chromosome 
group had significantly higher levels of IDO enzyme than tissue of 
the abnormal chromosome group. These results suggest that IDO 
enzyme dysfunction is linked to women suffering from recurrent 
miscarriages. Further research is necessary to test if IDO enzyme 
treatment can prevent women from miscarrying by preventing the 
maternal immune rejection that likely takes place (Obayashi, et. al. 
2016).
Similarly, researchers who believe that a Th2 cell bias is respon-
sible for maternal tolerance have studied the connection be-
tween helper T cells and recurrent miscarriages. In one exper-
iment, they mated female mice who were deficient in IL-4 and 
IL-10 with male mice who were genetically different. They found 
that these mice experienced fetal loss. They treated some of 
these mice with an intraperitoneal injection of IL-10 and found 
that it protected the fetuses from resorption. (Sykes, et. al. 2012) 
Women who are suffering from recurrent spontaneous miscar-
riages are assumed to have a dysfunction in the immunological 
response to their fetus. This study implicates that by intervening 
and manipulating the levels of Th2 cells at the beginning of a 
pregnancy can protect these women from future miscarriages. 
Further research is being done on specific treatment methods. 
Preeclampsia
Preeclampsia is a pregnancy complication characterized by high 
blood pressure. The high blood pressure seems to result from 
abnormal formation of blood vessels in the placenta. ET-1 is the 
peptide which causes vasoconstriction. Studies have found that 
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increased level of ET-1 in the plasma correlated with a bias of 
th1 cells. Upon further examination, this observation can in-
dicate that if maternal tolerance mechanisms do not function 
normally, preeclampsia can occur. 
When comparing women in middle of normal pregnancies to 
women with preeclampsia, they found that the ratio of th1/th2 
was 7.6 in normal pregnancies and 11.6 in preeclampsia preg-
nancies. This shows that significant increases in levels of th1 are 
associated with preeclampsia (Kuwajima, et. al. 2001). 
The th1/th2 cytokine imbalance that is found in preeclampsia 
can be explained since th1 cell is a proinflammatory cell and the 
vasoconstriction can be a result of inflammation of the placenta 
and umbilical cord (Vargas-Rojas, et. al. 2016).
Conclusion
The mystery of why a mother does not reject her fetus, as she 
would reject any other foreign object, is the focus of much re-
search and academic debate. There is clear evidence to prove 
that the maternal immune system is in contact with the fetus 
and aware of its presence. The fetus is surely expressing pater-
nal genes that are considered foreign to the immune system. 
Furthermore, the maternal immune system seems to otherwise 
function completely as normal, indicating that there is a specific 
mechanism which must protect the fetus. One suggested mech-
anism is that the fetus secretes IDO enzyme which inhibits a 
maternal amino acid, tryptophan, which supports the T cells of 
the immune system. This forces the maternal immune system 
to tolerize the fetus. Another explanation is that tolerization 
is due to th2 bias in t cell1/2 ratio. Th2 is an anti-inflammatory 
cell and can protect the embryotic tissue from a strong immune 
response. Details of these possible mechanisms has medical rel-
evance for recurrent spontaneous abortions and preeclampsia 
because both conditions seem to be caused by immunological 
dysfunctions of the tolerization mechanism. Further research is 
being done to uncover other details of the mechanism and learn 
the entire explanation for this immunological paradox.
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Introduction
In many social circles a good smile is considered indicative of a 
healthy lifestyle and a wholesome person. Anthropologists have 
shown that people with striking smiles are more successful and 
confident than their peers (Townsville Bulletin, 2005). It has 
been noted that the biggest indicator to a smile’s importance 
is the recent surge in purchase of whitening products and the 
reading of articles pertaining to such goods (Kihn, 2007). By na-
ture, most people have a low self-esteem and will do anything to 
gain confidence in themselves or others. This is the root cause 
for the recent popularity of whitening procedures being used by 
adults to restore their original white tooth shade.
Most people are born with the potential for untainted white 
teeth, yet when they reach their adult years this doesn’t be-
come the reality. What happened along the way to change this 
potential? The answer is that their teeth became stained in one 
of two manners, intrinsically or extrinsically. Extrinsic staining 
occurs when the enamel of the teeth is discolored by intensely 
colored pigments termed chromogens that possess ability to 
bind to its white, outer portion. Coffee, red wine, cola, and tea 
all have these chromogens and contribute to extrinsic staining. 
Smoking is another lead cause as the tobacco is composed of 
two different key components. Tar is naturally dark and pro-
motes staining, while nicotine is colorless. However, when the 
nicotine is mixed with oxygen it becomes a yellowish surface 
staining material. 
Intrinsic staining is an entirely different subject and is the re-
sult of a discoloration of the internal structure of the teeth, 
known as the dentin. Dentinogenesis imperfecta is a genetical 
disorder of tooth development which causes improper dentin 
formation and results in teeth that may take on a blue-gray or 
yellow-brown hue. Both deciduous and adult teeth are subject 
to this malady which may weaken teeth more than normal, mak-
ing them prone to erode, break, and even become permanently 
lost. Although fluoride is necessary to help prevent decay, if 
taken too far and ingested in excessive quantities it can lead to 
fluorosis.  Fluorosis will result in white streaks that appear on 
the teeth and can only be removed with dental measures like 
bleaching. Trauma to the teeth can either cause internal bleeding 
discoloration or alternatively lay down more dentin under the 
enamel layer. As a result of dentin being a darker shade than the 
enamel layer, the darkness shows through and gives off a darker 
appearance. Another source for internal staining is tetracycline 
staining. The minocycline binds to plasma proteins and becomes 
deposited into the collagen-rich connective tissues of the bone, 
teeth and pulp. It starts with a light yellow tinge and develops 
into stronger colors when it oxidizes upon exposure to light 
(Good, Hussey, 2003). Finally, the most prominent cause for the 
odd tone of teeth is the indefatigable age factor. As people age, 
their enamel wears thin and reveals the yellower dentin beneath 
it. All of these causes can lead people to seek change and inves-
tigate the subject of tooth whitening. 
The tooth whitening that will be dealt with in this thesis is far 
more effective in removing extrinsic stains than intrinsic ones. 
Tooth whitening by definition means the reestablishment of 
the initial and natural color of the tooth, while tooth bleaching 
is going beyond that which is natural. However, being that the 
terms are used interchangeably in varying circumstances and 
throughout the literature, the same pattern will be followed 
here. Both whitening and bleaching will thus always be refer-
ring to the general color change, without discussing its earlier 
appearance. Furthermore, it must be pointed out by way of in-
troduction that prior to bleaching, the way to change the color 
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of teeth was via laminated veneers or crowns. The invention of 
tooth bleaching was designed to be a more cost-effective and 
less invasive procedure.
The mechanism of the bleaching isn’t fully understood but the 
principle concept is almost universally accepted. The active in-
gredient is either HP (hydrogen peroxide), or CP (carbamide 
peroxide) which breaks down into 33% HP and is thus a weaker 
version of the former. An oxygen species which can vary between 
perhydroxyl anion (H02-), hydroxyl radical (HO-) and various 
other radicals subsequently forms from the HP. The structure of 
the radical depends on the reaction conditions such as presence 
of transition metals, light, temperature and pH (Joiner, 2006). This 
radical reacts with the extracellular matrix portion, specifical-
ly the chromophores and pigments it contains, to degrade the 
stains formed on the surface of the teeth (Goldberg, et. al. 2010). 
The chromophores are the part of the molecule of a dye that is 
responsible for its color, while the chromogens are those sub-
stances that can be converted into a pigment or dye. In a broad-
er sense, it can be said that HP or CP break stains into smaller 
pieces, making the color less concentrated and consequently the 
teeth brighter. In a more technical chemistry sense, it can be said 
that the reaction with HP or CP leads to the oxidation of carbon 
double bonds in organic chromogens. This in turn fragments the 
chromogens so that the power of their color is subdued or even 
eliminated (Carey, 2014).
A study aimed at determining the relative effectiveness of CP 
or HP tested six people, having three of them perform bleach-
ing with 3.5% HP and the other three by using 10% CP. These 
two concentrations are equivalent, as the more complex CP 
molecule breaks down into 33% HP and 67% other materials. 
Comparing results by using the Vitapan Classical shade guide to 
test the percentage of color change, the two substances were 
deemed to be statistically similar. Canines and incisors both de-
creased a few shades despite the fact that the concentration 
of peroxide was on the lower side of the bleaching spectrum 
in both cases (Berga-Cabarello et. al. 2005). Although the sam-
ple size was small, it is sufficient as it is merely confirming that 
which was previously understood as common knowledge. It can 
be seen from this study that pure HP is a more potent whiten-
er than CP, as CP requires three times the concentration for 
equal results. However, it has been postulated although not yet 
proven, that CP does have its own advantage over HP. Equivalent 
amounts of oxygen species are released in both HP and CP, 
but not in equivalent amounts of time. CP releases the oxygen 
species slower and is consequently more stable, yielding better 
long-term results. Due to a lack of experiments on this theory, 
further testing should be performed to substantiate this claim 
about the long-term results.
There are three methods of bleaching that effectively remove 
most extrinsic stains and some intrinsic ones as well. Whitening 
toothpaste isn’t among these three as it is only effective for 
light surface stains. The first is the power bleaching method 
performed chairside by a dentist. It requires usage of a high 
concentration of bleach (usually between 30% and 38% HP) and 
is applied for a duration of 30 minutes to an hour. During such a 
procedure, the dentist creates a seal around the bleaching area 
to ensure that the highly-concentrated bleach doesn’t end up 
being ingested or in contact with the gums and thus irritating 
them. A second method is the supervised take-home method 
that is also monitored by a dentist. First, the patient visits the 
office to create molds for the teeth that will be used for the 
treatment. Then the peroxide is given in a gel form to be placed 
in the trays and applied at the dentist’s recommended concen-
tration. This is usually between 10% and 20% CP (equivalent to 
3.5% and 7% HP respectively) and involves duration of a few 
hours daily for a couple of weeks. Periodic complementary 
appointments at the dentist’s office are recommended to en-
sure the success of the operation. A third method is the OTC 
(over-the-counter) bleaching method. The user can find these 
whitening strips or gels at their local pharmacy or even on the 
internet. The concentration of peroxide in OTC products is in 
the 5% to 7% HP range. 
The advantage of the chairside power bleaching is that it can 
be done at a rapid speed, with high concentrations, expediting 
the bleaching process. Its higher price tag, requirement to visit 
an office for treatment and use of dangerous concentrations of 
powerful chemicals makes some people wary of its usage. OTC 
products are far cheaper and can be done at the user’s conve-
nience, however the lack of professional regulation makes some 
people hesitant to employ it. Furthermore, it can get messy and 
is less effective for strong stains, making some people question 
if it’s worth the bother. The take-home method is moderate-
ly priced and is the intermediate between the fully regulated 
power bleaching and the more controversial OTC products.
A study was performed to compare the color change and re-
bound effect of power bleaching in comparison to take-home 
bleaching. Rebound effect is a measure of how quickly the results 
of the whitening fade and the initial discoloration returns. A split 
mouth design was used where twenty patients were randomly 
assigned chairside bleaching to either their mandibular or max-
illary anterior teeth and then followed by take-home bleaching 
to the other. Excluded from this study as well as all other studies 
listed in this thesis were those with active caries, periodontal 
diseases, previous bleaching procedures and orthodontic treat-
ments. Additionally, those with tetracycline-staining, fluorosis 
and those who habitually smoke were omitted. This ensured 
that the results would be a direct indicator to the effectiveness 
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of bleaching to standard patients with regular extrinsic stains, 
and not tainted by outside factors during the treatment time. 
Patients were evaluated by a single examiner, blinded to each 
patient’s bleaching regimen, immediately after treatment and 
2 weeks, 1 month, 3 months and 6 months later. The testing 
was done to measure for bleaching effect, rebound effect and 
color difference between post-treatment and unbleached teeth. 
The results showed that there was no significant difference 
between power bleaching and take-home whitening on any of 
the matters being evaluated except for rebound effect at the 
6 month follow-up. While take-home whitening didn’t have a 
distinguishable rebound effect at 6 months, the power bleaching 
did. This can be explained by the dehydration effect that power 
bleaching has on the teeth, which will interfere temporarily with 
the evaluation of color differences. It can be said that a lot of 
the color improvement associated with power bleaching is an 
illusion caused by this dehydration effect rather that an actual 
improvement in the tooth shade.  Another explanation is the 
longevity of treatment. Take-home bleaching is continuous for 
two weeks which allows for bleaching demineralization to work 
together with natural remineralization and results in longer 
lasting effects. However, power bleaching is a one-time treat-
ment and thus remineralization begins right away, resulting in 
faster regression of the whitening effect. Although regression 
occurs faster in the power bleaching, there is no overall statisti-
cal difference in the color comparison of post-treatment teeth 
and those untreated (Moghadam, et. al. 2013).  
More recently, it has been suggested that the use of laser heating 
can enhance the effects of tooth whitening. Regular whitening 
without heating works because the peroxide releases hydroxyl 
radicals that diffuse into the outer enamel and break down the 
stains in a matter of hours. Lasers can heat the HP and expedite 
the chemical reaction that leads to radical formation, reducing 
bleaching time. However, despite the popularity of such heating 
devices, it really has no effect on the quality, durability or speed 
of the bleaching (Carey 2014). Although there are those who 
argue and that it does work faster, it is still more costly and 
has reportedly increased the subsequent tooth sensitivity. It can 
be concluded that the results of light-activated procedures are 
equal to those lacking such treatment and there is no real ben-
efit to using such methods (Kihn, 2007). 
A study was performed using third molars to test the effect of 
various concentrations of bleaching substances on the degree 
of whitening. Hydrogen peroxide of 5, 10, 15, 25 and 35% con-
centration was applied to test the degree of whitening each one 
would do in the same 3 x 10 minute sessions. Unsurprisingly 
the 35% HP was the most effective, while the 5% was the least 
effective in changing tooth shade. Furthermore, the 35% HP 
reached the maximum degree of whitening in just one session, 
showing that it’s the fastest method. However, the 5% HP took 
a staggering 12 sessions to reach the same maximum shade. The 
expectation was that the relationship would be linear and that 
5% HP would require only 7 sessions to equal its 35% HP coun-
terpart. Instead, results showed that the number of sessions 
increase exponentially with lower concentration and that the 
relationship isn’t merely linear. An explanation for this phenom-
enon is that tooth whitening is far more complex and involves 
numerous factors to attain the same results. Thus, the diffusion 
and reaction of the degraded components of the peroxide with 
chromogens may not work under expected patterns. Despite 
this strange peculiarity, once the maximum shade is reached, 
there is no difference between the higher and lower dosages of 
HP with regard to its longevity (Sulieman, et. al. 2004). 
As is the case with most medications and procedures, tooth 
bleaching has its fair share of side effects. Is tooth bleaching 
really as safe as advertised? Are potential by-products transient 
or are their effects felt over the long haul? The null hypothesis 
prior to investigation of the subject is that there are no serious 
negative results to tooth bleaching, regardless of technique. The 
procedures are ADA approved and it’s unlikely they would sanc-
tion the use of unsafe methods. Furthermore, the technique has 
been in use for many years and if it was really harmful, would 
undoubtedly have been banned by now.
Methods
Data was found using a variety of different internet sources. 
PubMed and EBSCOhost were very helpful in providing data. 
Additionally, Google Scholar was used as a powerful search engine.
Discussion
Dentin hypersensitivity (mostly thermal) is the cause for the 
aches and pains associated with tooth whitening. Increased sensi-
tivity is the most common by-product and some degree has been 
reported in over 50% of patients (Jorgensen, Carroll, 2002). A 
survey reported that 78% of tooth bleachers experienced pains 
of some sort ensuing their bleaching regimen. The chemical pro-
cess for whitening releases the dentinal plug that is thought to be 
protecting the region. With the plugs removed, the core of the 
tooth becomes exposed to things from which it is usually safe. A 
dentinal fluid flow occurs internally, as a result, and leads to the 
excitement of pulpal tissue and the consequent sensitivity.
There are two ways to counteract the sensitivity created by 
removal of the dentinal plug that accompanies tooth whitening. 
One method is to replace the dentinal plug by using dental seal-
ants to cover the exposed root. Varnishes, bonding agents, and 
restorative materials are all viable ways to physically close the 
gap. Another related way is to commence the usage of fluorides 
which will decrease the permeability of the teeth. A different 
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approach is to cause depolarization of the nerve. Application of 
5% potassium nitrate can cause a soothing effect on the nerve. 
It acts as a tranquilizer and slows the repolarization, which in 
turn eases the pain that is associated with the irritated nerve.
An experiment was conducted to compare the tooth sensitivity 
experienced in at-home bleaching with 10 and 20% CP vs. in-of-
fice power bleaching with 35 and 38% HP. Twenty-five patients for 
each of the four categories were gathered for this experiment. 
The at-home treatments were accompanied by the antidotes of 
potassium nitrate and fluoride to see if they would help. Tooth 
sensitivity was measured qualitatively, as each week the patients 
were asked if pain was absent, mild, moderate or severe. Thirteen 
percent withdrew with pain they deemed intolerable, showing 
that not all pain involved was so temporary and bearable. The 
results dictated that 43.2% of patients experienced pain, which 
fits well with Jorgensen and Carroll’s results in 2003.  The puzzling 
statistic was that a high volume of 71.4% of users of 20% CP 
experienced pain. This phenomenon was astonishing considering 
that only 15% of those power bleached with 38% HP experi-
enced the uncomfortable sensation. As a whole, 9.5% from the 
take-home treatments in comparison with 4.3% of the in-office 
whiteners felt the sensation (Basting, et. al. 2012). This experiment 
indicates that there are other factors besides concentration that 
play a role in causing tooth sensitivity. Had it been solely based on 
concentration, then the chairside whiteners would have endured 
more sensitivity than their counterparts at home. Perhaps it can 
be concluded that the duration of the take-home bleaching made 
up for its lack in concentration. Another disappointing conclusion 
was the minimal effect that remedies like fluoride and potassium 
nitrate had on quelling the pain.
The split mouth design experiment also tested for tooth sensitivi-
ty and is important in regards to comparing sensitivity of at-home 
treatments vs. in-office power bleaching. At all the time intervals 
that color change was measured, tooth sensitivity was assessed 
by use of a visual analog scale. The results showed no significant 
difference between the two types of whitening treatments as 
each reported sensitivity in the 40-60% range. Using standard 
deviation this is deemed statistically insignificant and thus both 
were considered to be equally irritating (Moghadam, et. al. 2013). 
Another adverse by-product of bleaching is the oral mucosa 
irritation that will occur if not applied properly. Oral mucosa 
is the mucous membrane that covers the entire inside of the 
mouth with the exclusion of the teeth. This protective mem-
brane helps maintain oral health and is composed of strong 
keratin fibers which makes it resistant to injury. At a concen-
tration in excess of 10%, HP is deemed to be corrosive to the 
mucous membrane and can cause burns and tissue damage. 
When power bleaching is performed it’s imperative that there 
be something that holds back the highly potent peroxide from 
entering the oral cavity. Furthermore, patients shouldn’t be 
numbed during such procedures, as they must be able to alert 
the practitioner in the event they feel a burning sensation (Li, 
2011). However, a patient’s perception of pain can’t be relied 
upon and the dentist must constantly check the adequacy of the 
barrier that was constructed. It would be prudent to use some 
form of dyed substance to test how the barrier really is. If no die 
leaks through, it can then be considered safe enough to proceed 
with the whitening procedure.
A related issue is the gingival irritation that often occurs 
post-bleaching. Gums are a soft pinkish tissue that is com-
posed of oral mucosa, and is vital in supporting, surrounding, 
and protecting the teeth. Issues with gums have been linked to 
cardiovascular and respiratory disease by some health profes-
sionals. Therefore, it is highly alarming that patients who have 
undergone whitening treatment have in certain cases developed 
gingivitis. This inflammation of the gums will lead to red and 
swollen gums that tend to bleed easily. The onset of gingivitis oc-
curs because gums, like all oral mucosa, are subject to damage at 
concentrations exceeding 10% HP. The cause for gingivitis is an 
ill-fitting tray or a leaky and failing barrier during office whiten-
ing treatments. Although mucosal irritation is often temporary, 
gingivitis is a dangerous disease that must be taken into account 
when balancing the merits and dangers of whitening. With such 
dangers lurking, it’s quite clear that such substances shouldn’t be 
placed in the hands of minors or irresponsible people. 
An interesting study of an innovative OTC bleaching tray system 
helps shed some light on the mucosal and gingival irritation that 
often accompanies whitening. Thirty-eight subjects were provid-
ed with the Pearl Brilliant White Ionic Teeth Whitening System 
which contains 9% HP and uses electrodes in the wall of trays to 
deliver an electrical current. The 4-15 milliamperes current acti-
vates the gel, causing it to diffuse through the enamel, and leads 
to the oxidation of pigments and chromophores that is standard 
in all whitening methods. The purpose of the electrical power is 
to speed up the formation of radicals and thus reduce applica-
tion time of trays. The 38 patients applied the trays twice daily 
for five minutes and a mere five days. This contrasts with stan-
dard OTC strips which must be worn for excess of an hour per 
application and multiple weeks per cycle. Patients were checked 
after the first treatment and after five days for irritations, sen-
sitivity and for effectiveness of the bleaching protocol. Results 
after the first treatment reported a mean improvement of 2.3 
shades and only 20% discomfort, with two patients reporting 
slight burns of oral mucosa. After five days, only 15% of patients 
reported any discomfort and nobody had to stop treatment 
early. The average gingival score didn’t have a significant change 
and there was no additional inflammation after application of 
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the gel. Only seven of 38 patients had any blanching of oral mu-
cosa during any point of the treatment, and such side effects 
lasted just a few minutes and didn’t require intervention. The 
results showed a sharp contrast between the electric powered 
tray system’s 20% discomfort level and standard OTC whitening 
strips 50% sensitivity incidence (Ghalili, et. al. 2014) 
The cause for the lower sensitivity and irritation prevalence 
may have been a result of the addition of potassium nitrate to 
the HP gel which slows repolarization of the nerve and lessens 
the pain. However, it was shown in an earlier experiment that 
such treatment doesn’t necessarily work (Basting, et. al. 2012). A 
more likely explanation is the decrease in wearing time of trays 
and contact time of the peroxide gel. These results and accom-
panying explanation would fit well with the conclusion that was 
made earlier regarding that experiment, where it was stated 
that increase in duration of bleaching can lead to increased sen-
sitivity. The usage of this novel OTC treatment is slowed by its 
heavy price tag of $200 per tray, but its prowess is important to 
note. If time can be reduced significantly in an affordable manner, 
then many of the main side effects of bleaching will disappear. 
The most harmful effect that any substance can have is carcino-
genicity, the ability to cause cancer, primarily by genotoxicity. 
Genotoxicity is the negative effect that harmful substances can 
have on the genome by causing mutations to the cell’s DNA. The 
method for testing for genotoxicity is via a micronucleus test 
that quantitatively measures chromosomal damage by counting 
all cells that have inducted micronuclei into their cytoplasm after 
exposure to genotoxic agents. These micronuclei form when all 
or part of a chromosome isn’t incorporated into a daughter cell 
during cell division. A high micronucleus count is indicative of 
severe chromosomal instability and genotoxic effects that pose 
a health risk. The DNA fragments will occur only in those cells 
that have completed one round of cell division after exposure 
to the genotoxic agent. The lack of incorporation of the micro-
nuclei is due to a lack of centromeres that prevents the frag-
ments from migrating to the spindle poles during late anaphase. 
The end result is that fragments are left behind and they form a 
secondary nucleus that is kept in the cell cytoplasm.
When compiling a list of the drawbacks to tooth bleaching, the 
potential correlation to genotoxicity and carcinogenicity must 
be thoroughly investigated. The theory had been proposed that 
HP may raise the carcinogenic effect, much like it does in ex-
perimental animals. However, it has also been argued that those 
artificial conditions are of no relevance to tooth bleaching, as 
they have much higher levels of HP than tooth bleaching does. A 
study was performed to find the genotoxic effect of 10 and 16% 
CP on bleached patients. Particularly concerning is the presence 
of reactive oxygen species in the peroxides that could damage 
proteins and cell nucleus. Thirty-seven patients were randomly 
divided into two concentration groups and given customized 
trays to wear for two hours daily for a duration of three weeks. 
Collections of gingival margin cells were taken at baseline, 15 
days and 45 days by abrasion and then properly affixed to slides. 
One thousand cells were counted per slide and underwent a 
micronucleus assay. Comparing the results of the 10 and 16% 
CP there was no statistical difference between the rates of mi-
cronuclei formation at all three time periods. Most importantly, 
the rates were in fact on the lower end of the 0.3 to 1.7% range 
given in previous experiments (Bona
ssi, et. al. 2011).  These results showed that when not applied for 
long periods of time or improperly consumed, the use of perox-
ides alone isn’t cytotoxic. Hence it can be concluded that teeth 
bleaching doesn’t pose a threat to human gingival epithelial cells 
(Almeida, et. al. 2015).
Another study corroborated the results of the previous ex-
periment. Thirty smokers and thirty non-smokers were given 
10% CP to be used three hours daily for three weeks. The goal 
of this single-blind trial was to compare the genotoxicity and 
efficacy of at-home whitening between smokers and non-smok-
ers. The usage of a micronucleus assay is a good indication of 
cancer risk associated with genotoxicity, as most tumors in 
humans originate in the epithelium. The results indicated that 
bleaching didn’t increase the frequency of micronuclei in the 
cytoplasm. The number of micronuclei was higher in smokers 
than non-smokers, but that was the case prior to baseline (the 
starting point used for comparisons). This is merely indicative of 
the genotoxic effect of habitually smoking, and is unrelated to its 
effect on bleaching. Smokers and non-smokers alike didn’t have 
a significant increase in micronucleus formation after perform-
ing bleaching. Ten percent CP was thus proven to be safe when 
used at low concentrations for the three-week period that was 
required. The study did have limitations as it wasn’t truly a blind 
examiner that was testing for genotoxicity. The smokers had 
a stench on their clothing and in their breath, giving away the 
identity of the group to which they belonged. Furthermore, the 
timing of the post-bleaching micronucleus assay wasn’t optimal 
as it was given shortly after the whitening treatment. In contrast, 
the regeneration of the cells from gingival tissue takes approx-
imately ten to twelve days. Thus, had the assay been performed 
two weeks later it’s possible the results would have changed (de 
Geus, et. al. 2015). However, the limitations can be overlooked 
as the results are backed by other studies (Almeida, et. al. 2015).
A consensus opinion on the matter of genotoxicity and carcino-
genicity is given in a recent review article. Direct contact with 
peroxide can cause genotoxicity in cultured cells and bacteria. 
However, when in the presence of catalase and other biological 
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enzymes, the effect is mitigated. The free radicals of the reactive 
oxygen species need to reach the DNA to inflict damage and the 
presence of metabolizing agents inhibits their ability to reach the 
target in vivo. Thus, while it is a threat to bacteria in a lab, in humans 
it isn’t deemed a real threat. HP has a weak local carcinogenic po-
tential and nothing more. The International Agency for Research of 
Cancer put HP in group three as unclassifiable in its carcinogenicity 
in humans. Most certainly, the mild dose of 10% CP found in many 
at-home trays is of no threat to those not already predisposed to 
oral cancer (Perchyonok and Grobler, 2015). 
There was one case trial that did experience a higher rate 
of mutagenicity as a result of using tooth whitening in vivo 
on humans.  Two different groups received different types of 
in-office bleaching. The first group used ZOOM2, a 25% HP 
that also features light activation. The second group received 
Opalescence BOOST, a 38% HP which had no light treatment. 
Cell samples were collected from both the upper lip lining and 
the gingival area, via swab technique. Each sample was collected 
before bleach application, immediately after and then 72 hours 
post-whitening. The collection immediately after bleaching was 
a control group, as there wasn’t enough time for mutant cells 
to reproduce and appear in the results. The collection 72 hours 
after treatment was the experimental group, as that is ample 
time for reproduction of cells. Although there were only eleven 
members in each group, the design was to capture large effects 
and for this purpose Cohen’s size conventions test determined 
that eleven was large enough. 
Results showed slightly higher indicators of genotoxicity in 
BOOST, but both forms of bleaching caused a large increase 
in these markers. When comparing the control and experi-
mental groups, BOOST saw a 157% increase in micronucleus 
presence while ZOOM2 experienced a 142% hike. These re-
sults contradict those of other studies, however, there are nu-
merous explanations to reconcile the differing conclusions. The 
aforementioned experiments headed by both Almedia (2015) 
and de Geus (2015) used low concentrations of CP, while this 
experiment used high concentrations of the stronger HP. This 
may have led to the genotoxicity increase and wouldn’t be indic-
ative of issues in at-home bleaching. Furthermore, even power 
bleaching isn’t necessarily problematic as there were flaws in 
this experiment. Five out of 22 patients had minor restorations 
which is usually grounds for exclusion, as they have a negative 
effect and increase the micronucleus count. Also, patient’s life-
styles can’t be controlled and while in other experiments they 
may have refrained from negative behaviors, this experiment 
may have been an exception. Alcohol usage and improper diet 
have been linked to an increase in micronucleus count. All of 
these explanations make this case seem as more of an aberra-
tion than a rule (Klaric, et. al 2013). 
Tooth whitening can cause permanent damage to the enam-
el structure. In addition to the free radicals, CP produces urea 
which subsequently decomposes into CO2 and ammonia. This 
is key in the bleaching process as the urea degrades the organ-
ic matrix in the enamel. Hydrogen bonds in matrix proteins are 
dissociated by the urea and ammonium ions. These empty spaces 
caused by the degrading of matrix proteins make possible for 
penetration of the free radicals to enamel and even dentine layers. 
However, whatever breakdown the urea creates is in fact real and 
permanent damage to the enamel and is one of the more serious 
issues of tooth whitening (Elfallah and Swain, 2013).  
While enamel erosion is a serious issue, it has become well 
publicized that remineralization agents are a viable method for 
restoring tooth structure. An experiment was conducted to test 
enamel erosion generated by two different high concentration 
HP whiteners. Opalescence BOOST was used as a substance 
that is chemically active, while Mirawhite is a 30% HP substance 
that is activated by a diode laser. The experiment also tested four 
different remineralization agents to see which would be most ef-
fective in restoring initial tooth structure. Twenty-five molars for 
each whitening type were each subdivided into five groups, which 
featured one control group and four different remineralization 
experimental groups. The exact statistical measures for erosion 
and remineralization are unimportant, but the generalizations 
were quite startling. SEM/3D-SEM-micrographs revealed that 
both types of bleaching caused emphasized perikymata, which 
are the pits surrounding the long prisms of tooth enamel. These 
emphasized perikymata as well as the loss of interprizmatic sub-
stance both clearly indicated enamel erosion. These negative signs 
were even exacerbated in the teeth that were activated by the 
diode laser. Remineralization occurred in all four experimental 
groups, with calcium phosphate proving to be the best at cover-
ing the surface of the enamel. SEM/EDX-semiquantitative analysis 
showed that certain crucial elements were reduced from the 
tooth structure as a result of the bleaching procedure. Sodium 
and magnesium were most prolifically lost in the non-laser 
bleaching, while calcium and phosphorus were the hardest hit by 
the laser bleaching (Coceska, et. al. 2016).
Although remineralization agents can help repair the erosive 
effects of bleaching, this only works if patients are properly in-
formed to commence application upon the onset of whitening 
treatment. However, users of OTC products are generally not 
properly informed and also further their plight by not reading 
the instructions. Thus, even when side effects are indicated in 
the user’s manual, most consumers remain oblivious to the need 
for these remineralization agents. The loss of enamel causes a 
decrease in insulation from potential painful temperature and 
dangerous chemicals and can also lead to decay. Furthermore, 
enamel erosion makes the tooth more prone to chipping. Once 
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the enamel is lost it has no living cells to repair itself. All damage 
is permanent and costly alternative treatments such as bonding 
are now required. 
The leakage of restorative materials ensuing tooth whitening 
is another major by-product of the procedure. Restorative 
materials have been used for many years to fill caries, repair 
damage due to trauma and much more. Originally amalgam was 
the primary restorative material, until a recent surge in the use 
of composite resin material. Issues arise when there is a leakage 
of mercury ions from amalgam upon the initiation of bleaching. 
Mercury ions can be toxic and lead to numerous diseases when 
the threshold concentration is reached. 
The amalgam’s natural release is a redox (oxidation-reduction) 
reaction in which the mercury metal reacts with non-metallic 
elements to produce chemical compounds (von Fraunhofer and 
Staheli, 1972). This same reaction would take place in vitro, as 
the redox reaction takes place at the amalgam/bleach interface 
resulting in the deposits. An experiment was thus conducted to 
investigate how much of a role both concentration and time of 
treatment have on the release of mercury. Tytin amalgam con-
tains 42.5% mercury and is a typical dental restorative material. 
Sixty-five discs of tytin amalgam were prepared and divided into 
thirteen groups of five for the experiment. Four groups of discs 
were each treated with 0%, 3.6% and 6% HP. The various groups 
had varying times of exposure to HP of 1, 8, 48 and 156 hours 
respectively. The 0% HP groups were the control groups and 
contained saliva and other biological enzymes in place of the 
peroxide. The 3.6% HP groups represented the classical at-home 
concentration and the 6% HP represented a stronger version of 
these groups. The various times made this into a double exper-
iment that charted both concentration and time of exposure 
against amount of mercury ion leakage. The thirteenth group 
was treated with 30% HP for one hour and was an imitation of 
in-office power bleaching. Each disc was measured five times for 
amount of mercury ion release and each group had five discs to 
ensure the accuracy of the measurements.
The results showed a greater release of mercury ions as the 
concentration of bleach was increased. Time caused increased 
release until the eight hour mark, at which point its effect pla-
teaued. This showed that concentration was of greater effect 
than time and thus power bleachers should be cautious before 
starting whitening. However, the small amounts of mercury re-
leased don’t produce effects on humans, as the quantities are 
well below the acceptable daily intake of forty micrograms. The 
maximum sum released by any of the discs was 1.125 micro-
grams and thus would require 36 teeth with restorations to 
pose any threat. Despite its relative safety, it’s still not healthy 
to have any amount of harmful chemicals in the body and thus 
the release of amalgam is a side effect that must be taken into 
consideration when considering bleaching. In fact, this danger 
has caused Norway to ban amalgam restorations now that safer 
alternatives are available (Al-Salehi, 2009). 
Scientists hypothesized that upon the onset of bleaching, an ad-
ditional consequence would result from the redox reaction that 
occurs at the dentin. They feared bond strength at the dentin/
resin interface would be adversely affected. To confirm this sus-
picion, they performed an experiment to test all facets of bond 
strength after application of varying concentrations of bleach to 
teeth. For the shear bond strength test, forty slabs of intracoro-
nary dentin were obtained and split into four groups. One was a 
control group that was treated with artificial saliva that had no 
HP concentration. The second group was 20% HP and also had 
sodium perborate (a bleaching agent), a third group was com-
prised of 37% CP and a fourth group of 38% HP. Manufacturer 
protocol was performed for all bleaching regimens and a seven 
day waiting period ensued as a means to offer appropriate time 
for the residual bleach to leave the dentin. These teeth then 
received a shear bond strength test in a universal testing ma-
chine. Failure modes for the test were observed via microscope. 
Next, a flexural/fracture strength of dentin test was done on 
forty dentin bars from the cervical area of the buccal portion of 
roots. These forty bars were divided into the same four groups, 
underwent the same treatments and then received a three point 
test carried out by a universal testing machine. Finally, an SEM 
analysis of dentin surface and adhesive interface was prepared 
with five hemi-sections of lingual surface of crowns, for both the 
dentin surface and adhesive interface. 
The results showed that shear bond strength of the control 
group was nearly double to that of the experimental groups. The 
unbleached teeth had mixed failure modes of both cohesive and 
adhesive failures, while the bleached groups had predominantly 
adhesive failures. Flexural strength was statistically significantly 
higher for the unbleached group than the experimental groups. 
The 38% HP was the weakest of all groups, although it was sta-
tistically similar to the 20% HP coupled with sodium perborate. 
Lastly, unbleached teeth had SEM analysis that showed dentin 
surface covered with its smear layer, the two middle groups had 
some areas with fissures and the 38% HP sample had cracks 
all over the specimens. Analyzing dentin/material interface there 
was a continuous interface in the unbleached group, and pro-
gressively more discontinuity areas with the higher concentra-
tion bleached groups.
The explanation for the weaker shear bond strength in bleached 
groups, is that hydroxyl radicals penetrate into dentin and break 
down connective tissue, such as collagen and hyaluronic acid. 
This in turn increases dentin permeability, reduces hardness and 
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leads to the decrease in shear bond strength. The oxygen inhib-
its the entrance of the resin/material into dentinal tubules and 
prevents their polymerization. Even after seven days, residual 
oxygen remains and causes adhesive failure. Hence, the analysis 
of failure modes indicated more adhesive failure for bleached 
teeth, while unbleached teeth had less adhesion failure modes 
and instead more cohesion failure modes. This furthers the no-
tion that hydroxyl radicals formed from bleaching products in-
terferes with the bonding of restorative materials. This may also 
be a secondary reason for leakage of amalgam restorations, as 
the failure to properly bind at adhesive interface causes the sub-
sequent leakage.  The SEM results were consistent with those 
of the shear bond strength test, as those with the highest HP 
concentration had more cracks in the dentin surface than those 
with lower HP. Finally, the flexural strength test confirmed the 
scientist’s fears, as those with higher HP had less strength and 
would thus fracture faster in-vivo. All of these test results can be 
explained with the common theme, that the hydroxyl radicals 
ruin the structure of teeth while also reducing the ability of the 
resin to properly bond to the dentin (Vieira, et. al. 2012).
There have been numerous mechanisms proposed as ways 
to reduce and prevent the microleakage of composite resin 
restorations. This microleakage is particularly common when 
bleaching is done just prior to or soon after installation of the 
restoration. The bleach leaves behind residual peroxide that 
doesn’t allow for proper polymerization of the resin to the re-
maining portion of the natural tooth. A test was done to com-
pare various suggested means of mitigating the microleakage 
effect. Sixty intact premolars were split into six groups for the 
purpose of this trial. Group one was the control group, as the 
teeth were merely treated with saliva instead of the 10% CP 
applied to other groups. There has been a theory that allowing 
a three week time delay between bleaching and bonding would 
be ample time to allow residual peroxide to dissipate out of the 
teeth (Bittencourt, et. al 2010). Thus, group three was treated 
with 10% CP followed by a three week delay before installation 
of fillings. Group two provided the proper contrast to group 
three, as it was treated with 10% CP and didn’t have the de-
ferral of restorations found in group three. Group four had so-
dium ascorbate applied in between bleaching and the filling of 
caries. This chemical is an antioxidant and was seen as a faster 
alternative to the potentially equally effective but highly time 
consuming delay period. A recent study suggested that addition 
of surfactant (0.2% Tween 80) would enhance sodium ascor-
bate’s ability to prevent microleakage (Moosavi, et. al 2010). 
Thus, group five presented sodium ascorbate coupled with sur-
factant treatment between bleaching and restorations. Finally, 
group six was treated with catalase instead of the antioxidant 
and surfactant, following a report that catalase removes residual 
HP from the surrounding area after bleaching (Rotstein, 1993). 
Microleakage was measured semi-quantitatively by the accepted 
criteria of the depth of dye penetration at the interface between 
restoration and cavity wall.
Data from the trial indicated a significant difference in amount of 
microleakage between the unbleached group one and bleached 
groups two through six. Furthermore, group two had the great-
est microleakage as it had no preventive measures implemented 
preceding addition of composite resin. Groups five and six, al-
though significantly greater in microleakage than group one, was 
significantly less than group two. It is thus evident that sodium 
ascorbate in conjunction with surfactant and catalase by itself 
are a sufficient method of reducing (but not completely termi-
nating) composite resin microleakage. Groups three and four 
were statistically similar to group two, showing they were rel-
atively ineffective at preventing microleakage (Han, et. al. 2014). 
Extending the theory that explained the results found in this 
microleakage experiment, one can opine that application of cat-
alase can also help cure the woes of the weakening of bond 
strength caused by whitening. This in fact concurs with a pre-
viously performed experiment which also concluded that pre-
treatment of bleached surfaces with catalase prior to bonding 
improves composite-enamel bond strength (Kum, et. al. 2004). 
On the surface this seems very reasonable, as one of the causes 
for both microleakage of restorations and weakening of bond 
strength, is the oxidative materials left behind after bleaching 
which prevents polymerization of installed materials to the 
natural tooth. If catalase can serve as a deterrent to microle-
akage it should then follow that it should relieve the stress on 
bond strength that the same residual harmful materials cause. 
However, catalase wouldn’t be of any help for other side effects 
mentioned earlier in this report, as those aren’t a result of the 
residual oxidative materials that the bleach leaves behind.  
Cervical root resorption (reabsorption) is a naturally occurring 
process in primary teeth, as the deciduous teeth are uprooted 
to make way for the permanent teeth. This process is caused by 
the osteoclast differentiation that results from the pressure ap-
plied by the newly emerging teeth. However, as a result of trau-
ma or excessive pressure of various orthodontic treatments, it’s 
possible for a pathogenic resorption/breakdown of permanent 
teeth to occur. Such a condition can ruin a tooth if not properly 
treated. The problem is that this phenomenon is painless and 
unless detected via x-ray will go undiscovered until after carious 
lesions have taken hold in the external tooth. Bleaching is one of 
the orthodontic treatments that is a root cause for resorption 
due to the pressure associated with it. The disease is more com-
monly observed in those using HP bleaching than those using 
sodium perborate alone (Fearon, 2007). Sodium perborate is a 
milder procedure with less side effects, but shorter sustained 
70
Yehoshua Krasnow
results. Thus, the intensity of the bleaching regimen clearly has 
a direct effect on likelihood of cervical root resorption. Use 
of heating devices is another catalyst for this malady. This is a 
logical consequence, as the heat generates hydroxyl radicals 
from the HP which are highly reactive and subsequently break 
down connective tissue found in teeth. Together, high concen-
tration HP and heat can be a lethal combination for those try-
ing to preserve their teeth. Another explanation why bleaching 
causes root resorption, is that the acidic environment that the 
bleaching procedure supplies enhances the disease (Dhillon, et. 
al. 2011). The diffusion of hydrogen ions from the bleach makes 
the region more acidic and creates an environment that is ripe 
for bone resorption and osteoclastic activity. The proof to this 
theory is that osteoclastic activity is strongest in 35% HP (3.7 
pH), intermediate in 35% CP (6.5 pH), and weakest in sodium 
perborate (pH 9.9), a basic substance (Dhillon, et. al. 2007)   
Additionally, it has been suggested that the acidic environment 
that bleaching creates can adversely affect the beneficial mi-
crobes that regularly grow in the oral cavity. It’s important to 
have these essential microorganisms so that when adverse, ex-
ogenous viruses invade they are outnumbered and combatted 
by the symbiotic microbes. The harsh, acidic conditions could 
prove to be too much for the microbes to handle and thus di-
minish these protective organisms. Such a chain of events would 
leave whitening users with a greater risk for microbial disease. 
Four groups of eight were generated to test the effect various 
treatments and combinations of treatments would have on the 
overall concentration of microbes in saliva. The results would be 
a direct indication of the overall concentration in the oral cavity. 
The first group was treated with in-office CP 37% and at-home 
CP 10%. The second group received the in-office CP 37% and 
an at-home placebo, the third group an at-home 10% CP and an 
in-office placebo, and the final group a double placebo. All pa-
tients were given uniform brushes and dentifrices and inasmuch 
as possible were left under similar conditions. The in-office 
bleach was conducted in three sessions of one hour and the at-
home whitening was three weeks in duration. Saliva was taken 
at baseline, right after application of bleach, twelve hours later 
and repeated each week during treatment. The results were 
placed on various culture media, but all results showed no sig-
nificant difference between microbial levels at various periods. 
Thus, it was concluded that the bleaching of teeth has no effect 
as an antimicrobial agent (Franz-Montan, et. al. 2009).
The final major side effect of bleaching teeth is the potential 
to develop an addiction to the bleach. Such a disease is known 
as bleachorexia and those afflicted are dubbed bleachorexics. 
Much like anorexics who are convinced they aren’t skinny 
enough, bleachorexics are convinced that their teeth aren’t 
white enough. Instead of accomplishing a nice hue, these fanatics 
whiten to the point where teeth reach a translucent blue or 
grey appearance. This looks unnatural, especially when contrast-
ed by a person who may have a darker skin tone. Bleachorexia 
can lead patients to turn an eight week regimen into a full-year 
program. These tooth whitening junkies present an added health 
risk with gum, tooth or even throat problems from repeated 
exposure (Bee, 2006). The relatively recent increase of bleach-
orexics is due to the prevalence of OTC methods which allows 
patients to take whitening into their own hands. The enamel 
becomes permanently damaged, root canal problems arise and 
free radicals damage cells and pulp in teeth due to the over-in-
dulgence of bleach. Gums may recede, teeth become weaker 
and all other aforementioned side effects become amplified by 
the excessive use. Psychological intervention may be required 
to relieve patients of their plight.
Prior to drawing any conclusions, it’s important to examine the 
long-term effectiveness of tooth whitening. A study was con-
ducted to test for any difference in rebound effect at the two-
year mark vs. baseline and the one-week mark vs. baseline. This 
was done for both at-home bleaching and in-office bleaching, 
to test which one has more sustainable results over the long 
haul. The general perception among clinicians has been that 
the at-home bleaching lasts longer than the in-office bleaching. 
Results in the split-mouth design experiment corroborated this 
general view (Moghadam, et. al. 2013). For this experiment thir-
ty patients were given power bleaching for two sessions of 45 
minutes during a one-week span. Another thirty patients were 
given at-home bleaching kits of 16% CP, to be applied for six 
hours per night for four weeks. Color change was detected 
using the Vita Lumina shade guide and was measured at base-
line, one week later and two years subsequently.  Results for 
at-home whitening showed a mean increase of six shade guide 
units for both one week and two years successive to bleaching. 
Rebound effect was 0.25 shade guide units over two years and 
this was deemed statistically insignificant. The in-office bleach-
ing indicated a 5.5 shade guide unit improvement for both one 
week and two years after whitening. Rebound effect was 0.30 
shade guide units and this too is considered statistically insig-
nificant. Contrary to the common perception, the longevity of 
results for in-office bleaching was up to par with the take-home 
bleaching’s durability (Tay, et. al. 2012). 
The difference between the results of the in-office bleach-
ing’s six-month instability in Moghadam’s experiment and 
the two-year durability in Tay’s experiment is a simple dis-
tinction. In Moghadam’s experiment only one session of 45 
minutes was given to chairside bleaching patients. In Tay’s 
experiment two such sessions were administered on each 
patient. According to some experts, it is only after the sec-
ond bleaching of in-office treatments that tooth color does 
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change significantly (Al-Shethri, et. al, 2003). Thus, to equal 
the long-term stability of at-home bleaching, two sessions of 
chairside bleaching are required.
Conclusion
Although tooth whitening doesn’t create a higher probability of 
carcinogenicity or genotoxicity, it is far from innocuous. Almost 
50% of patients experience some form of tooth sensitivity for 
the first month of treatment. Oral mucosal and gingival irri-
tation are very common as a result of ill-fitting trays and the 
subsequent leakage of peroxides. Tooth integrity is affected as 
a result of urea degrading the enamel matrix, and hydrogen 
bonds in matrix proteins becoming dissociated by the urea and 
ammonium ions. Due to the redox reaction, there is often an 
increase in the leakage of restorations, most notably amalgam. 
Weakening of bond strength is a direct result of the oxygen 
molecules causing a failure of resin to properly bond to dentin. 
Cervical root resorption is more likely to occur following the 
orthodontic treatment associated with bleaching. Finally, there 
is even a psychological issue named bleachorexia that is caused 
by a whitening obsession. With this excessive list of side effects 
it is clear that such dangerous substances must be regulated to 
some degree and not available over-the-counter as they cur-
rently are. It is a travesty that such harmful materials are acces-
sible to minors and are not exclusively in adult’s hands. 
Various methods have been mentioned throughout the course 
of this work to help mitigate a number of the by-products of 
bleaching. While long-term rebound effect is unchanged by the 
form of bleaching (when power bleaching is done twice), the 
form of peroxide does matter. CP is said to yield longer-lasting 
results due to its slower and more stable release of oxygen 
species. Laser heating doesn’t speed up the reaction rate and 
only serves to increase tooth sensitivity and speed up enamel 
erosion. Fluoride and potassium nitrate don’t mitigate tooth 
sensitivity but decreasing the application time of bleach cer-
tainly can. In fact, usage of a novel electric powered bleach 
showed that decreasing wearing time can also cause a decrease 
in gingival and oral mucosal irritations. The best remineralization 
agent is calcium phosphate and should be taken in conjunction 
with whitening. Catalase helps remove residual oxygen species 
and should also be taken while commencing bleaching. The cat-
alase should help relieve some of the woes of weakened bond 
strength and the leakage of amalgam restorations. Cervical root 
resorption can be diminished when a lower concentration of 
peroxide is used and laser treatment is avoided. Thus, the prop-
erly informed whitening patient can be shielded from some of 
the by-products of bleaching if he/she is proactive in treating 
them. However, the issues arise for patients who are not prop-
erly informed or are negligent in providing the proper care for 
their teeth.
It is clear from the abundance of research provided in this 
report, that while cheaper, whitening isn’t a safe alternative to 
laminated veneers or crowns. Thus, those who can afford to do 
so, should choose the more conventional route when looking to 
make cosmetic repairs on teeth. The future of whitening seems 
to lie in the ability of companies to create a cheaper system 
that allows for shorter exposure time to peroxide. The Pearl 
Brilliant White Ionic Teeth Whitening System which contains 
9% HP and uses electrodes in the wall of trays to deliver an 
electrical current, is definitely a positive start for making this 
a reality. Ultimately this system needs to be tested more to 
confirm that it really is effective, while decreasing the side ef-
fects. Furthermore, the hefty price tag doesn’t allow this bril-
liant technology to gain enough popularity. A cheaper alternative 
must be created to allow all members of the populace to have 
access to this newest advance in the field. Only when this comes 
to fruition will whitening truly be a safe and cheaper alternative 
to laminated veneers and crowns.
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Introduction
Hair loss, known medically as alopecia, is a very common phe-
nomenon, affecting both males and females. Demographically, 
it effects about half of males and a quarter of females by the 
age of 50 (Vary , 2015) This makes it very likely we will be 
affected by hair loss during our lifetime. Hair loss can manifest 
itself in various forms, the most common being male pattern 
baldness defined as the progressive loss of hair beginning in 
some cases at puberty, and proceeding throughout adulthood 
(Berman, 2015). Another form of hair loss is alopecia areata, 
an autoimmune condition where the body mistakenly attacks 
healthy hair follicles. Alopecia areata effects men, women and 
children with hair loss occurring in the form of patches on the 
scalp, and in extreme forms, a complete loss of hair (subtype 
known as alopecia totalis) (Moskowitz , 2014). True, hair loss 
is not a disease in a sense that it effects our physical wellbeing, 
however, it is a condition which may cause severe psycho-
logical distress, particularly anxiety and depression upon the 
affected individuals (Hunt, McHale, 2005). These psychological 
effects, combined with the widespread prevalence of hair loss 
make it imperative for us to find a cure. In this paper, the pri-
mary focus will be on exploring whether or not hair loss can 
be prevented, and if hair lost hair can be regrown. Since hair 
loss due to hormonal causes is the most prevalent and studied 
form, it will be the focus of this paper.
Anatomy of the Hair Follicle
To get a better understanding of the mechanisms responsible 
for hair loss, it is vital we discuss how hair growth occurs in 
a healthy individual. In mammals, formation of the hair follicle 
takes place during fetal skin development. Cells which form 
the hair follicle, sebaceous and apocrine glands (responsible for 
producing oils and sweat) are all derived from ectodermal stem 
cells. In contrast, cells derived from mesodermal stem cells will 
develop into the follicular dermal papilla and the connective 
tissue sheath, while the neural crest derived melanocyte pro-
genitors produce the pigmentary cells, which are responsible 
for the coloring of hair (Fuchs, 2008). 
Although hair follicles vary in shape and size, they all have the 
same basic structure. The base of the follicle known as the papil-
la, is primarily composed of connective tissue and a capillary 
loop which supplies nutrients to the hair follicle. Cell division at 
the papilla is very rare (Pawilna, Ross , & Kaye, 2003). 
Superficial to the papilla, lies the hair matrix, the site of hair 
formation. In mammals the matrix contains trichocytes, the 
cells responsible for hair production. These epithelial cells 
produce modified keratin proteins, which contain ample 
amounts of the amino acid cysteine. Cysteine has a reactive 
sulfhydryl group which creates both inter and intra-chain 
linkage within a protein structure, thereby giving hair high 
tensile strength, and flexibility (Langbein & Schweizer, 2005). 
Also, contained within the matrix are scattered melanocytes. 
Just superficial to the matrix, lies the root sheath. The root 
sheath is further subdivided into the inner and outer root 
sheath. The inner sheath contains three different layers, a cu-
ticle layer, Huxley, and Henle’s layer. The outer layer contains 
the bulge, a stem cell rich area which supplies the entire 
follicle with new stem cells. These stem cells are vital in the 
healing process of an epidermal wound. Also, contained in 
the outer sheath is the sebaceous gland, responsible for hair 
lubrication. In the uppermost region of the outer sheath are 
the attachment sites of the arrector pili, smooth muscles that 
serve to help the hair maintain a vertical position (Ma & Yang, 
2004). The entire unit consisting of the hair, hair follicle, pili 
muscles and sebaceous gland is referred to as the piloseba-
ceous unit (PSU). 
Hair Growth Cycle
There are three phases of hair growth, the anagen, catagen, and 
telogen. The anagen phase is what is known as the growth phase. 
During this stage the cells in the root divide rapidly. After dividing, 
the cells produce a new hair that pushes the old hair out of the 
shaft. At this time, the hair grows approximately 1cm every 28 
days. The anagen phase is active for about 2-6 years.
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Individuals who have trouble growing their hair to a proper 
length might have a short anagen phase, whereby their hair falls 
out to a renewed anagen phase. In contrast, individuals who have 
the ability to grow their hair exceedingly long are likely have a 
growth phase lasting very long. It should be noted that auxiliary 
hair such as that of the eyebrows, eyelashes and arms have a very 
short growth phase, lasting 30-40 days. This is why we don’t have 
eyelashes that are more than a few millimeters in length.
The catagen phase is a transitional stage, which lasts from two 
to three weeks. At any given time about 3% of all hair are in this 
stage. During the catagen stage, hair growth stops, and the outer 
root sheath shrinks due to its detachment from the nutrient 
rich capillaries. At this point, a hard, club begins to form at the 
base of the hair, which is composed of hard keratinized tissue. 
This club holds the hair in place for as long as three months.
The telogen phase is the resting phase and usually last for about 
100 days on the scalp and longer for the hair of the eyebrow, 
eyelash, arm and leg. During this phase the hair follicle is com-
pletely inactive, and the club becomes more solidified. If one 
pulls out a hair at this stage, a hard, dry and solid root will be 
visible. In a normal individual, about 25-100 telogen hairs shed 
each day (Elzouki, et al. ,2012). People with androgenetic alo-
pecia don’t have regrowth occurring at the same rate. Typically, 
the hair loss begins above the temples and vertex of the scalp, 
and as it progresses, a rim of hair remains at the side and the 
back of the scalp.
Causes of Male Pattern Baldness
Androgens and their role in hair loss 
Androgens (the hormones responsible for the characteristic 
male appearance) play an important role in some, but not all 
hair growth. During puberty, the body produces significantly 
greater amounts of androgens to stimulate male development. 
One of the more noticeable effects androgens have is on the pi-
losebaceous units in the pubis, axilla (armpit), and lower face. In 
these regions, the hair goes from a fine, straight and almost col-
orless appearance, to a darker, thicker and curlier appearance. 
Additionally, in the areas of the upper face and trunk, the pilose-
baceous units respond to these same androgens, by drastically 
increasing the size of the sebaceous gland, thereby increasing 
the amounts of oils they produce (Alonso & Rosenfeld, 2003). 
In the male body, the major bioavailable form of androgens is 
testosterone. Testosterone can also be converted to a similar 
compound know as dihydrotestosterone (DHT) by the enzyme 
5α−reductase, which reduces the 4,5 double bond. DHT has a 
significantly greater binding affinity and lower dissociation con-
stant with the androgen receptor when compared to testoster-
one, hence DHT is a lot more potent. In men, approximately 5% 
of all testosterone molecules get converted by 5α−reductase 
into DHT (French, et al., 1990). 
The importance of DHT in males is clearly demonstrated in 
individuals who have a deficiency in the 5α−reductase. Such in-
dividuals display phenotypical pseudohermaphroditism, a condi-
tion where the male genitalia and prostate are underdeveloped, 
even though they have a genetic makeup of a male (Imperato-
McGinleyet al., 1979).
 The androgen receptor is a 110kD protein with a ligand bond-
ing domain, a DNA binding domain and two activation function 
regions that confer transcriptional regulatory activity. When a 
ligand binds to the androgen receptor in the cytoplasm, it ex-
poses the nuclear localization signal. This allows it to dimerize 
with another androgen receptor and then be transported to 
the nucleolus. In the nucleus, the androgen receptor complex 
binds to a specific region of DNA known as the hormone 
response element, where it either up-regulates or down-reg-
ulates translation of specific genes. The effects of mediation by 
the androgen receptor complex are highly variable (Alonso & 
Rosenfeld, 2003). 
It is widely believed that DHT is the major cause of baldness. 
Paradoxically, individuals with a genetic predisposition to baldness 
have an opposite response in some of their pilosebaceous units. 
In such individuals, the units in the scalp revert from being thick 
and darker in color, to being thin and lighter. However, the exact 
mechanism as to how DHT causes baldness remains to be deter-
mined. Furthermore, we have yet to understand why DHT acts in 
a paradoxical manner when affecting hair growth, creating baldness 
in some areas while stimulating new hair growth in other areas.
Although no definitive theories exist, Ustuner (2013) has pro-
posed that gravity might play a role in causing baldnesss. He seeks 
to explain the unique pattern of manifestation in effected individ-
uals by which is hair loss starts at the temples and the vertex of 
the scalp and proceeds to other areas. Ustuner believes that the 
weight of the facial tissue, which is supported by the scalp, causes 
damage to the hair follicles after puberty. During youth, there is 
sufficient fat tissue under the skin, which acts as a buffer to the 
hair follicles, and protects them from scalp pressure. However, 
this buffer gets diminished after puberty. The increase in DHT 
levels causes the fat layer to becomes increasingly thinner, essen-
tially losing its buffering ability. As a result, pressure in the hair 
follicles increases causing follicular damage, eventually leading to 
hair loss. He notes that women have a lower incidence of balding, 
due to the effect estrogen has on maintaining the subcutaneous 
fat, thereby preventing baldness until at least menopause (when 
estrogen levels decrease) (Ustuner, 2013). 
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Ustuner continues to say that resulting increase in pressure 
weakens the follicle. To compensate for the increased pressure, 
the follicle sequesters more DHT more testosterone to make 
the hair follicle stronger.  As a result, the subcutaneous fat layer 
becomes even thinner, creating a vicious cycle. Ultimately, the 
hair follicle becomes smaller and smaller, resulting in greater 
amounts of hair loss. According to this theory, areas in the 
front of the scalp should have greater pressure, due to greater 
amounts of soft tissues (the face) pulling down the scalp. This 
is consistent with the actual pattern observed (Ustuner, 2013). 
One should be skeptical about this theory for several reasons. 
First, Ustuner does not explain the mechanism of how testos-
terone decreases the subcutaneous fat in the scalp.  Even though 
there is a correlation between an increase in testosterone and 
its derivatives and a decrease in subcutaneous scalp fat follow-
ing puberty, it is not proof of causation. Additionally, Ustuner 
does not address why or how testosterone causes an increase 
in hair growth in axillary areas (paradoxical effect of DHT).
Prostaglandin D2 and their suspected role in 
Hair Loss
Recently, there has been a new hypothesis as to what caus-
es baldness. Researchers have found that individuals with 
androgenetic alopecia have elevated levels of prostaglandin 
D2 (PGD2) in areas of the scalp that are balding, while not 
having elevated PGD2 levels in haired areas of the scalp in 
the same individual. They note that in normal individuals, 
PGD2 is elevated in the catagen (regression) phase. This 
alludes to PGD2 having an inhibitory effect on hair, as the 
catagen phase is the transitional stage where the hair begins 
the process of falling out (Garza, et al., 2012). Additionally, 
when researchers targeted prostaglandin synthase (enzyme 
responsible for prostaglandin synthesis) in transgenic mice, 
the mice displayed symptoms characteristic of androgenetic 
alopecia due the increased synthesis of PGD2.
Genetic Factors
Many different genes have been suspected to play a role in hair 
loss. Thus far, most genetic studies investigating genetic causes 
have implicated the androgen receptor (AR) gene. This gene lies 
on the X chromosome, and its biological identifier is Xq11-12 
(Ellis , et al., 2001). This is very intriguing, since as we have men-
tioned above, the most widely accepted cause of male pattern 
baldness is increased DHT levels. It would therefore be expect-
ed that the 5α−reductase gene be responsible for hair loss.
Treatments:
Finasteride (5α−reductase inhibitor)
In accordance with the theory that DHT is responsible for male 
pattern baldness, a 5α−reductase inhibitor should reduce male 
pattern baldness. Indeed, finasteride, a 5α−reductase inhibitor, has 
been one of only two FDA approved drugs used to treat hair loss. 
The recommended dosage for male pattern hair loss treatment is 
1 mg/day taken orally. During trials conducted to determine the 
efficacy of finasteride in treating male pattern baldness, a place-
bo controlled study was conducted with 42 healthy participants. 
The trial demonstrated that administration of finasteride from 
0.4 to 100 mg/day for up to 2 weeks significantly reduced the 
mean serum DHT from a baseline level. The reduction reached a 
maximum at the 1mg/day dosage. However, the study also found 
that 14 days after drug withdrawal, DHT returned to baseline 
levels. (Gormley, et al., 1990). In another study, individuals who 
were taking 1mg/day finasteride had a mean reduction in DHT of 
68.4% versus the placebo (Kaufman , et al., 1998). 
In the phase III placebo-controlled studies, the effects of finas-
teride on hair regrowth was assessed. Three studies were con-
ducted in this phase; all were randomized, double-blinded and 
placebo controlled, and included 1879 male patients ages 18-41 
years. All the individuals reported active shedding of hair at least 
3 years prior to volunteering for the study. Hair loss among sub-
jects ranged from mild to moderate. After categorically classify-
ing subject’s hair loss based on severity, they were given either a 
placebo or 1mg/day finasteride for 1 year. To detect whether or 
not finasteride increased hair growth, a baseline hair count was 
obtained before and after treatment, using macro-photographs 
of a 5.1cm2 area of the leading edge of the vertex with hair loss. 
After analyzing these photographs, finasteride was found to 
cause significant progressive increase in hair counts in all areas 
of the scalp studied (vertex, mid and frontal) during 12 months 
of treatment. There was an 11% increase in hair count in sub-
jects taking finasteride, compared to a 2.7% reduction in hair 
count during the same 12-month period in placebo subjects. 
Subjects taking finasteride for an additional year maintained 
their hair count, while those on the placebo continued to lose 
hair. After the 2-year period, 83% of those taking finasteride had 
no further hair loss, compared to only 28% of those taking the 
placebo. (Waldstreicher, et al., 1997). 
Overall, tolerability was the same for both the placebo and fi-
nasteride receiving groups. The only difference was in sexual 
function disorders which were reported in a higher percentage 
in the group receiving finasteride. It should be noted that al-
though there was a difference between both groups, the differ-
ence was relatively small, 3.8% in the placebo group and 2.1% 
in the group receiving finasteride. Additionally, of the subjects 
reporting sexual disorders during therapy, many cases were 
resolved even though they continued taking finasteride. All 
subjects who withdrew from the trial due to sexual disorders 
reported that the problems were resolved after discontinuing 
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the drug (Waldstreicher, et al., 1997). Based on these studies, it 
appears that finasteride does indeed reduce hair loss in most 
men. And since finasteride causes hair regrowth by altering 
DHT levels, it supports the DHT theory of baldness. 
More research has to be carried out to determine whether 
there is a link between male breast cancer and the use of fi-
nasteride, as has been suggested by the UK Medicines and 
Healthcare Products Regulatory Agency. They have suggested 
that male breast cancer might be linked to the decrease in the 
ratio of testosterone to estrogen when taking finasteride. For 
individuals using finasteride to treat hair loss, this suggestion 
should be taken with a bit of skepticism, as a majority of cases 
of male breast cancer was found in males taking the 5mg/day 
dose as a form of treatment for benign prostatic hyperplasia. In 
contrast, only a small percentage of prostate cancer was report-
ed in individuals taking the 1mg/day dose suggested for hair loss 
treatment (Shenoy & Prabhakar, 2010).  However, as one must 
continue using the drug to prevent further loss of hair, there is a 
need for long term studies of possible side effects.
It should also be noted that non-Caucasian participants ap-
peared to have less regrowth of hair compared to Caucasians. 
However, one has to be cautious in interpreting this, since only 
a small portion of the study subjects were non-Caucasian. To 
definitively state that non-Caucasians experienced less hair re-
growth, future studies conducted must include a representative 
number of non-Caucasian subjects.
Dutasteride
Similar to finasteride, dutasteride is also a 5α−reductase inhibitor, 
however, dutasteride inhibits not only type II, but also type I forms 
of 5α−reductase. Scientists don’t exactly know the effect type I 
5α−reductase inhibitor has on hair loss, since no deficiency has 
been found for it. However, evidence suggests that dutasteride is 
three times more potent than finasteride in inhibiting type II, and 
more than 100 times more potent in type I enzyme. (Clark , et al., 
2004). This would suggest that dutasteride would have a greater 
ability preventing hair loss, and promoting hair regrowth. Indeed, 
dutasteride has been found to decrease serum levels of DHT 
by more than 90% when compared to only 70% in finasteride. 
(Dallob, et al., 1994). 
In 2002, the FDA approved dutasteride as a treatment for benign 
prostatic hyperplasia. Phase trials were also conducted on its use 
as a treatment for male pattern baldness. During the phase II 
trails, researchers found increased hair growth on the scalp. They 
also found that a 2.5mg dosage of dutasteride was more effective 
than a 5mg dosage of finasteride (Olsen , et al., 2006). However, 
the phase III trials were put on hold due to concerns of side 
effects. For this reason, one should be hesitant in using this drug.
Minoxidil (Vasodilator)
Minoxidil, the second of only two drugs the FDA approved for 
treating hair loss, was initially developed as a treatment for ul-
cers. When minoxidil was applied to dogs during the trail phase, 
the ulcers did not improve, however, minoxidil was found to be 
a strong vasodilator. As a result, the FDA approved minoxidil 
tablets as a treatment for high blood pressure in 1979 (Conrad 
, 2008). Initially, when studies on the effectiveness of minoxidil 
as a vasodilator in humans were conducted, researchers found 
unexpected hair growth. That is when it occurred to research-
ers that minoxidil might be an effective treatment for hair loss 
(Gilmore, et al., 1970)
Although the mechanism of minoxidil’s ability to cause hair 
growth is poorly understood, some theories have been suggest-
ed. Minoxidil might increase hair growth by either shortening 
telogen or prolonging the anagen phase. Others propose that 
minoxidil is a potassium channel opener. When the potassium 
channel opens, it causes a hyperpolarization in cell membranes, 
this widens the blood vessels surrounding the hair follicle, 
thereby allowing more oxygen and nutrients into the follicle 
(Goren, et al., 2015). 
In the 1980s, studies reported that a 2% topical solution of mi-
noxidil reduced baldness in about 50% of patients. Although the 
study found that few mature terminal hairs were regrown, the 
number of fine, non-pigmented villus hairs were reduced. These 
studies acknowledged that the ideal candidates for minoxidil 
therapy were those who had been bald for less than five years, 
and whose baldness was less than 10cm in diameter and located 
on the vertex. They found that minoxidil was not useful for fron-
tal hair loss. Additionally, patients who discontinued treatment 
showed a rapid loss of the newly regrown hair. After 3 months 
of discontinuing therapy, their hair count was below baseline 
levels (Savin , 1987). 
After getting approved by the FDA as a treatment for hair loss 
in men, minoxidil became available under the name Rogaine, 
and was obtainable only by prescription. In 1996, Rogaine was 
approved for over-the-counter sale, and for the production of 
generic versions. Eventually a 5% topical solution was approved 
by the FDA (Conrad , 2008). 
Two studies have been conducted comparing the 2% versus the 
5% solution. One of the studies measured hair mass before and 
after a two-year period. This study found a greater hair mass in 
individuals taking the 5% solution. The difference was most ap-
parent early in the study. After taking the 5% solution for five 
months, these individuals experienced a 55% increase in total hair 
mass compared to the baseline, while those on the 2% solution 
only experienced a 25% increase. After the end of the 2-year 
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period, the 5% group had an increase of 25% over the baseline, 
while those on the 2% had only 15% (Price, 1996).  The second 
study found that the 5% minoxidil produced a significantly greater 
amount of non-villus hair by count as compared to the 2% group. 
They also found that patients using the higher dosage had an in-
creased likelihood of noticing more hair coverage on the scalp in 
their assessment of treatment benefits (Trancik, 1998). 
Generally, minoxidil is well tolerated, however, some side effects 
have been reported. The most frequent side effect is itching, red-
ness, or irritation of the scalp in the treated area. Unwanted hair 
growth elsewhere on the body has also been reported. Some indi-
viduals reported exacerbation of hair loss after applying minoxidil. 
Severe allergic reactions have also been reported including, rash, 
hives, difficulty breathing, tightness in the chest, swelling of the 
mouth, face, lips, or tongue, chest pain, dizziness, fainting, tachycar-
dia, headache, sudden and unexplained weight gain, and swelling of 
the hands and feet (Rogain Side Effects, 2015). Overall, it seems 
safe to say that minoxidil is a somewhat effective treatment for 
male pattern hair loss, however, compared to finasteride, it is less 
effective but has the advantage of being a topical. 
Ketoconazole (anti-fungal)
Ketoconazole, a common anti-fungal shampoo widely used in treat-
ing seborrheic dermatitis (dandruff), has also been suggested to 
contain hair regrowth properties. Recently, a study demonstrated 
that individuals applying a 2% solution of ketoconazole produced 
comparable levels of hair growth when compared to those using 2% 
minoxidil. Both groups achieved greater levels of hair growth com-
pared to those using un-medicated shampoo (Pierard-Franchimont, 
et al., 1998). Similar results were obtained when treating model 
mice with androgenetic alopecia with 2% ketoconazole, when com-
pared to the placebo group (Jiang, et al., 2005). 
Why ketoconazole causes hair regrowth is not clearly under-
stood. Some have suggested that ketoconazole plays a role in 
local disruption of the DHT pathway. They have suggested that 
when used in combination with finasteride, it may have a great-
er affect in reducing DHT levels compared to using finasteride 
on its own. (Perez, 2004). Its effect on DHT has been used to 
explain why some individuals using ketoconazole experience 
gynecomastia (enlargement of the breasts) (Wolverton , 2002). 
Clearly, it seems like ketoconazole has some hair regrowth abil-
ities, however, there is a need for more studies to be carried 
out to demonstrate how effective it is compared to placebo 
and other treatments. Additionally, more research needs to 
be done on the mechanism behind how it causes hair growth. 
Finally, studies have to demonstrate whether or not using keto-
conazole for an extended period of time is safe.
Low-level Light Therapy
Use of a ruby red laser (694nm) , resulted in increased hair 
growth in  mice who had their backs shaved (Mester, et al., 
1968). Although light therapy has been shown to effectively re-
duce inflammation, improve wound healing and reduce stroke 
symptoms, the mechanism behind it is poorly understood. Some 
have hypothesized that the light increases levels of ATP synthe-
sis in the mitochondria. There has been evidence that there is an 
increase in activity in complexes II and V in the electron trans-
port chain (Oron , et al., 2007). 
Many light therapies are marketed as treatments for hair loss. 
Typically, these devices are brushes or combs that have a red 
light shining out of the tips onto the scalp. Such devices are 
available for purchase over the counter. So far only one such 
device has been approved by the FDA as not being harmful, 
but does attest to its ability to treat hair loss. Such approval is 
sought after, as using certain wavelengths of light can be harmful. 
Companies have capitalized on the little research showing hair 
regrowth abilities and have produced light therapy devices for 
consumers, despite the little research that has been conducted 
to determine the safety and efficacy of it. As a consumer, one 
must therefore be very skeptical of buying such light therapy 
devices. More research must be done before anything definitive 
can be said about using light therapy to treat hair loss. 
Discussion
In light of research indicating that drugs can prevent further 
progression of hair loss, we may effectively conclude that hair 
loss can be treated. We cannot however conclude that hair loss 
can be cured, for a cure implies a reversal of a problematic med-
ical phenomenon. Hair loss as of yet cannot be cured because 
the effectiveness of hair loss drugs is only for as long as they 
are administered. To find a cure, a definitive theory explaining 
the causative mechanisms behind hair loss is necessary. Once 
we understand the mechanism behind hair loss, most certainly 
a cure will follow.
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Introduction
Vitamin D₃ is a fat soluble vitamin, stored mainly in the liver 
and adipose tissue. It is primarily obtained by the conversion of 
cutaneous 7-dehydrocholesterol to previtamin D₃ by sunlight, 
specifically Ultraviolet (UV) B radiation with a wavelength of 
290–320 nanometers. Previtamin D₃ then spontaneously isom-
erizes to vitamin D₃, or cholecalciferol. Vitamin D3 is biologically 
inert and must undergo two hydroxylation to be biologically 
active. The first hydroxylation occurs in the liver, by 25-hydrox-
ylase, converting vitamin D3 to calcidiol, or 25-hydroxyvitamin 
D [25(OH)D]. The second hydroxylation occurs by 1α-hydrox-
ylase, found primarily in the kidneys, although recent research 
found this enzyme in many other tissues. The second hydrox-
ylation converts the 25-hydroxyvitamin D to the biological-
ly-useful calcitriol, or 1,25-dihydroxyvitamin D [1,25(OH)2D] 
(Vitamin D: Fact, 2016). 
Besides for obtaining vitamin D by sun exposure, vitamin D can be 
obtained by food. However, very few foods in nature contain vita-
min D. Therefore, a better way of obtaining vitamin D is from chole-
calciferol-fortified foods or supplements (Vitamin D: Fact, 2016). 
Serum concentration of 25-hydroxyvitamin D is the best indica-
tor of vitamin D status, because it reflects vitamin D obtained 
by sun exposure and ingestion. It also has a fairly long circulating 
half-life of 15 days and its concentration is not affected by other 
metabolites. However, it does not indicate how much vitamin 
D is stored in body tissues. In contrast, 1,25-dihydroxyvitamin 
D has a short circulating half-life of 15 hours and its levels are 
closely regulated its own concentration and by hormones and 
electrolytes like parathyroid hormone, calcium, and phosphate. 
Additionally, levels of 1,25(OH)2D only decreases when vitamin 
D deficiency is severe. Therefore, 25-hydroxyvitamin D levels 
are used to assess sufficiency (Vitamin D: Fact, 2016).
There is considerable discussion of what serum concentrations 
of 25-hydroxyvitamin D indicate vitamin D deficiency, adequacy 
for bone health and optimal health overall. As of now, there 
is no specific cut points established by a scientific consensus 
process. However, the committee of the Institute of Medicine, 
based on its review of data of vitamin D needs, have concluded 
that there is a risk of vitamin D deficiency at serum 25(OH)
D levels of less than 30 nmol/L (<12 ng/mL). Additionally, some 
people are potentially at risk for inadequacy at concentrations 
ranging from 30-50 nmol/L (12–20 ng/mL). They stated that 50 
nmol/L is the serum 25-hydroxyvitamin D level that is adequate 
for 97.5% of the population. Only at concentrations of greater 
than 125 nmol/L (>50 ng/mL) is there potential adverse effects 
of overdose (Vitamin D: Fact, 2016).
Cutaneous vitamin D levels are mainly dependent on climate, 
overall skin exposure, skin melanin content and age. Residing 
in a climate closer to the equator results in more year-round 
sun exposure and more vitamin D synthesis. Although surpris-
ingly, geographic location does not consistently predict average 
serum levels in a population. Opportunities exist to form vita-
min D from exposure to sunlight during the spring, summer, and 
fall months even in the far north or south, and it can be stored 
in fat for periods of little sunlight. Darker skin absorbs less 
sunlight and, therefore, more melanin reduces the production 
of vitamin D. Perhaps, this characteristic may contribute to the 
consistency in average serum levels of those near the equator 
and those further away, because those who live near the equa-
tor generally have a darker skin tone that synthesis less vitamin 
D than those farther away with a lighter skin tone.  Vitamin 
D synthesis may also decline with age because skin synthesis 
declines (Johnson, 2016). 
Major depressive disorder (MDD) is a common disorder and 
leading source of disability worldwide. It is a major global health 
problem, with more than 50% of all suicides contributed to 
clinical depression (Bay-Richter, Janelidze, Hallberg, & Brundin, 
2011). Classically, the prevailing hypothesis on the cause of major 
depression was a deficiency of monoamines, a class of neu-
rotransmitters and neuromodulators, like serotonin. Therefore, 
current available medications for major depression mainly tar-
get monoamine pathways. However, research has not shown 
a consistent relationship between serotonin and depression 
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(Gardner & Boles, 2011). And although relatively affective, 30% 
of depressed patients do not achieve remission even with mul-
tiple, monoamine-regulating, treatment trials (Miller, Maletic, & 
Raison, 2009). Additionally, 50% to 80% of all patients treated for 
major depression will experience relapse (Bay-Richter, Janelidze, 
Hallberg, & Brundin, 2011). These monoamine regulating drugs 
can have serious side effects, which include worsening of depres-
sive symptoms and suicidal ideation. Therefore, it is imperative 
to find novel pathways involved in depression and consequently 
more effective treatments for those suffering.
Historically, in literature, and in art and religion, happiness and 
positivity have been associated with summertime, daylight, and 
sunny and open landscapes. In contrast, fear and gloom have 
been associated with winter, night and dark and polluted ur-
banscapes. At the height of early industrialism, in such polluted 
cities, rickets, which is extreme vitamin D deficiency was first 
recognized. Among the symptoms of rickets, mental symptoms 
were also described and Florence Nightingale stated: “People 
say the effect [of sunlight] is on the mind. So it is, but the enlight-
ened physician tells us it is on the body too.” (Humble, 2010) 
Mental disturbances caused by reduced sun exposure seemed 
self-evident that no one seemed to note the mental health ben-
efits of rickets treatment, which was primarily to increase sun 
exposure. Because of the awareness of adequate sun exposure, 
rickets disappeared as a public health problem. Nevertheless, 
from the 1950s and on, with increasing modernization, the time 
spent indoors increased for all ages worldwide. Additionally, 
since the 1980s, the public is being warned about the dangers of 
UV rays and its contribution to malignant melanoma. Therefore, 
people have developed concern of excessive sun exposure and 
are applying sunscreen and covering up more when they are 
outside. At the same time, as these changes are taking place, the 
incidence of depression, especially in children and adolescents, 
has become more and more prevalent in the United State and 
Europe (Humble, 2010). Additionally, it is a long, well-known and 
perplexing observation that death by suicide is highest in the 
springtime for people living in temperate climates, which is also 
when vitamin D levels are the lowest in the population (Umhau 
et al., 2013). Is there a correlation between these two observed 
phenomena of depression and vitamin D synthesis, and what 
would be there relationship?
Materials and Methods
Materials for this comprehensive review were obtained from 
Touro College’s online library, PubMed, PubMed central, 
Proquest, National Institute of Health website and Merck 
Manual website. The material consisted of clinical research pa-
pers, peer-reviewed journal articles and clinician-directed infor-
mational reports. The material was reviewed, critically analyzed 
and compiled to answer research questions.
Discussion
Vitamin D and Inflammation:
Classically, Vitamin D is associated with bone health. Vitamin 
D aids calcium absorption in the gut and maintains adequate 
serum calcium and phosphate levels for normal mineralization 
of bone (Vitamin D: Fact, 2016). It is also needed by osteoblasts 
and osteoclasts bone growth and repair. Vitamin D deficiency 
was mostly associated with rickets and osteomalacia at extreme 
deficiency. Rickets is a disease in children where vitamin D de-
ficiency leads to bones not being able to properly mineralize, 
which results in soft bones and skeletal deformities. In adults, 
vitamin D deficiency can lead to osteomalacia, or weak bones 
(Vitamin D: Fact, 2016).
Recently, many other functions of vitamin D have been discov-
ered and vitamin D receptors have been found in many tissues. 
One of the most significant findings is the function of vitamin 
D in immune system modulation. There is an increasing num-
ber of studies that demonstrate the importance of vitamin D in 
the reduction of inflammation and the association of vitamin D 
deficiency with increased inflammation (Peterson & Heffernan, 
2008). Most of the known effects of vitamin D are facilitated 
through vitamin D receptors (VDR). These vitamin D receptors 
have been found extensively in immune system cells, specifically 
in T lymphocytes and macrophages. Furthermore, macrophages 
have been found to express 1α-hydroxylase, which is the en-
zyme that is responsible for the final step in synthesizing bio-
logically-active vitamin D. Additionally, they have been found to 
express 24-hydroxylase, the major degrading enzyme of vita-
min D. This means that these cells can regulate the production 
and secretion of vitamin D in their own vicinity (Peterson & 
Heffernan, 2008).
Additional evidence now suggests that vitamin D insufficiency 
may play a role in immune system dysfunction and low 25-hy-
droxyvitamin D serum levels are shown to be associated with 
autoimmune diseases like multiple sclerosis, Type 1 diabetes 
and rheumatoid arthritis. Recently, this insufficiency has been 
correlated to macrophage dysfunction, such as impaired che-
motaxis, phagocytosis and increased production of proinflam-
matory cytokines. Proinflammatory cytokines are produced 
predominantly by activated macrophages. These cytokines take 
part in cell signaling and up-regulation of inflammatory reac-
tions. Vitamin D has been shown to reduce inflammation by 
down-regulating the expression of monocyte toll-like receptors 
(TLRs), which are known to activate inflammation and aggravate 
autoimmune disease and sepsis (Peterson & Heffernan, 2008).
In light of the research, Peterson and Heffernan (2008) sought 
to investigate the relationship between serum vitamin D status 
(25(OH)D) and inflammatory markers in 69 healthy women. 
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They recruited people with high UVB and minimal UVB ex-
posure, as assessed by a screening questionnaire, to obtain a 
range of serum levels. Volunteers were excluded for multiple 
factors, including, if they took a vitamin D supplement, had a 
current or previous medical condition or took medication af-
fected immune function. The results revealed that serum TNF-
α, a proinflammatory cytokine, was significantly lower in the 
group of women with high UVB exposure, after controlling for 
multiple factors. However, there was no significant statistical 
difference shown between the two groups in regards to other 
proinflammatory cytokines, like IL-10, CRP, IL-6. Serum TNF-α 
concentrations are increased in several diseases like multiple 
sclerosis, inflammatory bowel disease, rheumatoid arthritis, 
heart disease and osteoporosis, and lowering TNF-α concen-
trations through sufficient vitamin D levels may improve disease 
outcomes. The main limitation of this study was the small sam-
ple size. Additionally, women who frequently tan are character-
istically different from non-tanners and may engage in behaviors 
that can affect the study outcomes. This study shows a negative 
correlation between vitamin D status and TNF-α concentration 
in healthy individuals. More research is needed to determine if 
vitamin D can be used as a therapy in inflammatory diseases.
A case where vitamin D deficiency seems to contribute to 
immune modulation, is in diabetic foot infection. Diabetic foot 
infection is a reflection of a diabetic patient’s altered immune 
system. In an infectious state, pro-inflammatory cytokines are 
released in the body, such as IL-1β, IL-6, interferon-γ (IFN-γ) 
and TNF-α, or chemokines such as IL-8. To counteract these 
factors and avoid a hyper-inflammatory state, the body releases 
anti-inflammatory cytokines such as IL-10. In a diabetic patient, 
several factors lead to decreased wound-healing abilities, includ-
ing impaired cytokine production. This abnormal wound healing 
is attributed to immune dysregulation because of vitamin D de-
ficiency in addition to hyperglycemia (Timms et al., 2002).
Another study, investigating the relationship between vitamin D 
deficiency and increased inflammatory cytokines, was done by 
Timms et al. (2002), by evaluating the influence of vitamin D on 
the concentrations of IL-1β, TNF-α, IFN-γ and IL-6 in patients 
with diabetic foot infection. Subjects were 112 diabetic patients 
with diabetic foot infection while 107 diabetic patients with no 
evidence of infection served as controls, additionally, 40 healthy 
subjects were included in the study. Vitamin D deficiency, a 
serum 25-hydroxyvitamin D < 50 nmol/l, was found in 71.4% of 
the diabetic foot infection patients, 61.6% of the diabetic con-
trols and 48.6% of the healthy volunteers, but severe deficiency, 
with a serum 25-hydroxyvitamin D of < 25 nmol/L, was mostly 
found in diabetic foot infection patients than in diabetic controls 
and healthy volunteers. In both patients and controls, 25-hy-
droxyvitamin D levels was found to be significantly negatively 
correlated with IL-1β as well as IL-6 levels and moderately neg-
atively correlated with TNF-α levels, but not correlated with 
IFN-γ levels. In this study, diabetic patients with foot infection 
serve as a model for immune system abnormality resulting from 
hyperglycemia and infection, with increased pro-inflammato-
ry cytokine concentrations. The results of the present study 
showed that elevated cytokine responses occur as a factor of 
vitamin D deficiency in patients with diabetic foot infection. 
Vitamin D deficiency, particularly when serum levels were very 
low, intensified inflammatory cytokine release in patients with 
diabetic foot infection.
Because of this increasingly strong correlation and possibly 
causation of vitamin D deficiency to amplified inflammation, and 
to try to prove causation more visibly, Hoe et al. (2016) recently 
performed a study ex vivo. They studied the effects of 1,25-di-
hydroxyvitamin D, the active metabolite of vitamin D, on pe-
ripheral blood mononuclear cells (PBMCs) and purified immune 
cell subsets isolated from healthy patients, when they exposed 
those cells to stimulation with Gram-positive heat-killed pneu-
mococcal serotype 19F (HK19F) and Gram-negative Escherichia 
Coli serotype 055:B5 derived lipopolysaccharide (LPS) bacterial 
ligands. They found that in 1,25(OH)2D3 pretreated samples 
compared to non-treated, for both ligands, 1,25(OH)2D3 
suppressed proinflammatory cytokines, like TNF-α, IFN-γ and 
IL-1β, and chemokine IL-8, in peripheral blood mononuclear 
cells (PBMCs) and TNF-α and IL-1β in CD14+ Monocytes. 
Anti-inflammatory IL-10 was increased in HK19F-stimulated 
monocytes. Additionally, when comparing the blood samples of 
the healthy subjects, they found that levels of HK19F-specific 
IFN-γ were significantly higher in vitamin D-insufficient adults 
(<50 nmol/L) compared to sufficient adults (>50 nmol/L). This 
study suggests Vitamin D causes modulation of inflammation of 
the immune system response which is critical for host defense.
Inflammation and Depression
The progression and complications of many diseases and disor-
ders, like cardiovascular disease, diabetes and cancer, are being 
increasingly attributed to inflammatory dysfunction. Additionally, 
this theory of disorder is being extended to neuropsychiatric 
disorders, with mounting evidence suggesting that defective al-
terations of the immune system seen in psychiatric patients may 
contribute to their disorders, and with mounting evidence of 
inflammation contributing to major depressive disorder. Patients 
with major depression have been found to exhibit elevated 
proinflammatory cytokines, like IL-1β, TNF-α and IL-6, which 
have been shown to interact with areas known to be involved 
in depression, including neurotransmitter metabolism, neuroen-
docrine function, and neural plasticity. Furthermore, psychosocial 
stress, a common precipitator to major depression, has been 
shown to have the ability to stimulate inflammation, owing to 
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the fact that it activates sympathetic nervous system pathways. 
Moreover, depressed patients with increased inflammatory mark-
ers have been found to have greater resistance to treatments, and 
in studies, antidepressant drugs have been found to be correlated 
with decreased inflammation (Miller, Maletic, & Raison, 2009). 
Recurrent coinciding comorbidities and drug efficacies suggest 
that depression is part of a group of related conditions, all of 
which are associated with inflammation dysfunction. They are 
sometimes referred to as the “affective spectrum disorders”, 
and include migraine, irritable bowel syndrome, chronic fatigue 
syndrome, fibromyalgia and generalized anxiety disorder, among 
many others. Based on current knowledge, these diseases, in-
cluding depression, seem to be a function of three connected 
abnormalities: monoamine dysfunction, increased inflammation, 
and mitochondrial disorder (Gardner & Boles, 2011)
To test if inflammation may correlate or even cause major 
depression, several studies performed on animals who have 
been injected with the endotoxin lipopolysaccharide (LPS) to 
generate inflammation, showed that these subjects subsequent-
ly developed depressive-like symptoms. In clinical practice, it 
has been seen that patients treated with interferons and in-
terleukins, to promote inflammation against certain forms of 
cancer and viral infections, like Hepatitis C, frequently develop 
depression. To further investigate this relationship Bay-Richter, 
Janelidze, Hallberg, & Brundin (2011) induced inflammation in 
rats by administering Escherichia coli serotype 055:B5 lipopoly-
saccharides (LPS) intraperitoneally for four days. They measured 
their levels of cytokine markers at the state of sickness and 
then at the state of depressive-like behaviors. They also mea-
sured mRNA transcription of cytokines in specific brain areas 
related to depression as well as levels of cytokines in serum 
and cerebral spinal fluid. Cyclooxygenase enzymes, inflammato-
ry stimulating COX-1 and COX-2, have previously been shown 
to correlate with depressive-like behavior, thus, it is suggested 
that proinflammatory cytokines can induce depressive-like be-
havior by activating prostaglandins, and inflammation, through 
the cyclooxygenase enzyme. Therefore, they also measured cy-
clooxygenase enzymes in the brain of the mice. This is the first 
published study examining the relationship between proinflam-
matory cytokines and cyclooxygenase enzymes in the blood, 
CSF and depression-related brain areas and their capacity to 
cause sickness and behavioral changes.
In this study, they found that there was a clear distinction be-
tween the phase of sickness, which is 2 hours after injection 
of lipopolysaccharides, and the phase of depressive symptoms, 
which is 24 hours after injection, for cytokines, cyclooxygenase 
enzymes and mRNA transcription of cytokines. During the sick-
ness behavior, IL-1β and IL-6 were elevated in the blood, IL-1β 
was elevated in the CSF, and TNF-α was elevated in the striatum 
of the brain. Also, IL-1β mRNA transcript was increased in the 
frontal cortex and hippocampus. Curiously, in this phase, IL-6 
and COX enzymes were decreased in the hippocampus. After 
24 hours of injection, the rats did not show signs of sickness but 
began displaying depressive symptoms in the forced swim test. 
This test is used on rodents to evaluate depression and is used 
when assessing antidepressant drugs and therapies.  During the 
depressive phase of behaviors, the transcription of TNF-α mRNA, 
IL-6 levels and COX enzymes levels shifted back to normal lev-
els in all brain areas, but the cytokine IL-1β was still significantly 
elevated in the frontal cortex and hippocampus and there was 
an increase in the concentration of IL-1β in the cerebral spinal 
fluid. This increase was only found in the CSF and not in blood 
serum. This may explain why studies measuring the serum level of 
cytokines in patients with major depressive disorder, did not find 
any significant difference when comparing depression levels with 
normal levels. In this study, they found that Lipopolysaccharide-
induced depression is primarily associated with the increase of 
IL-1β. This cytokine remains elevated in the brain even after the 
initial inflammatory phase and continues to contribute to a de-
pressive-like phenotype in the rats. This suggests that a short term 
immune inflammatory response may lead to long term changes 
in transcription of inflammatory markers and that transcription 
levels may even increase after the initial immune response (Bay-
Richter, Janelidze, Hallberg, & Brundin, 2011).
Although, elevated inflammatory markers are found in many pa-
tients with psychiatric disorders, there is no clear differentiation 
or explanation why some patients have elevated cytokine concen-
trations and some do not. Perhaps, there is a specific subgroup 
of patients that will display signs of inflammation. To advance and 
investigate if the phenomenon of increase cytokine concentra-
tions in psychiatric patients is specific to a subgroup of depressed 
patients, Janelidze, Mattei, Westrin, Traskman-Bendz, & Brundin 
(2011) designed a study dividing their subjects by non-suicidal 
and suicidal patients. In this study, they compared plasma cytokine 
levels in 47 treated and untreated patients with depression that 
had attempted suicide, 17 untreated patients with a diagnosis of 
major depressive disorder that did not have any suicidal ideation 
and 16 somatically healthy controls with no current or previous 
history of neuropsychiatric disorder. They found statistically sig-
nificant elevated plasma concentration of proinflammatory cyto-
kines IL-6 and TNF-α and decreased plasma concentrations of 
anti-inflammatory cytokine IL-2 in the suicide attempters, com-
pared to the non-suicidal depressed patients and healthy con-
trols. Elevated cytokines were seen in suicidal patients, regardless 
if they had received treatment or not. Although a limitation of 
this study is that the duration of the disorder and duration of 
treatment were not considered. Interestingly, these patients with 
elevated cytokines did not show any signs of systemic or local 
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infection or inflammation. This suggests that inflammation seen in 
depressed patients is specific to those that are suicidal, although 
it may also be specific to different subgroups of depression too. 
Furthermore, it suggests that these elevations are associated 
and may contribute to suicidal ideation. Because this study used 
patients with untreated major depression, one group it did not 
control for specifically, is patients with treatment-resistant de-
pression, and therefore, perhaps increased cytokines is seen in all 
patients with treatment-resistant depression, not only those who 
have attempted suicide. Evidence of abnormal cytokine elevations 
were observed in suicidal patients, compared to non-suicidal 
depressed patients and healthy controls, and may contribute to 
suicidality.
As the mechanism that causes depression and suicide is locat-
ed in the brain, it is important to understand if these systemic 
inflammatory changes relate to changes in the central nervous 
system. Lindqvist et al. (2009) tested the proinflammatory cy-
tokine profile of the cerebral spinal fluid (CSF) of 63 institu-
tionalized patients who had recently attempted suicide com-
pared to healthy controls. They also evaluated if there was a 
difference in the cytokine profile of patients who had attempt a 
violent method of suicide compared to the patients who used 
a nonviolent method. The patients underwent a “wash-out” 
period where they discontinued all antidepressant and antipsy-
chotic medication until there was no trace of it in their blood. 
Depressive symptoms were assessed using the Montgomery-
Åsberg Depression Rating Scale (MADRS) and suicidal ideation 
was assessed using the Suicide Assessment Scale (SUAS). They 
found that the patients who had attempted suicide had higher 
levels of cytokine IL-6 in their cerebral spinal fluid to healthy 
patients, and the violent suicide attempters had the highest con-
centration of IL-6. They also found that CSF IL-6 had a positive 
correlation with intensity of depressive symptoms in all suicid-
al patients. Additionally, they found that IL-6 levels correlated 
positively with current suicidal ideation and suicidal symptoms, 
as in patients expressing a “wish to die” and “preoccupation 
with suicidal thoughts.” These results suggest that, as discussed 
previously, IL-6 may have specific relevance to suicide. They did 
not find any significant difference in proinflammatory cytokine 
IL-1β, TNF-α, and IL-8 between the groups studied. Lindqvist et 
al. then went further to try to determine a mechanism of how 
these abnormalities may contribute to suicidality. They com-
pared levels of cytokines with known biomarkers of depression 
and suicide and found that both IL-6 and TNF-α was related to 
increased levels of 5-HIAA, which is a metabolite of serotonin, 
and HVA, which is a metabolite of dopamine, in the fluid of the 
patients who attempted violent suicide methods. This suggests 
that proinflammatory cytokines may modulate monoamines in 
the central nervous system. Further, longitudinal studies would 
be helpful in studying the effects of cytokine and monoamine 
fluctuation and its neuropsychiatric effects. In summation, 
Lindqvist et al. found that inflammatory cytokines were directly 
correlated with the presence and extent of suicidal thought and 
behavior and the degree of violence of a suicide attempt.
Vitamin D and Depression
As discussed previously, there is strong evidence that vitamin 
D deficiency may be contribute and cause immune system dys-
function, including elevated inflammatory markers. And elevated 
inflammatory markers may play a role in depression with suicid-
al ideation. Therefore, there are many that suggest that vitamin 
D deficiency may be a contributing factor in those who suffer 
from suicidal thoughts accompanying major depressive disorder. 
The presence of vitamin D receptors (VDR), in the central ner-
vous system was first discovered in 1982 by Stumpf, Sar, Clark, 
and DeLuca. And nowadays, there is significant evidence of vi-
tamin D’s presence and actions on different parts of the brain 
and nervous system functioning. There is increasing evidence 
that the vitamin D receptor (VDR) mediates transcription of 
more than 1,000 genes (Umhau et al., 2013). Calcitriol is known 
to function in the regulation of neurotransmitters, specifically 
dopamine, adrenaline, noradrenaline and acetylcholine, regulates 
several neurotrophic factors of the central nervous system, by 
enhancing nerve growth factor (NGF) and glial derived neuro-
trophic factor (GDNF), and assist with anti-oxidative properties 
in the brain (Humble, 2010). Many of the effects that vitamin D 
has on the brain, share pathways with factors, when abnormal, 
are known to be associated with several neuropsychiatric disor-
ders including major depressive disorder (Humble, 2010). Based 
on this, inadequate levels of vitamin D may lead to changes in 
the central nervous system that may interfere with brain func-
tion and contribute to mood disorders.
As depression is underdiagnosed in non-institutionalized healthy 
populations and subclinical depression and chronic low mood is 
common in older adults, and is a factor in morbidity, mortality 
and quality of life, one study seeking to clarify if vitamin D may be 
associated with depression in healthy adults was done by Lee et 
al. (2011). Lee et al. used baseline data from the European Male 
Ageing Study (EMAS), a cohort study of male aging in Europe, to 
determine whether concentrations of serum 25-hydroxyvitamin 
D were associated with levels of depression in a large sample 
size of 3151 subjects, well-characterized, community-dwelling 
sample of middle-aged and older men with a mean age 60 ± 11. 
Subjects were assessed on social issues, lifestyle behaviors, and 
any related comorbidities, like heart conditions, pituitary dis-
ease, diabetes, and cancer. Depressive symptoms were assessed 
using the Beck Depression Inventory-II (BDI-II). Their results 
found that serum vitamin D concentrations were significantly 
lower in men with depressive symptoms, scoring ≥14 on the 
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BDI-II, 10 nmol/L decrease in 25-hydroxyvitamin D was associ-
ated with an average increase of 5.2% in the BDI-II score. Even 
after adjusting for age, smoking, alcohol consumption, physical 
activity, BMI, comorbidities and adverse life events, there was 
still a significant difference in serum vitamin levels. Additional 
adjustment for season did not change this inverse association. 
Only 22 men (0.7%) reported taking vitamin D supplements and 
exclusion of these men did not change the results. A major lim-
itation of this study, is its difficulty in assessing causality or even 
if vitamin D contributes to depression. It may be that vitamin D 
insufficiency may just be a ‘risk marker’ of general poor health 
and lifestyle. Depressive behaviors of decreased physical activity 
and exposure to sunlight may by itself lead to lower vitamin D 
levels. Lee et al. did attempt to adjust for this factor by assessing 
if physical activity can contribute to low vitamin D levels but 
this adjustment does not measure sunlight exposure or rule out 
reverse causality. The main strengths of this study is their large 
sample size of healthy subjects of similar origin and uniform 
methods of assessing depressive symptoms. Their study did find 
an inverse relationship between serum vitamin D levels and de-
pressive symptoms, mostly independent of confounding factors.
To further this relationship and see if low vitamin D levels is a 
conclusively a predisposing factor of suicide, Umhau et al. (2013), 
did a case-control study of 25-hydroxyvitamin D concentration, 
of serum samples stored in the Department of Defense Serum 
Repository, of deployed active-duty service members who had 
subsequently committed suicide. 495 subjects were selected 
from the Armed Forces Health Surveillance Center (AFHSC) 
who had officially verified suicides occurring between 2002 
and 2008 and had blood sampled within 24 months of death. 
Controls were randomly selected from the same data bank, and 
were matched as taking the blood work within 12 months of 
those who had committed suicide, to minimize for any tempo-
ral changes in military environment. They found an increased 
risk of suicide in lower levels of serum 25-hydroxyvitamin D, 
and all those who committed suicide has a seasonally adjusted 
levels below 20 ng/mL. Additionally, they found that 30% of the 
suicides assessed occurred in those in the lowest levels of vita-
min D status. When they graphed the data, they found a curve 
that is characteristic of nutritional intake, which appears to have 
benefit until a threshold is reached and after that, any additional 
enrichment shows little benefit. Meaning, that if sufficient nu-
trient input is reached then further input will have no effect 
on outcomes. Which is important when considering Vitamin 
D supplementation as a treatment method, as discussed later. 
One limitation of this study, is that vitamin D levels were not 
measured at the time of suicide but sometimes months before. 
This problem is lessened by the fact that vitamin D levels are 
shown to be correlated up to 3 years apart. Perhaps, active-du-
ty service members may have a higher risk of suicide because 
they often work at night and are excessively covered up in the 
daytime, therefore, their reduced sun exposure and subsequent 
reduced vitamin D synthesis contributes to their suicidality. In 
this study, vitamin D status before suicide attempt was inversely 
correlated with suicide risk in a large sample size of a specific 
subset of the population with a general high risk of suicide.
 Suicidal ideation may be sudden and in most cases, the first 
thoughts of suicide often occur less than 10 minutes before the 
suicide attempt. In a young, and somewhat aggressive, popula-
tion like military service members, impulsivity may contribute 
to their risk of suicide. There seems to be a link between vita-
min D and impulsivity, as vitamin D increases proinflammatory 
cytokines in the brain. Proinflammatory cytokines reduces se-
rotonin activity which is long associated with impulsive suicide 
(Umhau et al.,2013). As discussed in detail earlier, perhaps, this 
effect of vitamin D is the mechanism by which vitamin D defi-
ciency contributes to higher suicide rates. 
Is present vitamin D concentration associated with suicide at-
tempt? As a similarly designed study discussed previously, done 
by Janelidze, Mattei, Westrin, Traskman-Bendz, & Brundin (2011) 
to show that increased inflammatory cytokine concentration 
of IL-6 and TNF-α contributes to suicide risk, Grudet, Malm, 
Westrin, & Brundin (2014), takes it a step further, to see if vi-
tamin D concentrations, which also contributes to increased 
inflammatory cytokine concentrations, differ in suicidal de-
pressed patients compared to non-suicidal depressed patients. 
They included a total of 59 patients who had attempted suicide, 
and had two control groups of 17 untreated patients with major 
depressive disorder who had no suicidal ideation and 14 somat-
ically and psychiatrically healthy patients. They found a significant 
difference in serum 25-hydroxyvitamin D levels between groups, 
with the suicide attempters have a significantly lower mean vi-
tamin D concentration, of 47 ± 20 nmol/L, than the non-suicidal 
patients, 62 ± 27 nmol/L, and healthy patients, 65 ± 26 nmol/L. 
Additionally, 58% of patients in the suicidal group had a clinical 
vitamin D deficiency of below 50 nmol/L, compared to 30% in 
the other two control groups. When comparing vitamin D levels 
and inflammatory cytokines in all groups, they found a correla-
tion between 25-hydroxyvitamin D serum concentrations and 
proinflammatory cytokine serum concentration of IL-1β. They 
did not find a statistically significant correlation between vitamin 
D and cytokines IL-6 and TNF-α in all groups. When comparing 
individual groups, they found an inverse association between 
25-hydroxyvitamin D and IL-1β in the patients who attempted 
suicide and an inverse association between 25-hydroxyvitamin 
D and IL-6 in the non-suicidal depressed patients. In conclusion, 
they found a negative correlation between vitamin D levels and 
suicide risk and a negative correlation between vitamin D levels 
and proinflammatory cytokines. The cross-sectional design of 
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this study does not allow any conclusions whether low vitamin 
D status can be a direct contributing factor of suicide, but based 
on previous knowledge of the mechanism of 1,25-dihyroxyvita-
min D on brain function and regulation, there is considerable 
evidence to suggest a direct causality.
Vitamin D deficiency is common in the modern world and 
Vitamin D supplementation is relatively inexpensive nutritional 
additive. If this vitamin D insufficiency has a direct contribution 
on depression and suicide, can vitamin D be used a treatment 
to reduce depressive symptoms and stop the epidemic of de-
pression and suicide worldwide?
As a vitamin D intake is an easy nutritional therapy, Bertone-
Johnson et al. (2011) seeks to clarify if vitamin D supplemen-
tation can prevent or treat depression. They patients used for 
this study were part of a large and diverse sample size that 
was tracked for a long period of time. The subjects used for 
this study were part of the observation study (OS) compo-
nent of the Women’s Health Initiative (WHI) This is a database 
composed by the National Institute of Health which allowed 
Bertone-Johnson et al. to follow the health of 81,189 post-
menopausal women over an 8-year period. Baseline intake was 
assessed by asking patients about diet and any vitamin D sup-
plementation and estimates of total solar irradiance was cal-
culated based on the geographic location of the clinic centers 
and controlled when interpreting the results. At each clinic 
visit, depressive symptoms were assessed using the Burnam 
8-item scale for depressive disorders. When controlling for 
confounding factors, they found that lower vitamin D intake 
of <100 IU/day had a strong inverse correlation in women 
who met criteria for prevailing depressive symptoms at the 
baseline visit. And the reverse was also true, those patients 
with a substantial intake of vitamin D was associated with a 
lower prevalence of depressive symptoms. This effect seemed 
to have a threshold, as those positive effects of increased in-
take was only shown in patients who consumed 400 to <800 
IU/day and an intake of ≥800 IU/day was not associated with 
decreased risk of depression. At year 3 of the study increased 
vitamin D intake was correlated with lower risk of depressive 
symptoms in patients with no evidence of depression at base-
line. A limitation of this study, is that it did not measure serum 
25-hydroxyvitamin D levels in conjunction with intake levels. 
This is important as the effects of vitamin D intake on serum 
vitamin D levels may differ in individuals. Individuals may differ 
in the processing of vitamin D ingestion; these differences are 
in part because of genetic factors, vitamin D metabolism and 
general dietary intake. This study saw an inverse relationship 
between vitamin D intake and depressive symptoms in older 
women.
One study, looking at the direct effects of vitamin D supple-
mentation on depressive symptoms in conjunction with meta-
bolic profiles, c-reactive protein (CRP), an inflammatory marker, 
and oxidative stress. Sepehrmanesh et al., (2016) performed a 
randomized, double-blind, clinical trial in performed in Kashan, 
Iran, from October 2014 to December 2014. They included 36 
patients, ages 18–65 years, equal parts men and women, diag-
nosed with major depressive disorder and randomly assigned 
18 of them to receive a single capsule of 50,000 IU vitamin D 
weekly and 18 patients to receive a placebo weekly for 8 weeks 
in total. The Beck Depression Inventory (BDI) was used to as-
sess depressive symptoms before and after supplementation. As 
expected, after 8 weeks, changes in vitamin D concentrations 
were greater in the vitamin D group than in the placebo group. 
The group taking vitamin D supplements had improved insulin 
function and decreased oxidative stress than the patients that 
took a placebo. No changes were seen in c-reactive protein lev-
els between both groups. This may be because of the duration 
of the study or the specific inflammatory marker studied, as dif-
ferent inflammatory markers have been found to be associated 
with vitamin D deficiency and depression. But most importantly, 
this study found that the patients taking vitamin D supplements 
had significant decreased depressive symptoms, and decreased 
BDI total scores, post-nutritional therapy compared to before. 
As all these patients had vitamin D deficiency of less than 20 
μg/L at the start of this study, it is not possible to assess if the 
effects of supplementation are seen only in vitamin D deficient 
individuals or this therapy may also be useful in those who have 
clinically sufficient levels of vitamin D. Perhaps the beneficial ef-
fects of supplementation can be explained by the fact that both 
groups had a low baseline mean serum 25-hydroxyvitamin D 
level. Therefore, a relatively short supplementation period was 
effective in lowering depressive symptoms. Overall, vitamin D 
supplementation had a positive effect on lowering depressive 
symptoms in patients with major depressive disorder. 
Conclusion
Vitamin D status seems to be directly linked to mood disor-
ders and particularly major depression. A mechanism for this 
association is demonstrated in detail, as both are correlated 
to inflammatory cytokine status. Vitamin D deficiency is asso-
ciated with an elevation of proinflammatory cytokines because 
vitamin D modulates and prevents uncontrolled inflammation 
systemically and in the central nervous system. This elevation of 
proinflammatory cytokines may have adverse psychiatric effects. 
It can contribute to depressive symptoms and even suicide. 
Patients with suicidal thoughts specifically, seem to have abnor-
mal proinflammatory cytokines and lower levels of vitamin D in 
their body, than patients with major depression that do not have 
suicidal thoughts.
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As the conceptual understanding of vitamin D’s activity as a 
neuro and immune modulator on the brain is an innovative and 
relatively new area of study, there are few direct-link studies on 
how the supplementation of vitamin D may reduce instances of 
major depressive disorder and suicide risk. Vitamin D supple-
mentation treatment for major depressive disorder should be 
tested in a larger sample size, in patients with clinically sufficient 
vitamin D status, and for longer periods of time. Additionally, this 
treatment should be tested in patients with suicidal ideation, as 
this is the subgroup that has been differentiated to be effect-
ed most by vitamin D deficiency. Furthermore, studies should 
assess the difference between treatments that raise vitamin D 
levels by intake versus UV ray exposure. Perhaps, vitamin D sta-
tus and its effects may differ when synthesized naturally in the 
skin with direct access to subcutaneous fat for storage and the 
bloodstream, in contrast the supplementation being first pro-
cessed in the gastrointestinal tract. Vitamin D as a treatment 
method for major depressive disorder is a new and exciting area 
of research that may impact the global population tremendous-
ly due to the large number of people suffering of depression 
worldwide. More research on the effectiveness and limitations 
of this treatment should be done to maximize its impact.
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Introduction
In 1671 when Antony van Leeuwenhoek first spied “animal-
cules,” now known to us as single cell organisms, through his 
homemade microscope, he set into motion a centuries long 
scientific endeavor to discover, describe, catalogue and gain 
a deeper understanding of the vast microbial world that sur-
rounds us. This laid the groundwork for the development of 
the germ theory by Louis Pasteur and Robert Koch over the 
course of the 1860’s and 1870’s. Germ Theory, the theory that 
many diseases are caused by microbial agents, revolutionized 
medicine leading to many advances such as the disinfecting 
of wounds, the appreciation of the need for a sterile envi-
ronment during surgery, and in 1921 the fortuitous discovery 
of penicillin by Alexander Fleming. Germ theory also had a 
profound influence on the attitudes of medicine and society 
at large towards “germs.” Although only a tiny fraction of 
microbes are pathogenic, they became indelibly associated, 
both in the popular imagination and in medical practice, with 
sickness and disease. This focus on microbe pathogenicity has 
yielded tremendous benefits to public health, in fact antibiotics 
were among the primary drivers of rising life expectancy in 
developed countries in the mid twentieth century (Armstrong, 
1999), but antibiotics, for all their benefits, came with costs as 
well, namely their effect on the native flora. 
Discovery of the body’s native flora began in the mid 1880’s 
when an Austrian pediatrician, Theodore Escherich, observed 
the eponymously named Escherichia coli in the stool of healthy 
children. Discovery continued apace and the realization set in 
that there was a large, diverse, community of microbes that 
colonized the skin, nasal and oral cavities, and the urogenital 
and gastrointestinal tracts of healthy people, making up their 
native flora. As early as the 1970’s there was already an idea 
of the number of microbes, then estimated to number rough-
ly 1014, living primarily in the gastrointestinal tract, and some 
idea of ecology of this diverse community (Savage, 1977). Until 
relatively recently, it was assumed that the microbes living in 
the colon lived a largely commensal existence, dining on food 
indigestible to the human host but not interacting with the 
host in any meaningful way. With this understanding collateral 
damage to the gut bacteria because of antibiotics was no great 
concern, with the worst-case scenario being an unwanted 
bloom of C. Difficile. However, in recent years and particularly 
since the launch of the Human Microbiome Project, an entirely 
different picture has emerged, one that includes many symbi-
otic relationships between the native flora and the host, in 
fact so enmeshed is the host-symbiont relationship, that they 
have been described as one “supraorganism (Turnbaugh, et al., 
2007). This new understanding demands a closer look at the 
possible effects of antibiotics on our microbiome.
This paper will explore the possible link between antibiotics 
and obesity. First it will lay the groundwork with a thorough 
exploration of the literature linking the state of the micro-
biome to obesity as well as an understanding of the under-
lying mechanisms. Then it will consider the evidence that a 
disturbance of the microbiota through antibiotic treatment 
can cause obesity along with proposed causative mechanism. 
Finally, it will propose ways to mitigate the effects of the anti-
biotic treatment. 
Methods
Information for this paper was obtained primarily through on-
line searches utilizing google scholar as well as well as numerous 
databases accessed through Touro college’s library system.
Abstract
In recent years, science has made great strides in its understanding of the microbiome, discovering that it plays a role in 
regulating many body processes. One area of study is the microbiomes interaction and influence on host metabolic pro-
cesses. Studies using both mice and humans have established a clear correlation between obesity and the composition of 
the microbiome, identifying a microbiome unique to obese individuals. Furthermore, experiments with germ-free mice 
have shown that the microbiome effects host metabolism, causing germ free mice to increase in mass when inoculated 
with normal microbiota. Inoculation with microbiota from obese mice yielded greater increases in mass, showing the 
obesogenic effect of the microbiota. The mechanisms through which the microbiome can contribute to obesity are en-
hanced extraction of energy from food, and increased capacity for nutrient uptake in the gut, and alteration of metabolic 
pathways by suppressing fasting induced adipose factor and decreasing AMPK activity. Many of these pathways show 
increased activity in obese mice. The enhanced energy extraction coupled with greater deposition of fat mediated by 
altered metabolic pathways can contribute to obesity.
The role of the microbiota in obesity, combined with decades-old observations that antibiotics, particularly early in life, 
increased the weight of livestock, led to a hypothesis that antibiotics can disrupt the development of the microbiome, 
causing metabolic changes, leading to obesity. Recently, this hypothesis has been tested, both in studies utilizing mice, and 
in many epidemiological studies. This paper will evaluate the available evidence to determine if exposure to antibiotics 
early in life can lead to increased incidence of obesity later. 
Do Antbiotics in Early Life Contribute to Obesity?
Shimon Kadosh
Shimon Kadosh will graduate with a BS in Biology in June 2017.
88
Shimon Kadosh
Definition of “Core Microbiome”
The first step to determining if obesity is associated with an 
altered microbiome is establishing the baseline values defining 
what a “normal” gut microbiome looks like. This task is compli-
cated by the wide diversity of gut microbial populations found 
across different geographical areas and cultures, and even within 
communities and cultures. In fact, in one study “there was not 
a single abundant (defined as >0.5% of the community) bacte-
rial species shared by all 154 individuals” involved in the study 
(Turnbaugh P. J., 2009) . However, if one looks at the microbiome 
on the level of phyla, a strong pattern begins to emerge, with 
bacteria from the phyla Firmicutes and Bacteriodetes repre-
senting, in one study, 92.6% of the microbiota (Ley, et al., 2006). 
These 2 phyla and their respective ratios can serve as one defi-
nition of a core microbiota.
Another way of defining the core microbiome is, rather than 
focusing on the species or phyla present, focusing on the var-
ious genes present. Various studies utilizing this methodology 
have found that regardless of the vast diversity of the microbial 
makeup of the gut flora, there exists a “wide array of shared mi-
crobial genes, comprising an extensive, identifiable ‘core micro-
biome’ at the gene, rather than at the organismal lineage, level” 
(Turnbough, et al., 2009). While both definitions are useful, this 
paper will primarily utilize the second definition of the micro-
biome as a set of genes rather than ratio of different bacterial 
phyla. The reason for this is that a focus on genes can better 
illuminate any products of the microbiome that may affect host 
metabolic pathways, possibly contributing to obesity. 
Association of Obesity with Altered Microbiome
Having established a baseline microbiome, we can now explore 
any obesity associated changes that may occur. First, we will ex-
plore the changes in the ratio of Firmicutes and Bacteroidetes 
associated with obesity.
  In one experiment, mice heterozygous for obesity ob/+ (due to 
a defective leptin gene) were mated producing litters consisting 
of a mix of obese (ob/ob) and lean (ob/+ and +/+) phenotypes. 
Microbial ecology in the gut, specifically the ratio of Firmicutes 
to Bacteroidetes, which is typically similar among members of 
a family living together, was found to be consistent in the het-
erozygous mothers as well as the ob/+ and +/+ children. In the 
homozygous ob/ob mice of the same litter however, a sharp 
increase in abundance of Firmicutes relative to Bacteroidetes 
was observed (Ley, et al., 2005). This shows a clear correlation 
between obesity and the composition of the gut microbiome.
In another experiment, 12 obese individuals were randomly 
placed on either a fat or carbohydrate restricted diet and their 
gut microbiota was monitored over the course of a year for any 
discernible shift in the microbiota as they lost weight. Initially, 
obese people had more firmicutes and fewer Bateroidetes than 
lean controls. However, over the course of the year as their 
weight dropped, the ratio of Firmicutes to Bacetoidetes began 
to more closely resemble a typical lean profile (Ley, et al., 2006). 
Together, these two studies, encompassing both mice and men 
and showing both an increase in abundance of Firmicutes as an 
obese phenotype was acquired in the mouse experiment and 
a decrease in its abundance as weight was lost in the human 
experiment, firmly establish that obesity is associated with an 
altered microbiome.
Can the Gut Microbiome Cause Obesity?
Having established a strong correlation between obesity and al-
tered gut microbial ecology, we can now explore the possibility 
that the microbiome can be a causative agent in obesity. 
There seems to be good experimental evidence, at least with 
mice, that this is the case.
In one experiment, mice were divided into three groups. One 
group was raised “Germ Free” meaning that their gut was ster-
ile. Another group consisted of regular, conventionally raised 
mice, and acted as a control. A third group was initially raised 
germ, free but subsequently inoculated with gut bacteria at 7-10 
weeks by spreading a suspension of cecal content from the con-
trol group mice on their fur. Comparison of germ free and regu-
lar mice at 8 to 10 weeks found that regular mice had 42% more 
body fat than their germ-free companions and had epidydimal 
fat pads weighing 47% more, all while eating 29% less food. After 
a 14-day colonization, a process known as conventionalization, 
the third group of mice experienced a dramatic 57% increase in 
total body fat and a 61% increase in epididymal fat pad weight 
all while their chow consumption decreased to that of the nor-
mal mice (Backed, et al., 2004). This experiment shows that gut 
microbiota has a powerful effect on metabolism and fat storage. 
The initial low-fat state of the germ-free mice even with their 
above average food intake and their dramatic increase in fat, 
even in the face of decreased chow consumption, as they were 
conventionalized, indicates that a normal microbiome plays a 
key role in regulating fat in mice. 
Having established the effects of a normal microbiome, let us ex-
amine the effects of an obese one. Toward this end, an experiment 
was constructed in which germ-free mice were colonized by ga-
vage (meaning they were fed by tube) with the cecal contents of 
either wild type +/+ or genetically obese ob/ob (leptin deficient) 
mice. In the 14-day period following the colonization food con-
sumption in the (ob/ob) and (+/+) transplanted groups was not 
statistically different (55.4±2.5g for ob/ob against 54.0±1.2g for 
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+/+) and they both ate the same type of chow (no difference in 
caloric density). Despite this, the mice colonized with ob/ob mi-
crobiota exhibited a significantly greater increase in body fat than 
those colonized with +/+ microbiota with the ob/ob colonized 
mice increasing body fat by 47±8.3% and the +/+ colonized mice 
increasing by just 27±3.6% (Turnbaugh,et al., 2006).  
The dramatic difference in body fat between the two groups 
strongly indicates that the obese microbiome causes greater 
adiposity, and gives rise to the possibility that the microbiome 
can play a role in its development.
Mechanisms of Microbiome Influence on Adiposity
The classic, somewhat simplistic understanding of the devel-
opment of obesity is to take the calories of the food eaten, 
subtract calories burned by both the basal metabolic rate and 
any additional energy expenditures for various activities, and 
assume that the remainder is stored as fat in adipose tissue 
throughout the body. Our exploration of the mechanisms 
through which the gut microbiota increase adiposity will illu-
minate several ways that this seemingly straightforward and 
commonsense equation can be altered.
One mechanism proposed is that all microbiomes increase the 
bodies capacity for energy harvest from food eaten by excret-
ing exoenzymes that break down polysaccharides that the host 
is unable to metabolize. Once degraded into monosaccharides 
and short chain fatty acids, both the bacteria and the host 
readily take up the product, accruing extra calories to the host 
from the same food. It is further hypothesized that the changed 
obese microbiome performs these tasks more efficiently ex-
tracting even more calories from the same unit of food with the 
host reaping some of the benefits. This hypothesis is buttressed 
by numerous lines of evidence.
The first of these is a simple comparison of the energy re-
maining in the feces of regular mice as opposed to genetically 
obese mice. Bomb calorimetry showed that ob/ob mice have 
significantly less energy remaining than regular mice, yielding 3.2 
kcal/g compared to 3.4 in regular mice (Turnbaugh, et al., 2006). 
This is simple, clear, empirical evidence that an obese microbi-
ome harvests more energy than a standard, lean microbiome.
Another line of evidence involves a genetic analysis of the mi-
crobiome, specifically of genes encoding enzymes that catalyze 
the breakdown of polysaccharides indigestible to their hosts. 
In one study, a sequencing of 18 Human microbiomes identified 
genes for 156 carbohydrate- active enzymes, which are enzyme 
families that break down carbohydrates, including 77 glycoside 
hydrolase, 21 carbohydrate-binding module, 35 glycosyltrans-
ferase, 12 polysaccharide lyase and 11 carbohydrate-esterase 
families. These genes consisted of fully 2.62±.013% of all the 
microbial genes sequenced, a higher percentage than any other 
identified group of genes. Furthermore, an analysis of lean and 
obese twins found that the obese twins had a microbiome that 
was significantly enriched in genes coding for carbohydrate, 
lipid, and amino acid metabolism as compared to that of their 
lean twins (Turnbough, et al., 2009). 
Mice studies have yielded similar results, with ob/ob mice 
having microbiomes containing more genes coding for various 
carbohydrate-active enzymes as compared with their lean lit-
termates. A predicted result of this would be an increased con-
centration of the products of bacterial fermentation of these 
polysaccharides, such as butyrate and acetate, in the cecum 
of the ob/ob mice. This prediction was borne out, with cecal 
butyrate concentration of obese mice double those of lean 
mice and acetate levels 20% higher (Turnbaugh, et al., 2006). 
Interestingly this same study also found a greater abundance 
of archaea in the obese mice than their lean counterparts. 
Archaea oxidize the hydrogen produced as a by-product 
of fermentation by gut bacteria, turning it into methane. By 
removing a product of the fermentation reaction, they in-
crease its efficiency, serving to further enhance energy ex-
traction by the obese microbiome. Indeed, in a study of mice 
colonized with archaea commonly found in the human gut, 
Methanobrevibactor smithii and B. thetaiotamicron, a signifi-
cant increase in the efficiency of bacterial polysaccharide fer-
mentation leading to an increase in adiposity in the mice was 
observed (Samuel & Gordon, 2006)
In addition to increasing energy extraction from food, there is 
also evidence that the microbiome increases the hosts capacity 
for uptake of nutrients in the gut. In one experiment, germ-free 
and conventionalized mice were fed a glucose solution.  After fif-
teen minutes, the level of glucose uptake was found to be twice 
as high in the conventionalized mice as in the germ-free ones 
(Backed, et al., 2004). Additionally, the microbiome is essential to 
the development of the capillary network to transfer these nu-
trients from the intestines to the hepatic portal vein. Germ-free 
mice were found to have arrested development of this capillary 
network, and upon conventionalization, developed it to normal 
levels within ten days (Stappenbeck & Hooper, 2002). 
These lines of evidence collectively paint a picture of a micro-
biome that extracts more energy from food by breaking down 
complex polysaccharides that the host is unable to metabolize 
on his own and amplifying the hosts ability to absorb the resul-
tant monosaccharides, providing one possible mechanism for 
the microbiome to contribute to obesity. 
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Another mechanism proposed is that the microbiome modifies 
cell signaling pathways to increase fat storage, that is, to direct 
more of the energy harvested toward adipocyte storage rath-
er than other metabolic functions. Two metabolic pathways are 
involved, one of which involves fasting-induced adipose factor 
(Fiaf) which is a lipoprotein lipase inhibitor (Backed, et al., 2004). 
Lipoprotein lipase facilitates deposition of fat in adipocytes. Fiaf, 
which inhibits it, is a crucial regulator of this process. Fiaf is pro-
duced by brown and white fat, the liver, and the intestine. The 
microbiome suppresses the production of Fiaf in the intestinal 
epithelium, thereby increasing the activity of lipoprotein lipases, 
resulting in more triglycerides being incorporated into adipocytes. 
Experimental evidence for this machanism comes from a study 
that compared regular germ-free mice, germ-free mice incapa-
ble of producing Fiaf (Fiaf-/-), and conventionalized mice both 
with and without the Fiaf gene. The regular germ free mice, 
as expected were the leanest. Germ free Fiaf-/- mice howev-
er, were found to have nearly the same amount of fat as their 
conventionalised wild type peers. Furthermore, a conventional-
ization of the germ free Fiaf knockout mice yielded a minimal 
increase in body fat of 10±8% versus 55±16% for the wild type 
germ free mice. Conventionalization of heterozygotes (Fiaf +/-) 
yielded an intermediate result, consistant with the hypothesis. 
Additionally comparison of mRNA of conventionalised and 
germ free wild type mice revealed camparitively less Fiaf ex-
pression in the small intestines of the the former, expression 
elswhere though was unaffected (Backed, et al., 2004). Other 
studies have had similar findings, including one that found that 
while regular germ free mice were resistant to obesity induced 
by consuming an “american diet” in their case chow with higher 
fat content and more easily  digested sugars, Fiaf -/- mice had 
lost this resistance (Backhed, et al., 2007).  These findings point 
to fasting induced adipose factor as a major component of the 
microbiomes contribution to adiposity. 
Another pathway involves levels of AMP-activated protein ki-
nase, or AMPK (Backhed, et al,. 2007). AMPK is a key enzyme 
regulating metabolism, serving as the lynchpin of a complex web 
of metabolic pathways maintaining proper ATP levels. AMPK 
ramps up energy production in response to metabolic stresses. 
It is triggered primarily, as its name indicates, by an increased 
ratio of AMP to ATP, but also by numerous other factors such as 
an elevated ratio of NAD to NADH, and the hormones leptin 
and adiponectin (Kahn, et al,. 2005) . The microbiome is thought 
to decrease AMPK activity, leading to lower energy expenditure, 
with more calories remaining to be deposited as fat.
Evidence for this mechanism is based on a number of obser-
vations. The first is that germ free mice were found, using an 
immunoblot assay, to have phospho-AMPK, which is the active 
form, at concentrations 40% percent greater than their regular 
peers in their gastrocnemeus muscles. Consistant with these 
findings AMP levels in the germ-free mice were foud to be 50% 
higher. Additionally, many other enzymes involved in the fatty 
acid oxidation pathway triggered by AMPK showed fluctuations 
consistant with increased fatty acid oxidation. In this pathway, 
AcetylCoA carboxylase converts Acetyl CoA to Malonyl CoA, 
Malonyl CoA inhibits carnitine-palmitoyl transferase-1 (Cpt1), 
which catalyzes the rate-limiting step for uptake of long chain 
fatty acids by mitochondria, AMPK phosphorylates AcetylCoA 
carboxylase, inhibiting it and thereby increasing fatty acid 
oxidation (Kahn, et al, 2005). A 43% increase in the levels of 
phosphorylated AcetylCoA carboxylase was found using an 
immunoblot assay and a 17% increase in the level of Cpt1 was 
found with a biochemichal assay, in germ free over that of reg-
ular mice,both consistant with increased fatty acid oxidation 
(Backhed, et al,. 2007). 
Collectively, these lines of evidence paint a picture of a microbi-
ome that acts on both sides of the energy equation, harvesting 
more energy from food through greater polysaccharidase ac-
tivity, conserving more of that energy through, and depositing a 
greater portion of it as fat. 
Can Antibiotics Contribute to Obesity?
Having gained some appreciation of the influence of our micro-
biota on our metabolism and its role in promoting adiposity, 
we can now explore the role of antibiotics on this complex 
system. Specifically, we will explore whether the disruption to 
the microbiota caused by antibiotics, particularly early in life, can 
affect the body mass of the host later in life by either promoting 
or inhibiting weight gain.
There is extensive evidence that antibiotics promote weight 
gain, from veterinary medicine, animal models, and epidemio-
logical studies. 
In the 1950’s Veterinary scientists showed that giving pigs (Taylor 
& Gordon, 1955) and other livestock (Jukes & Williams, 1953) 
sub-therapeutic doses of antibiotics increased their growth 
causing them to gain more weight without increasing feed 
consumption. It subsequently became common practice among 
farmers to mix low doses of antibiotics into the feed of pigs, 
cows, sheep, and poultry, increasing their weight, a practice that 
continues to this day. The effect on weight gain is significant, a 
meta-analysis of numerous studies gauging the weight boosting 
effects of adding antibiotics to feed in pigs found an increase in 
weight gain of up to 15% and an increase in feed efficiency (an 
industry term for amount of meat produced per unit of feed) of 
up to 6%. The strongest effects were found when the antibiotics 
were given from birth with lesser, though still significant effects 
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found if they were given at later dates (Hays, 1969).  Evidence 
that the weight gain is connected to disruption of the microbio-
ta comes from experiments with germ free chickens. Germ free 
chickens given feed containing antibiotics that had a growth pro-
moting effect on regular chickens showed no similar increase in 
growth from the treatment (Coates, 1963), indicating that the 
weight gain is a result of modulation of the microbiome. These 
veterinary studies on regular and germ free animals, combined 
with the everyday experience of farmers for the last 70 years 
provide one line of evidence that antibiotic use has a role in 
weight gain. Importantly, as the data showed, the effect is greatly 
magnified in early life, suggesting that the early microbiome may 
be particularly vulnerable to whatever disruption causes the 
weight gain, a theme that will be expanded on shortly.
More evidence comes from experiments with model organisms, 
namely Mus Musculus, the mouse. Additionally, these experi-
ments shed light on the magnified effects of antibiotics found 
in early life.
In one experiment the effects of sub-therapeutic antibiotic 
treatment (STAT) was tested on mice to attempt to replicate its 
observed effect on farm animals and gain some insight into its 
mechanisms. In the experiment mice were exposed, starting at 
weaning, to various common antibiotics by putting them in their 
drinking water at sub-therapeutic levels, and were compared 
to a control group using various metrics. After a seven-week 
exposure, the STAT mice were found to have greater fat mass 
than the control group as well as a significantly higher percent 
body fat. Curiously although fat mass was greater in the STAT 
mice, total mass was not significantly greater at seven weeks, 
though later measurements taken from 8 to 26 weeks did show 
increased mass in the STAT mice (Cho, et al., 2012).
Utilization of other metrics allows for a deeper understanding 
of the processes driving the adiposity of the STAT mice. One 
important measure taken was the level of Gastric Inhibitory 
Polypeptide (GIP). GIP, a hormone secreted by K cells in the 
small intestine, stimulates lipoprotein lipase activity, increasing 
fat storage and contributing to adiposity (Miyawaki, et al., 2002). 
GIP levels were found to be substantially elevated in STAT mice 
(39.1±2.5 pg/ml) compared to the controls (24.4±4.2 pg/ml). 
This provides a possible mechanism for the observed increase 
in adiposity.
Microarray analysis of differential gene expression in hepatic tis-
sue yielded deeper insights into the metabolic changes wrought 
by STAT. Comparison of STAT and control mice found upregula-
tion of pathways for lipogenesis and triglyceride synthesis in the 
STAT mice, further contributing to adiposity.
Examination of the gut bacteria in the STAT mice yielded fur-
ther insight. Although the overall number of bacteria did not 
change significantly, the composition of the microbiome did 
change, with the abundance of Firmicutes increasing relative to 
that of Bacteroidetes, which, as discussed earlier, is typical of 
obese microbiomes. Additionally, examination of the cecal con-
tents of the STAT mice found higher levels of butyrate and ace-
tate, suggesting increased energy capture through fermentation 
of complex carbohydrates indigestible to the mice, as discussed 
earlier. Supporting evidence came from metabolic cage exper-
iments showing no difference in caloric intake but a lower ca-
loric output in fecal pellets in STAT mice compared to controls 
(Cho, et al., 2012). 
Taken together, these measurements paint a picture of antibi-
otics changing the composition of the microbiome, leading to 
metabolic changes causing adiposity and weight gain, and suggest 
that perhaps antibiotics can contribute to obesity in humans as 
well.
Increased Effect in Early Life
Greater weight gain was observed in farm animals when STAT 
was started earlier in life. Mouse studies have explored the im-
portance of the timing of antibiotic exposure further, exper-
imentally confirming these observations and expanding upon 
them. They found that early life is a critical time in metabolic 
development and exposure to antibiotics at this sensitive stage 
can permanently alter host metabolism.
Evidence for these claims comes from an experiment comparing 
mice started on low dose penicillin (LDP) at weaning (LDP-w) to 
mice where LPD was started shortly before birth(LDP-b) so that 
the initial colonization with maternal microbiota would be altered. 
A control group was maintained that was not exposed at all. 
The experiment found that earlier administration of antibiotics 
did have amplified effects. The growth rate for LDP-b was great-
er than the control, the fat mass as well as the total mass of 
adult LDP-b male mice was greater than that of LDP-w mice and 
the control (Cox, et al., 2014), demonstrating enhanced effects 
of earlier antibiotic administration. Sexual dimorphism was ap-
parent in the results with the females experiencing lesser if any 
effects, a finding that remains unexplained. Metabolic differences 
between the LDP-b and LDP-w mice were found as well with 
the LDP-b mice having greater expression of genes involved in 
adipogenesis than LDP-w mice. 
The mammalian early microbiome is a dynamic, changing en-
vironment typically showing a pattern of succession as differ-
ent taxa first dominate then diminish (Pantoja-Feliciano, et al., 
2013). Altered representation of some of these taxa has been 
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associated with obesity (Kalliomaki, et al,. 2008). Typically, 
Lactobacillus is prominent in nursing animals, as was indeed the 
case with the controls. The LDP-b mice however, showed much 
lower levels of Lactobacillus, as well as other groups whose pop-
ulation typically peak in early life such as Candidatus Arthomitus 
and Allobaculum  (Cox, et al., 2014). Although the precise roles 
of these microbes are not known, their suppression by LDP and 
the dramatic phenotypic effects that follow suggest some role 
in metabolic development. 
In an experiment with worrying implications for human obesity, 
some LDP mice were switched to high fat diet at 17 weeks, and 
were compared to control groups with just a high fat diet or 
just LDP. The growth promoting effects of LDP were accentuat-
ed by the high fat diet producing fat and weight gain surpassing 
that produced by the high fat diet or LDP alone.
More worrying still, the metabolic effects of LDP lasted into 
adulthood even after treatment finished. Mice that received LDP 
for only four weeks after birth still experienced greater fat and 
total mass accumulation from 6-20 weeks. This weight gain per-
sisted even though the microbiota had appeared to normalize. 
Finally, to demonstrate that the metabolic and phenotypic 
changes observed were a result of an altered microbiota 
and not some direct effect of the penicillin, cecal microbiota 
were transferred from 18-week-old control and LDP mice to 
3 week germ-free mice. The mice inoculated with the LDP 
microbiota increased total mass and fat mass at a faster rate 
(.078 g/day total mass and .058 g/day fat mass faster) than 
those inoculated with the normal microbiota (Cox, et al., 
2014). 
These studies provide convincing evidence, as much as can be 
inferred from model organisms, that antibiotics contribute to 
obesity through disruption of the microbiota, and that early life 
is a particularly sensitive time when disruption of the developing 
microbiome can have long lasting metabolic effects.
Epidemiological Studies
The findings in model organisms that antibiotic exposure, par-
ticularly in early life, can lead to obesity, have important impli-
cations for human health. However, results in model organisms 
do not always translate into results in humans. Since ethical 
concerns preclude the types of randomized, controlled studies 
routinely performed with model organisms from being done on 
humans, we must rely on epidemiological evidence. Fortunately, 
there are a wealth of well-constructed epidemiological studies 
demonstrating that antibiotic exposure in infancy is correlated 
with obesity later in life.
In a study involving 28354 mother baby pairs from the Danish 
National Birth Cohort, antibiotic exposure in the first six 
months of life was correlated (with an odds ratio of 1.54, 
well above the threshold for showing correlation) with an in-
creased risk of being overweight at 7 years (Ajslev, et al., 2011). 
Supporting these findings are results from a study utilizing 
11532 children from the Avon Longitudinal Study of Parent and 
Children. This study examined antibiotic exposure during three 
early-life time windows, 6< months, 6-14 months, and 15-23 
months.  Exposure under six months was, once again, strongly 
correlated (p<.001) with increased body mass at 10, 20, and 
38 months. However, exposure from 6-14 months showed no 
effect and exposure at 15-24 showed a modest weight gain at 7 
years (Trasande, et al., 2013). A Canadian study combining data 
from health records and a Canadian longitudinal birth cohort 
study further bolstered these findings. The study found that 
children who received antibiotic treatment in the first year of 
life were more likely to be overweight at ages 9 and 12 than 
their untreated peers (32.4% overweight if exposed vs. 18.2% 
if not). Additionally, researchers noted a greater prevalence of 
elevated central adiposity, a precursor of metabolic syndrome, 
among the treated children (Azad, et al, 2014).  A longitudinal 
study in the USA (Bailey, et al., 2014)and a global cross sectional 
study (Murphy, et al., 2013) found similar results as well. Several 
the studies (Trasande, et al., 2013) (Murphy, et al., 2013) found a 
strong sexual dimorphism, with the effect much greater in boys, 
and nearly all the studies showed some difference between girls 
and boys, with the boys seeing greater weight gain than the 
girls, a finding that while replicated many times in both model 
organisms and in humans, has not been satisfactorily explained.
The collective weight of these epidemiological studies gives 
great credence to claims that antibiotics contribute to obesity.
Mitigating the Effects of Antibiotics
Even with all the evidence of detrimental side effect of antibi-
otics, stopping their use is obviously not an option. Antibiotics 
are a cornerstone of modern medicine, without which life ex-
pectancy would surely drop precipitously. However perhaps a 
bit of restraint in prescribing antibiotics to children is in order. 
Rates of antibiotic prescriptions in the USA are unnecessarily 
high, with some analyses finding that fully half of all antibiotic 
prescriptions written are unnecessary (Nyquist, et al., 1998). 
Although antibiotic prescription rates among children and ado-
lescents have dropped since that finding (Lee, et al., 2014), pre-
scription rates in the USA are still high compared to some other 
countries. In Sweden, for example, antibiotic use is 53% lower 
than in the USA (Ternhag & Hellman, 2010). This indicates that 
prescription levels can still be lowered significantly without ad-
versely effecting public health. While some antibiotic exposure 
may be unavoidable for many children, even merely reducing the 
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number of rounds of antibiotics they take reduces their chance 
of developing obesity later in life (Bailey, et al., 2014).
One final action possible to mitigate the obesogenic effects of 
antibiotics on children is to prescribe narrow spectrum anti-
biotics when possible. One study, despite finding significant 
correlation between broad-spectrum antibiotics in the first two 
years of life, found no such correlation for narrow-spectrum 
antibiotics (Bailey, et al., 2014).
Conclusions
In conclusion, the evidence for an obesogenic effect of early-life 
exposure to antibiotics is substantial and convincing. The many 
mouse studies demonstrating the influence of the microbiome 
on metabolism and its role in obesity give ample reason to sus-
pect that perturbations of the microbiome with antibiotics may 
have some effect on obesity. The evidence from farm animals, 
mice, and epidemiological studies serve to confirm that suspi-
cion, showing that antibiotic exposure in infancy contributes to 
one’s chances of developing obesity later in life.
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